UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM ~~10-Q/A~~

~~Amendment No. 1~~

10-Q

(Mark One)


☒ý			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~June 30, ~~2021~~

2022


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to

_____

Commission ~~File No.~~ file number 001-39248

~~THE~~ ~~ONCOLOGY INSTITUTE, INC.~~

The Oncology Institute, Inc.

(Exact name of registrant as specified in its ~~charter~~)

charter)


Delaware			84-3562323
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

18000 Studebaker Rd, Suite 800	Cerritos	California	90703
(Address of Principal Executive Offices)			(Zip Code)

~~18000 Studebaker Rd.~~

~~Cerritos~~, ~~California~~~~90703~~

~~(Address of Principal Executive Offices, including zip code)~~

(~~213~~) ~~760-1328~~

~~(Registrant’s~~

(562) 735-3226

Registrant's telephone number, including area ~~code)~~

code

~~N/A~~

~~(Former name, former address and former fiscal year, if changed since last report)~~

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value ~~$0.0001~~ per share	TOI	The Nasdaq Stock Market LLC
~~Reedemable warrants, each whole warrant exercisable for one share of~~Warrants to purchase common stock ~~each at an exercise price of $11.50 per share~~	TOIIW	The Nasdaq Stock Market LLC

Securities registered pursuant to section 12(g) of the Act: None

Indicate by check mark whether the ~~registrant~~registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),; and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ý No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ý No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting ~~company, or an emerging growth~~ company. See the definitions of “large accelerated filer,” “accelerated ~~filer,”~~filer” and “smaller reporting ~~company,” and “emerging growth~~ company” in Rule 12b-2 of the Exchange Act.

(Check one):


Large accelerated filer ☐	☐	Accelerated filer ☐	ý
Non-accelerated filer ☒	☐	Smaller reporting company☒	ý
		Emerging growth company☒	ý

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the ~~Exchange~~ Act):. Yes ☐ No ☒ý ~~No ☐~~

As of ~~November 8, 2021, 23,000,000 Class A~~August 9, 2022, the registrant had 72,140,372 shares of common stock ~~$0.0001 par value, and 5,750,000 Class B common stock, $0.0001 par value, were issued and~~ outstanding.

Table of Contents

~~Explanatory Note~~

References throughout this Amendment No. 1 to the Quarterly Report on Form 10-Q to “we,” “us,” the “Company” or “our company” are to The Oncology Institute, Inc. (formerly, DFP Healthcare Acquisition Corporation), unless the context otherwise indicates.

This Amendment No. 1 (“Amendment No. 1”) to the Quarterly Report on Form 10-Q/A amends the Quarterly Report on Form 10-Q of the Company as of and for the periods ended September 30, 2021, as filed with the Securities and Exchange Commission (“SEC”) on November 8, 2021 (the “First Amended Filing”).

On November 8, 2021, the Company filed its Form 10-Q for the quarterly period ending September 30, 2021 (the “Q3 2021 Form 10-Q”), which included a Note 2, Revision of Previously Issued Financial Statements, (“Note 2”) that describes a revision to the Company’s classification of its Class A common stock subject to redemption issued as part of the units sold in the Company’s initial public offering (“IPO”) on March 13, 2020. As described in Note 2, upon its IPO, the Company classified a portion of the Class A common stock as permanent equity to maintain net tangible assets greater than $5,000,000 on the basis that the Company will consummate its initial business combination only if the Company has net tangible assets of at least $5,000,001. Previously, the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. The Company’s management revised this interpretation to include temporary equity in net tangible assets. As a result, management corrected the error by revising all Class A common stock subject to redemption as temporary equity. This resulted in an adjustment to the initial carrying value of the Class A common stock subject to possible redemption with the offset recorded to additional paid-in capital (to the extent available), accumulated deficit and Class A common stock.

In connection with the change in presentation for the Class A common stock subject to possible redemption, the Company revised its earnings per share calculation to allocate income and losses shared pro rata between the two classes of shares. This presentation differs from the previously presented method of earnings per share, which was similar to the two-class method.

The Company determined the changes were not qualitatively material to the Company’s previously issued financial statements and did not restate its financial statements. Instead, the Company revised its previously financial statements in Note 2 to its Q3 2021 Form 10-Q. Although the qualitative factors that management assessed tended to support a conclusion that the misstatements were not material, these factors were not strong enough to overcome the significant quantitative errors in the financial statements. The qualitative and quantitative factors support a conclusion that the misstatements are material on a quantitative basis. Management concluded that the misstatement was such of magnitude that it is probable that the judgment of a reasonable person relying upon the financial statements would have been influenced by the inclusion or correction of the foregoing items. As such, upon further consideration of the change, the Company determined the change in classification of the Class A common stock and change to its presentation of earnings per share is material quantitatively and it should restate its previously issued financial statements.

Therefore, on December 8, 2021, the Company’s management and the audit committee of the Company’s board of directors (the “Audit Committee”) concluded that the Company’s previously issued (i) balance sheet as of March 13, 2020 (the "Post IPO Balance Sheet"), as previously restated in the Company’s Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2020, filed with the SEC on May 24, 2021 (“2020 Form 10-K/A No. 1”), (ii) financial statements included in the 2020 Form 10-K/A No. 1, (iii) unaudited interim financial statements included in the Form 10-Q for the quarterly periods ended March 31, 2020, June 30, 2020 and September 30, 2020 as previously restated in the 2020 Form 10-K/A No. 1; (iv) unaudited interim financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, filed with the SEC on May 28, 2021; (v) unaudited interim financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, filed with the SEC on August 16, 2021; and (vi) footnote 2 to the unaudited interim financial statements and Item 4 of Part 1 included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the SEC on November 8, 2021 (collectively, the “Affected Periods”), should be restated to report all Public Shares as temporary equity and should no longer be relied upon.

As such, the Company has restated its financial statements for the 2020 Affected Periods in a Form 10-K/A, Amendment No. 2, for the Post IPO Balance Sheet and the Company's audited financial statements included in the 2020 Form 10-K/A No. 1, and the unaudited condensed financial statements for the quarterly periods ended March 31, 2020, June 30, 2020 and September 30, 2020. The Company is restating the unaudited condensed financial statements and notes, and Item 4 or Part 1 for the periods ended March 31, 2021, June 30, 2021, September 30, 2021 in this Quarterly Report on Form 10-Q/A.

~~None of the changes impacted the Company’s cash position and cash held in the trust account established in connection with the IPO.~~

After re-evaluation, the Company’s management has concluded that in light of the errors described above, a material weakness existed in the Company’s internal control over financial reporting during the Affected Periods and that the Company’s disclosure controls and procedures were not effective. The Company’s remediation plan with respect to such material weakness is described in more detail in Item 4 of Part I in this Quarterly Report on Form 10-Q/A.

~~Table of Contents~~

In addition, the Company’s Chief Executive Officer and Chief Financial Officer have provided new certifications dated as of the date of this filing in connection with this Amendment No.1. Except as disclosed above, no other information included in the Q3 2021 Form 10-Q is being amended or updated by this Amendment No.1 and this Amendment No.1 does not purposed to reflect any information or events subsequent to the Q3 2021 Form 10-Q. This Amendment No.1 continues to describe the conditions as of the date of the Q3 2021 Form 10-Q and, except as expensly contained herein, we have not updated, modified or supplemented the disclosures contained in the the Q3 2021 Form 10-Q to give effect to any subsequent events, including the closing of the Company’s business combination, accordingly, this Amendment No.1 should be need in conjuction with the Q3 2021 Form 10-Q and with on filings subsequent to the Q3 2021 Form 10-Q.

~~Table of Contents~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~Quarterly Report on Form 10-Q~~

~~TABLE OF CONTENTS~~

		~~Page~~

~~PART I – FINANCIAL INFORMATION~~
		Page
~~Item 1.~~Part I – Financial Information		~~Condensed Consolidated Financial Statements~~3				1
Item 1. Financial Statements (unaudited)		3
		Condensed Consolidated Balance Sheets as of ~~September~~June 30, ~~2021 (unaudited)~~2022 and December 31, ~~2020~~2021		9			1

	~~Unaudited~~ Condensed Consolidated Statements of Income (Operations ) for the ~~three~~Three and ~~nine months ended September~~Six Months Ended June 30, ~~2021~~2022 and ~~2020~~2021	11			2

	Condensed Consolidated Statements of Convertible Preferred Shares and Changes in ~~Stockholders’~~Stockholders' Equity ~~(Deficit)~~ (Def i cit) for the ~~three~~Three and ~~nine months ended September~~Six Months Ended June 30, ~~2021~~2022 and ~~2020~~2021	13			3

	~~Unaudited~~ Condensed Consolidated Statements of Cash Flows for the ~~nine months ended September~~Six Months Ended June 30, ~~2021~~2022 and ~~2020~~2021	15			4

	Notes to ~~Unaudited~~ Condensed Consolidated Financial Statements ~~(As Restated)~~	17			5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	36			23

Item 3.	Quantitative and Qualitative Disclosures ~~about~~About Market Risk	49			28
Item 4. Controls and Procedures					50
~~Item 4.~~Part II – Other Information		~~Control and Procedures (Restated)~~51				29
Item 1. Legal Proceedings					51
~~PART II – OTHER INFORMATION~~Item 1A. Risk Factors		51

~~Item 1.~~	~~Legal Proceedings~~		30

~~Item 1A.~~	~~Risk Factors~~		30

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	51			30

Item 3.	Defaults Upon Senior Securities	51			30

Item 4.	Mine Safety Disclosures	51			30
Item 5. Other Information		51
Item 5.6. Exhibits		~~Other Information~~52				30
Signatures		54
~~Item 6.~~	~~Exhibits~~		31

~~SIGNATURES~~			32

Table of Contents

PART I ~~- FINANCIAL INFORMATION~~

~~ITEM~~

Item 1. ~~UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

Financial Statements and Supplementary Data

THE ONCOLOGY INSTITUTE, INC.

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

CONDENSED CONSOLIDATED BALANCE SHEETS

September 30,2021

December 31, 2020

(unaudited)

Assets:




Current assets:




Cash

$
204,865

$
916,987
Prepaid expenses

82,245

152,474
Total current assets

287,110

1,069,461
Cash and investments held in Trust Account

230,012,623

230,254,149
Total Assets

$
230,299,733

$
231,323,610

Liabilities, Class A Common Stock Subject to Possible Redemption, and Stockholders' Equity (Deficit):




Current liabilities:




Accounts payable

$
961,084

$
—
Accrued expenses

2,625,925

50,000
Accrued expenses - related parties

17,500

17,500
Franchise tax payable

29,639

200,050
Total current liabilities

3,634,148

267,550
Deferred underwriting commissions

6,300,000

6,300,000
Derivative warrant liabilities

15,268,170

18,791,170
Total liabilities

25,202,318

25,358,720

Commitments and Contingencies





Class A common stock subject to possible redemption, $0.0001 par value; 23,000,000 shares at $10.00 per share as of September 30, 2021 and December 31, 2020

230,000,000

230,000,000

Stockholders' Equity (Deficit):


Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding

—

—
Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 0 non-redeemable shares issued or outstanding

—

—
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 5,750,000 shares issued and outstanding as of September 30, 2021 and December 31, 2020

575

575
Accumulated deficit

(24,903,160)

(24,035,685)
Total stockholders' equity (deficit)

(24,902,585)

(24,035,110)
Total Liabilities, Class A Common Stock Subject to Possible Redemption, and Stockholders' Equity (Deficit)

$
230,299,733

$
231,323,610

(US Dollars in thousands, except share data)

June 30, 2022 December 31, 2021
(Unaudited)
Assets
Current assets:
Cash (includes restricted cash of $0 and $875 as of June 30, 2022 and December 31, 2021) $ 64,208 $ 115,174
Accounts receivable 28,947 20,007
Other receivables 422 1,237
Inventories, net 8,580 6,438
Prepaid expenses 10,048 11,200
Total current assets 112,205 154,056
Property and equipment, net 6,014 4,192
Operating right of use assets 17,255 —
Intangible assets, net 19,383 18,245
Goodwill 34,476 26,626
Other assets 407 320
Total assets $ 189,740 $ 203,439
Liabilities and stockholders’ equity
Current liabilities:
Current portion of operating lease liabilities $ 4,486 $ —
Current portion of long-term debt — 183
Accounts payable 13,900 15,559
Income taxes payable 132 132
Accrued expenses and other current liabilities 17,610 13,924
Total current liabilities 36,128 29,798
Operating lease liabilities 14,614 —
Derivative warrant liabilities 1,589 2,193
Derivative earnout liabilities 9,778 60,018
Other non-current liabilities 3,146 6,900
Deferred income taxes liability 502 371
Total liabilities 65,757 99,280
Commitments and contingencies (Note 15) — —
Stockholders’ equity:
TOI Common shares, $0.0001 par value, authorized 500,000,000 shares; 71,980,872 and 73,249,042 shares issued and outstanding at June 30, 2022 and December 31, 2021
7 7
TOI Convertible Series A Common Equivalent Preferred Shares, $0.0001 par value, authorized 10,000,000 shares; 166,640 shares and 163,510 issued and outstanding at June 30, 2022 and December 31, 2021 — —
Additional paid-in capital 173,377 167,386
Accumulated deficit (49,401) (63,234)
Total stockholders’ equity 123,983 104,159
Total liabilities, cumulative preferred shares and stockholders’ equity $ 189,740 $ 203,439

Table of Contents
Note: The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the Company’s consolidated VIEs totaling $62,887 and $42,332 as of June 30, 2022 and December 31, 2021, respectively, and total liabilities of the Company’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaling $121,983 and $79,579 as of June 30, 2022 and December 31, 2021, respectively. See Note 17 for further details.

See accompanying notes ~~are an integral part of these unaudited~~to the condensed consolidated financial statements.

Table of Contents

THE ONCOLOGY INSTITUTE, INC.

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~UNAUDITED~~

CONDENSED CONSOLIDATED STATEMENTS OF ~~OPERATIONS~~

~~For the Three and Nine Months Ended September 30, 2021 and 2020~~

INCOME (OPERATIONS)

(US Dollars in thousands, except share data)

(Unaudited)


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Revenue
Patient services	$	39,109	$	29,786	$	74,166	$	59,408
Dispensary	20,218		17,782		38,897		35,400
Clinical trials & other	1,594		2,276		3,019		3,616
Total operating revenue	60,921		49,844		116,082		98,424
Operating expenses
Direct costs – patient services	32,875		23,574		60,253		46,660
Direct costs – dispensary	16,754		15,237		32,078		30,360
Direct costs – clinical trials & other	150		143		287		312
Selling, general and administrative expense	28,348		11,212		58,154		22,390
Depreciation and amortization	1,098		794		2,085		1,571
Total operating expenses	79,225		50,960		152,857		101,293
Loss from operations	(18,304)		(1,116)		(36,775)		(2,869)
Other non-operating expense (income)
Interest expense	61		81		135		182
Change in fair value of derivative warrant liabilities	(2,065)		—		(604)		—
Change in fair value of earnout liabilities	(10,800)		—		(50,240)		—
Gain on debt extinguishment	—		(5,186)		(183)		(5,186)
Other, net	(15)		4		136		(1,072)
Total other non-operating income	(12,819)		(5,101)		(50,756)		(6,076)
Income before provision for income (loss) taxes	(5,485)		3,985		13,981		3,207
Income tax benefit (expense)	32		(780)		(148)		(998)
Net income (loss)	$	(5,453)	$	3,205	$	13,833	$	2,209
Net income (loss) per share attributable to common stockholders:
Basic	$	(0.06)	$	0.05	$	0.15	$	0.03
Diluted	$	(0.06)	$	0.05	$	0.15	$	0.03
Weighted-average number of shares outstanding:
Basic	72,996,836		66,021,829		73,123,895		64,446,377
Diluted	72,996,836		66,021,829		76,106,201		64,446,377

For the Three Months Ended September 30,

For the Nine Months Ended September 30,

2021

2020

2021

2020
General and administrative expenses

$
1,472,921

$
95,980

$
4,141,810

$
208,562
General and administrative expenses - related party

52,500

52,500

157,500

122,500
Franchise tax expense

50,411

50,000

149,639

149,750
Loss from operations

(1,575,832)

(198,480)

(4,448,949)

(480,812)
Other income (expense)

Interest income from investments in Trust Account

5,798

73,393

58,474

194,901
Change in fair value of derivative warrant liabilities

1,138,000

(2,279,000)

3,523,000

(5,198,670)
Financing cost - derivative warrant liabilities

—

—

—

(315,080)
Loss before income tax expense

(432,034)

(2,404,087)

(867,475)

(5,799,661)
Income tax expense

—

(12,573)

—

(12,573)
Net loss

$
(432,034)

$
(2,416,660)

$
(867,475)

$
(5,812,234)

Weighted average shares outstanding of Class A common stock, basic and diluted

23,000,000

23,000,000

23,000,000

16,956,204
Basic and diluted net loss per share, Class A

$
(0.02)

$
(0.08)

$
(0.03)

$
(0.26)

Weighted average shares outstanding of Class B common stock, basic

5,750,000

5,750,000

5,750,000

5,552,920
Weighted average shares outstanding of Class B common stock, diluted

5,750,000

5,750,000

5,750,000

5,750,000
Basic and diluted net loss per share, Class B

$
(0.02)

$
(0.08)

$
(0.03)

$
(0.26)

~~The~~

See accompanying notes ~~are an integral part of these unaudited~~to the condensed consolidated financial statements.

Table of Contents

THE ONCOLOGY INSTITUTE, INC.

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

~~For the Three and Nine Months Ended September 30, 2021~~

Common Stock

Total

Class A

Class B

Additional Paid-In

Accumulated

Stockholders’


Shares

Amount

Shares

Amount

Capital

Deficit

Deficit
Balance - December 31, 2020 (as restated)

—

$
—

5,750,000

$
575

$
—

$
(24,035,685)

$
(24,035,110)
Net income

—

—

—

—

—

5,685,300

5,685,300
Balance - March 31, 2021 (unaudited) (as restated)

—

$
—

5,750,000

$
575

$
—

$
(18,350,385)

$
(18,349,810)
Net loss

—

—

—

—

—

(6,120,741)

(6,120,741)
Balance - June 30, 2021 (unaudited) (as restated)

—

$
—

5,750,000

$
575

$
—

$
(24,471,126)

$
(24,470,551)
Net loss

—

—

—

—

—

(432,034)

(432,034)
Balance - September 30, 2021 (unaudited)

—

$
—

5,750,000

$
575

$
—

$
(24,903,160)

$
(24,902,585)

(US Dollars in thousands, except share data)

(Unaudited)


	Common stock			Preferred stock
	Shares	Amount		Shares	Amount		Additional paid in capital		Retained Earnings/ (Accumulated Deficit)		Total Stockholders’ Equity (Deficit)
Balance at December 31, 2021	73,249,042	$	7	163,510	$	—	$	167,386	$	(63,234)	$	104,159
Net income	—	—		—	—		—		19,286		19,286
Issuance of common stock upon vesting of RSUs	27,188	—		—	—		—		—		—
Share-based compensation expense	—	—		—	—		8,553		—		8,553
Balance at March, 31, 2022	73,276,230	$	7	163,510	$	—	$	175,939	$	(43,948)	$	131,998
Net loss	—	—		—	—		—		(5,453)		(5,453)
Issuance of common stock upon vesting of RSUs	150,958	—					—		—		—
Issuance of common stock upon exercise of options	366,684	—		—	—		337		—		337
Exchange of common stock for preferred stock	(313,000)	—		3,130	—		—		—		—
Repurchase and retirement of common stock	(1,500,000)	—		—	—		(9,000)		—		(9,000)
Net settlement of taxes for equity awards	—	—		—	—		(413)		—		(413)
Share-based compensation expense	—	—		—	—		6,514		—		6,514
Balance at June 30, 2022	71,980,872	$	7	166,640	$	—	$	173,377	$	(49,401)	$	123,983


	Legacy TOI preferred stock			Legacy TOI common stock			Common stock			Preferred stock
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		Additional paid in capital		Retained Earnings/ (Accumulated Deficit)		Total Stockholders’ Equity (Deficit)
Balance at December, 31, 2020 (as previously reported)	11,451	$	100	—	$	—	—	$	—	—	$	—	$	294	$	(52,307)	$	(52,013)
Retroactive application of the recapitalization due to the Business Combination (refer to Note 1)	(11,451)	(100)		—	—		59,160,192	6		—	—		80,108		—		80,114
Balance at December 31, 2020, effect of Business Combination (refer to Note 1)	—	$	—	—	$	—	59,160,192	$	6	—	$	—	$	80,402	$	(52,307)	$	28,101
Net loss	—	—		—	—		—	—		—	—		—		(996)		(996)
Legacy TOI preferred stock issued and issuance of common stock	—	—		—	—		6,861,637	1		—	—		19,998		—		19,999
Share-based compensation expense	—	—		—	—		—	—		—	—		42		—		42
Balance at March, 31, 2021	—	$	—	—	$	—	66,021,829	$	7	—	$	—	$	100,442	$	(53,303)	$	47,146
Net income	—	—		—	—		—	—		—	—		—		3,205		3,205

Share-based compensation expense	—	—		—	—		—	—		—	—		51		—		51
Balance at June 30, 2021	—	$	—	—	$	—	66,021,829	$	7	—	$	—	$	100,493	$	(50,098)	$	50,402

~~For the Three and Nine Months Ended September 30, 2020~~

Common Stock

Total

Class A

Class B

Additional Paid-In

Accumulated

Stockholders'


Shares

Amount

Shares

Amount

Capital

Deficit

Equity (Deficit)
Balance - December 31, 2019

—

$
—

5,750,000

$
575

$
24,425

$
(2,300)

$
22,700
Sale of private placement warrants to Sponsor in private placement, less fair value allocation to derivative warrant liabilities

—

—

—

—

1,120,000

—

1,120,000
Accretion of Class A common stock to redemption amount

—

—

—

—

(1,144,425)

(15,693,481)

(16,837,906)
Net loss

—

—

—

—

—

(776,839)

(776,839)
Balance - March 31, 2020 (unaudited) (as restated)

—

$
—

5,750,000

$
575

$
—

$
(16,472,620)

$
(16,472,045)
Net loss

—

—

—

—

—

(2,618,735)

(2,618,735)
Balance - June 30, 2020 (unaudited) (as restated)

—

$
—

5,750,000

$
575

$
—

$
(19,091,355)

$
(19,090,780)
Net loss

—

—

—

—

—

(2,416,660)

(2,416,660)
Balance - September 30, 2020 (unaudited) (as restated)

—

$
—

5,750,000

$
575

$
—

$
(21,508,015)

$
(21,507,440)

~~The~~

See accompanying notes ~~are an integral part of these unaudited~~to the condensed consolidated financial statements.

Table of Contents

THE ONCOLOGY INSTITUTE, INC.

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~UNAUDITED~~

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

~~For the Nine Months Ended September 30, 2021 and 2020~~

(US Dollars in thousands)

(Unaudited)

For the Nine Months Ended September 30,


2021

2020
Cash Flows from Operating Activities:



Net loss

$
(867,475)

$
(5,812,234)
Adjustments to reconcile net loss to net cash used in operating activities:

Interest earned on investments held in Trust Account

(58,474)

(194,901)
Financing cost - derivative warrant liabilities

—

315,080
Change in fair value of derivative warrant liabilities

(3,523,000)

5,198,670
Changes in operating assets and liabilities:

Prepaid expenses

70,229

(202,187)
Accounts payable

961,084

1,329
Accrued expenses

2,575,925

26,500
Accrued expenses - related parties

—

17,500
Franchise tax payable

(170,411)

149,300
Net cash used in operating activities

(1,012,122)

(500,943)

Cash Flows from Investing Activities



Cash deposited in Trust Account

—

(230,000,000)
Investment income released from Trust Account for working capital

300,000

—
Net cash provided by (used in) investing activities

300,000

(230,000,000)

Cash Flows from Financing Activities:



Proceeds received from initial public offering, gross

—

230,000,000
Proceeds received from private placement

—

(4,125,486)
Offering costs paid

—

5,600,000
Net cash provided by financing activities

—

231,474,514

Net change in cash

(712,122)

973,571

Cash - beginning of the period

916,987

25,000
Cash - end of the period

$
204,865

$
998,571

Supplemental disclosure of noncash activities:



Deferred underwriting commissions in connection with the initial public offering

$
—

$
6,300,000

Six Months Ended June 30,
2022 2021
Cash flows from operating activities:
Net income $ 13,833 $ 2,209
Adjustments to reconcile net income to cash and restricted cash used in operating activities:
Depreciation and amortization 2,085 1,571
Amortization of debt issuance costs — 35
Share-based compensation 15,067 93
Decrease in fair value of liability classified warrants (604) —
Decrease in fair value of liability classified earnouts (50,240) —
Deferred taxes 131 221
Gain on debt extinguishment (183) (5,186)
Bad debt expense 259 (722)
Loss on disposal of property and equipment 14 —
Changes in operating assets and liabilities, net of business combinations:
Accounts receivable (9,200) (1,794)
Inventories (1,733) (272)
Other receivables 815 (390)
Prepaid expenses 1,152 249
Other current assets — (6,085)
Operating lease right-of-use assets 2,191 —
Other assets (86) (60)
Accrued expenses and other current liabilities 2,562 1,487
Income taxes payable — 634
Accounts payable (1,658) 951
Current and long-term operating lease liabilities (1,767) —
Other non-current liabilities 2 393
Net cash and restricted cash used in operating activities (27,360) (6,666)
Cash flows from investing activities:
Purchases of property and equipment (2,344) (1,026)
Purchases of intangible asset in practice acquisitions — (200)
Cash paid for practice acquisitions, net (8,920) (827)
Net cash and restricted cash used in investing activities (11,264) (2,053)
Cash flows from financing activities:
Payments made for financing of insurance payments (2,481) —
Payment of deferred consideration liability for acquisition (759) —
Principal payments on long-term debt — (2,094)
Principal payments on financing leases (26) (16)
Common stock repurchase (9,000) —
Common stock issuance 337 —
Taxes for common shares net settled (413) —
Issuance of Legacy TOI preferred stock — 20,000
Net cash and restricted cash (used in) provided by financing activities (12,342) 17,890
Net (decrease) increase in cash and restricted cash (50,966) 9,171
Cash and restricted cash at beginning of period 115,174 5,998
Cash and restricted cash at end of period $ 64,208 $ 15,169
Supplemental disclosure of noncash investing and financing activities:
Deferred consideration as part of practice acquisitions $ 2,000 $ 1,118
Supplemental disclosure of cash flow information:
Interest and principal forgiven from Paycheck Protection Program loans $ 183 $ 5,186
Cash paid for:
Income taxes $ 25 $ 253
Interest $ 135 $ 137

~~The~~See accompanying notes ~~are an integral part of these unaudited~~to the condensed consolidated financial statements.

Table of Contents

THE ONCOLOGY INSTITUTE, INC.

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

NOTES TO ~~UNAUDITED~~ CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ~~(As Restated)~~

(UNAUDITED)

As of June 30, 2022 and December 31, 2021 and for the three and six months ended June 30, 2022 and 2021

(US Dollars in thousands, except share data)

Note 1. ~~Organization,~~Description of the Business ~~Operations.~~

Overview of the Business

~~Incorporation~~

The Oncology Institute, Inc.~~, formerly~~ (“TOI”) is the successor entity to DFP Healthcare Acquisitions ~~Corp, (the “Company,” or “DFP”~~Corp. ("DFPH") ~~was incorporated as~~. DFPH is a Delaware corporation ~~on November 1, 2019.~~

originally formed in ~~Sponsor~~2019

~~The Company’s sponsor is DFP Sponsor LLC,~~ as a ~~Delaware limited liability~~publicly-traded special purpose acquisition company ~~(the “Sponsor”).~~

~~Business Purpose~~

~~The Company was formed~~ for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or ~~other~~ similar business combination ~~with one or more operating businesses (“~~("Business ~~Combination”~~Combination"). TOI was originally founded in 2007 and is a community oncology practice that operates value-based oncology services platforms. TOI has 3 wholly-owned subsidiaries, TOI Parent, Inc. ("TOI Parent"), TOI Acquisition, LLC (“TOI Acquisition”) and TOI Management, LLC (“TOI Management”). Additionally, TOI Management holds master services agreements with affiliated physician-owned professional entities ("TOI PCs") that confer controlling financial interest over the professional entities and their wholly-owned subsidiaries (TOI PCs, together with TOI, the “Company”).

On November 12, 2021 ("Closing Date"), the Business Combination closed following a series of mergers, which resulted in DFPH emerging as the parent of the combined entity Orion Merger Sub II, LLC and TOI Parent (together, "Legacy TOI"). DFPH was renamed “The Oncology Institute, Inc.” and common stock and "Public Warrants" continued to be listed on Nasdaq under the ticker symbols “TOI” and “TOIIW,” respectively (See Note 16).

Operationally, the Company’s medical centers provide a complete suite of medical oncology services including: physician services, in-house infusion and pharmacy, clinical trials, radiation, educational seminars, support groups, counseling, and 24/7 patient assistance. TOI’s mission is to heal and empower cancer patients through compassion, innovation and state-of-the-art medical care. The Company brings comprehensive, integrated cancer care into the community setting, including clinical trials, palliative care programs, stem cell transplants, transfusions, and other care delivery models traditionally associated with non-community-based academic and tertiary care settings. In addition, the Company, through it consolidating subsidiary Innovative Clinical Research Institute, LLC ("ICRI"), performs cancer clinical trials through a network of cancer care specialists. ICRI conducts clinical trials for a broad range of pharmaceutical and medical device companies from around the world.

The Company has ~~neither engaged~~93 oncologists and mid-level professionals across 55 clinic locations located within 5 states: California, Florida, Arizona, Nevada, and Texas. The Oncology Institute CA, a Professional Corporation ("TOI CA"), one of the TOI PCs, is comprised of the clinic locations in ~~any operations nor generated revenue to date.~~

~~As of September 30, 2021, the Company had not commenced any operations. All activity for the period from November 1, 2019 (inception) through September 30, 2021, relates to the Company’s formation~~California, Nevada, and ~~the initial public offering (the “Initial Public Offering”) described below, and since the Initial Public Offering, identifying a target company for a Business Combination.~~Arizona. The Company ~~will not generate any operating revenues until after the completion~~has contractual relationships with multiple payors, serving Medicare, including Medicare Advantage, MediCal, and commercial patients.

Note 2. Summary of ~~its initial Business Combination, at the earliest.~~ Significant Accounting Policies

Unaudited Interim Financial Information

The ~~Company generates non-operating income~~accompanying interim condensed consolidated financial statements are unaudited and have been prepared in ~~the form~~accordance with Article 10 of ~~interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering.~~

The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering, although substantially all of the net proceeds of the Initial Public Offering are intended to be generally applied toward completing a Business Combination. Furthermore, there is no assurance that the Company will be able to successfully complete a Business Combination.

~~Financing~~

~~The registration statement for the Company’s Initial Public Offering was declared effective~~Regulation S-X issued by the Securities and Exchange Commission (the “SEC”) on March 10, 2020. On March 13, 2020, the Company consummated its Initial Public Offering of 23,000,000 units (the “Units” and, with respect to the Class A common stock included in the Units being offered, the “Public Shares”), including 3,000,000 additional Units to cover over-allotments (the “Over-Allotment Units”), at $10.00 per Unit, generating gross proceeds of $230.0 million, and incurring offering costs of approximately $10.4 million, inclusive of approximately $6.3 million in deferred underwriting commissions (Note 3). Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 3,733,334 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant in a private placement to the Sponsor, generating proceeds of $5.6 million (Note 4).

~~Trust Account~~

Upon the closing of the Initial Public Offering and the Private Placement, $230.0 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a trust account (the “Trust Account”) and invested in permitted United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended, which the Company refers to as the Investment Company Act, having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act that invest only in direct U.S. government treasury obligations.

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

The Company’s second amended and restated certificate of incorporation provides that, other than the withdrawal of interest earned on the funds that may be released to the Company to pay taxes, none of the funds held in Trust Account will be released until the earlier of: (i) the completion of the Business Combination; (ii) the redemption of the Public Shares to its holders (the “Public Stockholders”) properly tendered in connection with a stockholder vote to amend the Company’s second amended and restated certificate of incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares or with respect to any other material provision relating to stockholders’ rights or pre-initial Business Combination activity, or (iii) the redemption of 100% of the Public Shares if the Company does not complete a Business Combination within 24 months from the closing of the Initial Public Offering.

The Company, after signing a definitive agreement for a Business Combination, will either (i) seek stockholder approval of the Business Combination at a meeting called for such purpose in connection with which stockholders may seek to redeem their shares, regardless of whether they vote for or against the Business Combination, for cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account calculated as of ~~two~~ business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to fund its working capital requirements (subject to an annual limit of $500,000) and/or to pay its taxes, or (ii) provide the Public Stockholders with the opportunity to sell their shares to the Company by means of a tender offer for an amount in cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account calculated as of ~~two~~ business days prior to commencement of the tender offer, including interest earned on the funds held in the Trust Account and not previously released to the Company to fund its working capital requirements (subject to an annual limit of $500,000) and/or to pay taxes. The decision as to whether the Company will seek stockholder approval of the Business Combination or will allow stockholders to sell their shares in a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would otherwise require the Company to seek stockholder approval. If the Company seeks stockholder approval, it will complete its Business Combination only if a majority of the outstanding shares of common stock voted are voted in favor of the Business Combination. However, in no event will the Company redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001.

If the Company holds a stockholder vote in connection with a Business Combination, a Public Stockholder will have the right to redeem its shares for an amount in cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to fund its working capital requirements (subject to an annual limit of $500,000) and/or to pay its taxes. As a result, such common stock is recorded at redemption amount and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with ASC 480, “Distinguishing Liabilities from Equity.” The amount in the Trust Account is initially anticipated to be $10.00 per public share ($230.0 million held in the Trust Account divided by 23,000,000 public shares).

~~The Company will have 24 months from the closing of the Initial Public Offering, or until March 13, 2022, to complete its initial Business Combination (the “ Combination Period”~~("SEC"). If the Company does not complete a Business Combination within this period of time, it will (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible, but not more than ~~ten~~ business days thereafter, redeem the Public Shares for a per share pro rata portion of the Trust Account, including interest and not previously released to the Company to fund its working capital requirements (subject to an annual limit of $500,000) (less taxes payable and up to $100,000 of such net interest to pay dissolution expenses) and (iii) as promptly as possible following such redemption, liquidate and dissolve the balance of the Company’s net assets to its remaining stockholders, as part of its plan of dissolution and liquidation. The Sponsor and the Company’s officers and directors (the “initial stockholders”) have entered into a letter agreement with the Company, pursuant to which they have waived their rights to participate in any redemption with respect to their Founder Shares (as defined below); however, if the initial stockholders acquire shares of common stock in or after the Initial Public Offering, they will be entitled to a pro rata share of the Trust Account upon the Company’s redemption of common stock or liquidation in the event the Company does not complete a Business Combination within the required time period. In the event of such a liquidating distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than the initial price per Unit in the Initial Public Offering.

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

~~Going Concern~~

~~As of September 30, 2021, the Company had approximately $0.2 million in its operating bank account and a working capital deficit of approximately $3.3 million.~~

The Company’s liquidity needs to date have been satisfied through a $25,000 contribution from the Sponsor in exchange for the issuance of the Founder Shares to the Sponsor, the Note (defined below) of $200,000 from the Sponsor, and the proceeds from the consummation of the Private Placement not held in the Trust Account. On March 13, 2020, the Company repaid the Note in full to the Sponsor. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company with Working Capital Loans (see Note 4). As of September 30, 2021, and December 31, 2020, there were no Working Capital Loans outstanding.

In connection with the Company’s assessment of going concern considerations in accordance with ASC Topic 205-40, “Presentation of Financial Statements - Going Concern,” management has determined that the liquidity condition and date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after March 13, 2022.

~~2. Basis of Presentation and Significant Accounting Policies.~~

~~Basis of Presentation and Principles of Consolidation~~

The accompanying unaudited condensed consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and ~~footnotes~~note disclosures required by ~~GAAP.~~U.S. generally accepted accounting principles ("GAAP") for complete financial statements. However, the Company believes that the disclosures are adequate to ensure the information is not misleading. In the opinion of management, ~~the unaudited condensed consolidated financial statements reflect~~ all adjustments ~~which include only~~(of normal and recurring ~~adjustments~~nature) considered necessary for fair presentation have been reflected in these interim statements. As such, the ~~fair statement of~~information included in the balances and results for the period presented. Operating results for the period for the three and nine months ended September 30, 2021, are not necessarily indicative of the results that may be expected for the period ending December 31, 2021.

The unaudited condensed consolidated financial statements of the Company include its wholly owned subsidiaries in connection with the proposed business combination (as described below). All inter-company accounts and transactions are eliminated in consolidation.

~~The~~ accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes ~~thereto~~as of, and for the year ended December 31, 2021, issued on March 11, 2022.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of TOI, its subsidiaries, all of which are controlled by TOI through majority voting control, and variable interest entities (“VIE”) for which TOI (through TOI Management) is the primary beneficiary. The Company consolidates entities in which it has a controlling financial interest based on either the variable interest entity or voting interest model. All significant intercompany balances and transactions have been eliminated in consolidation.

Table of Contents

Variable Interest Entities

The Company consolidates entities for which it has a variable interest and is determined to be the primary beneficiary. Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Company are presented as a component of total equity to distinguish between the interests of the Company and the interests of the noncontrolling owners. Revenues, expenses, and net income from these subsidiaries are included in the ~~Form 10-K/A filed by~~consolidated amounts as presented on the Condensed Consolidated Statements of Income (Operations).

The Company ~~with~~holds variable interests in clinical practices, TOI PCs, for which it cannot legally own, as a result of entering into master services agreements ("MSAs"). As of June 30, 2022, TOI held variable interest in TOI CA, The Oncology Institute FL, LLC, a Professional Corporation ("TOI FL,"), and The Oncology Institute TX, a Professional Corporation ("TOI TX"), all of which are VIEs. The Company is the ~~SEC on May 24, 2021.~~

~~Restatement of Previously Reported Financial Statements~~

~~In preparation~~primary beneficiary of the ~~Company’s unaudited condensed~~TOI PCs and thus, consolidates the TOI PCs in its financial ~~statements~~statements. As discussed in Note 17, the shareholders of the Company's consolidating VIEs own a minority of the issued and outstanding common shares of the Company.

Business Combinations

The Company accounts for all transactions that represent business combinations using the ~~quarterly period ended September 30, 2021,~~acquisition method of accounting under Accounting Standards Codification Topic No. 805, Business Combinations (“ASC 805”). Per ASC 805, the ~~Company concluded it should restate its previously issued financial statements to classify all Class A common stock subject to possible redemption~~identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in ~~temporary equity. In accordance with technical accounting guidance~~the acquired entity are recognized and measured at their fair values on ~~redeemable equity instruments in ASC 480-10-S99, redemption provisions not solely within~~ the date an entity obtains control of the ~~Company, require Class A common~~acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed, and the noncontrolling interests obtained, limited to one year from the acquisition date) are recorded when identified. Goodwill is determined as the excess of the fair value of the consideration exchanged in the acquisition over the fair value of the net assets acquired.

The DFPH-Legacy TOI Business Combination was accounted for as a reverse recapitalization. Under this method of accounting, DFPH was treated as the “acquired” company for accounting purposes and the Business Combination was treated as the equivalent of Legacy TOI issuing stock ~~subject~~for the net assets of DFPH, accompanied by a recapitalization. The net assets of DFPH are stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to ~~redemption to be classified outside~~the Business Combination were those of ~~permanent equity.~~ TOI Parent.

Segment Reporting

The Company had previously classified a portion of its Class A common stock in permanent equity. Although the Company did not specify a maximum redemption threshold, its charter currently provides that the Company will not redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001. Previously, the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. Effective with these condensed financial statements, the Company revised this interpretation to include temporary equity in net tangible assets. In connection with the change in presentation for the Class A common stock subject to possible redemption, the Company restated its earnings per share calculation to allocate income and losses shared pro rata between the two classes of shares. This presentation contemplates a Business Combination as the most likely outcome, in which case, both classes of shares participate pro rata in the income and losses of the Company.

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

In accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” and SEC Staff Accounting Bulletin No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,” the Company evaluated the corrections and has determined that the related impact was material to the previously filed financial statements that contained the error, reported in the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2021 and June 30, 2021 (the “Affected Quarterly Periods”). Therefore, the Company, in consultation with its Audit Committee, concluded that the Affected Quarterly Periods should be restated to present all Class A common stock subject to possible redemption as temporary equity and to recognize accretion from the initial book value to redemption value at the time of its Initial Public Offering. As such, the Company is reporting these restatements to those periods in this quarterly report.

~~The impact of the restatement on~~presents the financial statements ~~for~~by segment in accordance with Accounting Standard Codification Topic No. 280, Segment Reporting (“ASC 280”) to provide investors with transparency into how the ~~Affected Quarterly Periods~~chief operating decision maker (“CODM”) manages the business. The Company determined the CODM is ~~presented below.~~

its Chief Executive Officer. The ~~table below presents the effect~~CODM reviews financial information and allocates resources across 3 operating segments: patient care, dispensary, and clinical trials & other. Each of the operating segments is also a reporting segment as described further in Note 20.

Use of Estimates

The preparation of condensed consolidated financial ~~statement adjustments~~statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates under different assumptions or conditions. Significant items subject to such estimates and assumptions include judgements related to ~~the restatement discussed above~~revenue recognition, estimated accounts receivable, useful lives and recoverability of ~~the Company’s previously reported unaudited condensed balance sheet as~~long-lived and intangible assets, recoverability of ~~March 31, 2021:~~

As of March 31, 2021 (unaudited)

As Reported

Adjustment

As Restated
Total assets

$
231,036,262

$
—

$
231,036,262
Total liabilities

$
19,386,072

$
—

$
19,386,072
Class A common stock subject to possible redemption

206,650,180

23,349,820

230,000,000
Preferred stock

—

—

—
Class A common stock

233

(233)

—
Class B common stock

575

—

575
Additional paid-in capital

7,656,106

(7,656,106)

—
Accumulated deficit

(2,656,904)

(15,693,481)

(18,350,385)
Total stockholders' equity (deficit)

$
5,000,010

$
(23,349,820)

$
(18,349,810)
Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders' Equity (Deficit)

$
231,036,262

$
—

$
231,036,262
Shares of Class A common stock subject to possible redemption

20,665,018

2,334,982

23,000,000
Shares of Class A common stock

2,334,982

(2,334,982)

—

~~The impact on the unaudited condensed statement~~goodwill, fair values of ~~stockholders’ equity is consistent with the changes to the impacted stockholders’ equity accounts described above.~~

~~The table below presents the effect~~acquired identifiable assets and assumed liabilities in business combinations, fair value of ~~the financial statement adjustments~~intangible assets and goodwill, fair value of share-based compensation, fair value of liability classified instruments, and judgements related to ~~the restatement discussed above of the Company’s previously reported unaudited condensed statement of cash flows for the three months ended March 31, 2021:~~

For the Three Months Ended March 31, 2021 (unaudited)


As Reported

Adjustment

As Restated
Supplemental Disclosure of Noncash Financing Activities:






Change in value of Class A common stock subject to possible redemption

$
5,685,300

$
(5,685,300)

$
—

deferred income taxes.

Net Income (Loss) Per Share

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

The table below presents the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported unaudited condensed balance sheet as of June 30, 2021:

As of June 30, 2021 (unaudited)

As Reported

Adjustment

As Restated
Total assets

$
230,754,006

$
—

$
230,754,006
Total liabilities

$
25,224,557

$
—

$
25,224,557
Class A common stock subject to possible redemption

200,529,440

29,470,560

230,000,000
Preferred stock

—

—

—
Class A common stock

295

(295)

—
Class B common stock

575

—

575
Additional paid-in capital

13,776,784

(13,776,784)

—
Accumulated deficit

(8,777,645)

(15,693,481)

(24,471,126)
Total stockholders’ equity (deficit)

$
5,000,009

$
(29,470,560)

$
(24,470,551)
Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Equity (Deficit)

$
230,754,006

$
—

$
230,754,006
Shares of Class A common stock subject to possible redemption

20,052,944

2,947,056

23,000,000
Shares of Class A common stock

2,947,056

(2,947,056)

—

~~The impact on the unaudited condensed statement of stockholders’ equity is consistent with the changes to the impacted stockholders’ equity accounts described above.~~

For the Six Months Ended June 30, 2021 (unaudited)


As Reported

Adjustment

As Restated
Supplemental Disclosure of Noncash Financing Activities:






Change in value of Class A common stock subject to possible redemption

$
(435,440)

$
435,440

$
—

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

~~There was no impact to the reported amount of~~Basic and diluted net income (loss) ~~as reported~~per share attributable to common stockholders is presented in conformity with the ~~condensed statements of operations. The impact~~two-class method required for participating securities. Basic and diluted net income (loss) per share has been retrospectively adjusted for all periods presented prior to the ~~reported amounts~~Business Combination. The retroactive adjustment is based on the same number of weighted average shares outstanding ~~and~~in each historical period.

Table of Contents

Under the two-class method, basic and diluted ~~earnings~~net income (loss) per share attributable to common stockholders is computed by dividing the basic and diluted net income (loss) attributable to common stockholders by the basic and diluted weighted-average number of shares of common stock outstanding during the period. Diluted net income per share attributable to common stockholders adjusts basic net income per share for the potentially dilutive impact of stock options, restricted stock units, earnout shares (defined in Note 14), public warrants and private placement warrants. For periods where the Company has net losses, diluted net loss per share is the same as basic net loss per share because inclusion of potential common shares in the diluted net loss per share calculation has an antidilutive effect.

The treasury stock method is used to calculate the potentially dilutive effect of stock options, RSUs, public warrants and private placement warrants. The earnout shares are contingently issuable; therefore, the earnout shares are excluded from basic and diluted EPS until the market conditions have been met (see more detail on the earnout shares in Note 14). For the periods presented, ~~below~~the public and private placement warrants are out of the money; therefore, the public and private placement warrants are antidilutive and excluded from diluted net income per share.

Fair Value Measurements

The Company accounts for fair value measurements under Accounting Standards Codification Topic No. 820, Fair Value Measurements (“ASC 820”). The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels (see Note 7 for further discussion):

Level 1inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2inputs: Other than quoted prices included in Level 1 inputs that are observable for the ~~Affected Quarterly Periods:~~

asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3

Earnings (Loss) Per Share

As Previously

Restated

Adjustment

Restated
For the three months ended March 31, 2021 (unaudited)









Net income

$
5,685,300

$
—

$
5,685,300
Weighted average shares outstanding - Class A common stock

23,000,000

—

23,000,000
Basic and diluted earnings per share - Class A common stock

$
—

$
0.20

$
0.20
Weighted average shares outstanding - Class B common stock

5,750,000

—

5,750,000
Basic and diluted earnings per share - Class B common stock

$
0.99

$
(0.79)

$
0.20
For the three months ended June 30, 2021 (unaudited)






Net loss

$
(6,120,741)

$
—

$
(6,120,741)
Weighted average shares outstanding - Class A common stock

23,000,000

—

23,000,000
Basic and diluted earnings per share - Class A common stock

$
—

$
(0.21)

$
(0.21)
Weighted average shares outstanding - Class B common stock

5,750,000

—

5,750,000
Basic and diluted earnings per share - Class B common stock

$
(1.06)

$
0.85

$
(0.21)
For the six months ended June 30, 2021 (unaudited)






Net loss

$
(435,441)

$
—

$
(435,441)
Weighted average shares outstanding - Class A common stock

23,000,000

—

23,000,000
Basic and diluted earnings per share - Class A common stock

$
—

$
(0.02)

$
(0.02)
Weighted average shares outstanding - Class B common stock

5,750,000

—

5,750,000
Basic and diluted earnings per share - Class B common stock

$
(0.08)

$
0.06

$
(0.02)

inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

Emerging Growth Company

~~The~~

Pursuant to the Business Combination, the Company isqualifies as an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933 ~~as amended (the “Securities Act”~~("Securities Act"), as modified by the Jumpstart ~~our~~Our Business Startups Act of 2012 (the “JOBS Act”), and ~~it may~~has elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth ~~companies, including, but not limited to, not being required to comply with the auditor attestation requirements of~~companies.

Further, Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

~~Further, section~~ 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the ~~Securities~~ Exchange ~~Act of 1934, as amended)~~Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies, but any such an election to opt out is irrevocable. ~~We have~~The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, ~~we,~~the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s ~~unaudited condensed consolidated~~ financial statements with ~~those of~~ another public company which is neither an emerging growth company, nor an emerging growth company which has opted out of using the extended transition period, difficult or impossible because of the potential differences in ~~accountant~~accounting standards used.

Recently Adopted Accounting Standards

Leases

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

~~Proposed Business Combination~~

On ~~June 28, 2021,~~January 1, 2022, the Company ~~entered into an Agreement~~adopted Accounting Standards Update 2016-02, Leases, with various amendments issued in 2018 and ~~Plan of Merger (as it may be amended, supplemented or otherwise~~2019 (collectively, “ASC 842”) using the modified ~~from time~~retrospective approach, for leases that existed on January 1, 2022. ASC 842 requires lessees to time, the “Merger Agreement”) by and among DFP, Orion Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of DFP (“First Merger Sub”), Orion Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of DFP (“Second Merger Sub”) and TOI Parent, Inc., a Delaware corporation (“TOI”).

~~Refer to the Company’s Current Report on Form 8-K, and Proxy Statement/Prospectus filed with the SEC on June 29, 2021 and October 22, 2021, respectively.~~

~~Use of Estimates~~

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts ofrecognize assets and liabilities for most leases. The Company evaluates whether an arrangement is or contains a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of an identified asset for a period of time in exchange for consideration. Upon lease commencement, the date on

Table of Contents

which a lessor makes the underlying asset available to the Company for use, the Company classifies the lease as either an operating or finance lease. The Company applied certain practical expedients permitted under the transition guidance, including the package of practical expedients, which permits the Company not to reassess its prior conclusions related to lease identification, lease classification, and ~~disclosure~~initial direct costs capitalization. The Company solely acts as a lessee and its leases primarily consist of ~~contingent assets~~operating leases for its real estate in the states in which the Company operates. The Company has other operating and financing leases for various clinical and non-clinical equipment.

Generally, upon the commencement of a lease, the Company will record a right-of-use (“ROU”) asset and lease liability. An ROU asset represents the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are measured at the present value of the remaining, fixed lease payments at lease commencement. The Company uses its incremental borrowing rate, based on the information available at the later of adoption, inception, or modification in determining the present value of lease payments. ROU assets are measured at an amount equal to the initial lease liability, plus any prepaid lease payments (less any incentives received) and initial direct costs, at the lease commencement date. The Company has elected to account for lease and non-lease components as a single lease component for all underlying classes of assets. As a result, the fixed payments that would otherwise be allocable to the non-lease components are accounted for as lease payments and included in the measurement of the Company’s right-of-use asset and lease liability.

Lease arrangements with an initial term of 12 months or less are considered short-term leases and are not recorded on the balance sheet. The operating lease payments are recognized as an expense on a straight-line basis over the lease term. The lease term includes any period covered by renewal options available that the Company is reasonably certain to exercise and any options to terminate the lease that the Company is not reasonably certain to exercise.

The Company displays ROU assets, current lease liabilities, and long term lease liabilities arising from operating leases as separate line items on the condensed consolidated balance sheet. The Company includes ROU assets, current lease liabilities, and long term lease liabilities arising from finance leases within property and equipment, net; accrued expenses and other current liabilities; and other non-current liabilities. As a result of the Company's adoption of ASC 842, the Company recorded an initial adjustment to the opening balance sheet of $16,439 to operating ROU assets, $3,970 to current portion of operating lease liabilities, $13,796 to long term operating lease liabilities, $43 to property and equipment, net; $19 to other current liabilities; and $21 to other non-current liabilities. The impact of ASC 842 was not material to the Condensed Consolidated Statement of Income (Operations).

Other

In May 2021, the FASB issued Accounting Standards Update 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). The guidance in ASU 2021-04 requires the issuer to treat a modification of an equity-classified written call option that does not cause the option to become liability-classified as an exchange of the original option for a new option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the option or as termination of the original option and issuance of a new option. The Company adopted ASU 2021-04 as of January 1, 2022. The adoption of this guidance did not have a material impact on the Company’s consolidated financial position or results of operations.

Recently Issued Accounting Standards

In June 2016, the FASB issued Accounting Standards Update 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which changes the way entities recognize impairment of many financial assets by requiring immediate recognition of estimated credit losses expected to occur over their remaining life, instead of when incurred. In November 2018, the FASB issued Accounting Standard Update 2018-19, Codification Improvements to Topic 326, Financial Instruments — Credit Losses (“ASU 2018-19”), which amends Subtopic 326-20 (created by ASU 2016-13) to explicitly state that operating lease receivables are not in the scope of Subtopic 326-20. Additionally, in April 2019, the FASB issued Accounting Standard Update 2019-04, Codification Improvements to Topic 326, Financial Instruments — Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments (“ASU 2019-04”); in May 2019, the FASB issued Accounting Standards Update 2019-05, Financial Instruments — Credit Losses (Topic 326): Targeted Transition Relief (“ASU 2019-05”); and in November 2019, the FASB issued Accounting Standards Update 2019-10, Financial Instruments — Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates and ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments — Credit Losses (“ASU 2019-10”), to provide further clarifications on certain aspects of ASU 2016-13 and to extend the nonpublic entity effective date of ASU 2016-13. The changes (as amended) are effective for the ~~unaudited condensed~~Company for annual and interim periods in fiscal years beginning after December 15, 2022. An entity may early adopt ASU 2016-13, as amended, for annual and interim periods in fiscal years beginning after

Table of Contents

December 15, 2018. While the Company expects its allowance for credit losses to increase upon adoption of ASU 2016-13, the Company does not expect the adoption of ASU 2016-13 to have a material effect on its consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which amends ASC 740, Income Taxes. This new standard is intended to simplify accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and amending existing guidance to improve consistent application of ASC 740. The new standard is effective for the Company beginning January 1, 2022, and for interim periods beginning January 1, 2023. The guidance in the new standard has various elements, some of which are applied on a prospective basis and others on a retrospective basis with earlier application permitted. The Company is currently evaluating the effect of ASU 2019-12 on the Company’s consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these unaudited condensed financial statements is the determination of the fair value of the derivative warrant liabilities. Accordingly, the actual results could differ significantly from those estimates.

~~Concentration of Credit Risk~~related disclosures.

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation limit of $250,000, and investments held in Trust Account. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

~~Investments Held in Trust Account~~

The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income on investments held in the Trust Account in the accompanying unaudited condensed consolidated statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

~~Cash and Cash Equivalents~~

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had 0 cash equivalents as of September 30, 2021 and December 31, 2020.

~~Fair Value of Financial Instruments~~

The fair value of the Company’s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements,” equal or approximate the carrying amounts represented in the condensed consolidated balance sheets.

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

~~Fair Value Measurements~~

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of:

●

~~Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;~~

●

Level 2: Quoted prices in markets that are not active or financial instruments for which significant inputs to models are observable (including but not limited to quoted prices for similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly or indirectly;

●

~~Level 3: Prices or valuations that require significant unobservable inputs (including the Management’s assumptions in determining fair value measurement).~~

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

As of September 30, 2021, the carrying values of cash, accounts payable, accrued expenses, prepaid expenses and franchise tax payable approximate their fair values due to the short-term nature of the instruments. The Company’s investments held in Trust Account are comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less or investments in money market funds that comprise only U.S. Treasury securities and are recognized at fair value. The fair value of investments held in Trust Account is determined using quoted prices in active markets.

~~Derivative Warrant Liabilities~~

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

The 5,750,000 Public Warrants and the 3,733,334 Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s unaudited condensed consolidated statements of operations. The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model and subsequently, the fair value of the Private Placement Warrants have been estimated using a Monte Carlo simulation model each measurement date. The fair value of Public Warrants issued in connection with the Initial Public Offering have subsequently been measured based on the listed market price of such warrants.

~~Offering Costs Associated with the Initial Public Offering~~

Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liabilities were expensed as incurred and presented as non-operating expenses in the condensed statements of operations.

Offering costs associated with the Class A common stock issued were charged against the carrying value of the shares of Class A common stock upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.

~~Class A Common Stock Subject to Possible Redemption~~

The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Shares of Class A common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Shares of conditionally redeemable Class A common stock (including Class A common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, shares of Class A common stock are classified as stockholders’ equity. The Company’s Class A common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of September 30, 2021, and December 31, 2020, 23,000,000 shares of Class A common stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ equity section of the Company’s condensed consolidated balance sheets.

Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit.

~~Net Income (Loss) Per Share of Common Stock~~

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A common stock and Class B common stock. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per share of common stock is calculated by dividing the net income (loss) by the weighted average shares of common stock outstanding for the respective period.

The calculation of diluted net income (loss) per share of common stock does not consider the effect of the warrants issued in connection with the Initial Public Offering and the Private Placement to purchase an aggregate of 9,483,334 shares of common stock in the calculation of diluted income (loss) per share, because their exercise is contingent upon future events and their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted net income (loss) per share is the same as basic net income (loss) per share of common stock for the three and nine months ended September 30, 2021 and 2020. Accretion associated with the redeemable Class A common stock is excluded from earnings per share as the redemption value approximates fair value.

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

~~The following table presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of common stock:~~

For the Three Months Ended September 30,
For the Nine Months Ended September 30


2021

2020

2021

2020



Class A

Class B

Class A

Class B

Class A

Class B

Class A

Class B

Basic and diluted net income (loss) per share of common stock:



Numerator:

Allocation of net income - basic

$
(345,627)

$
(86,407)

$
(1,933,328)

$
(483,332)

$
(693,980)

$
(173,495)

$
(4,378,377)

$
(1,433,857)

Allocation of net income - diluted

$
(345,627)

$
(86,407)

$
(1,933,328)

$
(483,332)

$
(693,980)

$
(173,495)

$
(4,340,374)

$
(1,471,860)

Denominator:

















Basic weighted average common shares outstanding

23,000,000

5,750,000

23,000,000

5,750,000

23,000,000

5,750,000

16,956,204

5,552,920

Diluted weighted average common shares outstanding

23,000,000

5,750,000

23,000,000

5,750,000

23,000,000

5,750,000

16,956,204

5,750,000

Basic net income (loss) per share of common stock

$
(0.02)

$
(0.02)

$
(0.08)

$
(0.08)

$
(0.03)

$
(0.03)

$
(0.26)

$
(0.26)

Diluted net income (loss) per share of common stock

$
(0.02)

$
(0.02)

$
(0.08)

$
(0.08)

$
(0.03)

$
(0.03)

$
(0.26)

$
(0.26)

~~Income Taxes~~

The Company complies with the accounting and reporting requirements of Financial Accounting Standards Board Accounting Standard Codification, or ASC, 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

There were 0 unrecognized tax benefits as of September 30, 2021, and as of December 31, 2020. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. NaN amounts were accrued for the payment of interest and penalties as of September 30, 2021, and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

~~Recent Accounting Pronouncements~~

In August 2020, the ~~Financial Accounting Standards Board~~FASB issued ~~Accounting Standard Update (“ASU”) No.~~ASU 2020-06, ~~Debt—Debt~~Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and ~~Hedging—Contracts~~Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity ("ASU 2020-06"), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ~~The~~ ASU 2020-06 also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. The new standard is effective for the Company beginning January 1, 2024. The Company is currently evaluating the effect of ASU 2020-06 on the Company’s consolidated financial statements and related disclosures.

In October 2021, the FASB issued ASU 2021-08, Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers ("ASU 2021-08"). Under ASU 2021-08, an acquirer must recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606. The guidance is effective for interim and annual periods beginning after December 15, 2023, with early ~~adopted the~~adoption permitted. The Company will adopt ASU 2021-08 on January 1, ~~2021. Adoption~~2024 on a prospective basis. The Company does not expect the adoption of ~~the ASU did not~~this standard to have a material impact on the Company’s consolidated financial statements and related disclosures.

Note 3. Significant Risks and Uncertainties Including Business and Credit Concentrations

Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and accounts receivable.

Cash accounts in a financial institution may, at times, exceed the Federal Deposit Insurance Corporation (“FDIC”) coverage of $250 per account ownership category. The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on such accounts.

The Company’s accounts receivable has implicit collection risk. The Company grants credit without collateral to their patients, most of whom are local residents and are insured under third-party payor agreements. The Company believes this risk is partially mitigated by the Company’s establishment of long-term agreements and relationships with third-party payors that provide the Company with insight into historic collectability and improve the collections process.

Revenue Concentration Risk

The concentration of net revenue on a percentage basis for major payors for the three and six months ended June 30, 2022 and 2021 are as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Percentage of Net Revenue:
Payor A	14	%	17	%	15	%	17	%
Payor B	17	%	14	%	17	%	14	%

The concentration of gross receivables on a percentage basis for major payors at June 30, 2022 and December 31, 2021 are as follows:

Table of Contents


	June 30, 2022		December 31, 2021
Percentage of Gross Receivables:
Payor B	19	%	19	%
Payor C	13	%	14	%

All of the Company’s revenue is generated from customers located in the United States.

Vendor Concentration Risk

The concentration of cost of sales on a percentage basis for major vendors for the three and six months ended June 30, 2022 and 2021 are as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Percentage of Cost of Sales:
Vendor A	55	%	50	%	54	%	49	%
Vendor B	43	%	48	%	44	%	49	%

The concentration of gross payables on a percentage basis for major payors at June 30, 2022 and December 31, 2021 are as follows:


	June 30, 2022		December 31, 2021
Percentage of Gross Payables:
Vendor B	45	%	47	%
Vendor A	33	%	39	%

COVID-19 Pandemic

In January 2020, the Secretary of the U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel strain of coronavirus (“COVID-19”). In March 2020, the World Health Organization declared the outbreak of COVID-19, a disease caused by this coronavirus, a pandemic. The resulting measures to contain the spread and impact of COVID-19 and other developments related to COVID-19 have affected the Company’s results of operations during 2022. Where applicable, the impact resulting from the COVID-19 pandemic during the three and six months ended June 30, 2022 has been considered, including updated assessments of the recoverability of assets and evaluation of potential credit losses. As a result of the COVID-19 pandemic, federal and state governments have passed legislation, promulgated regulations, and taken other administrative actions intended to assist healthcare providers in providing care to COVID-19 and other patients during the public health emergency. Sources of relief include the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020, the Paycheck Protection Program and Health Care Enhancement Act (the “PPPHCE Act”), which was enacted on April 24, 2020, and the Consolidated Appropriations Act, 2021 (the “CAA”), which was enacted on December 27, 2020. In total, the CARES Act, PPPHCE Act and the CAA authorize $178,000,000 in funding to be distributed to hospitals and other healthcare providers through the Public Health and Social Services Emergency Fund (the “PHSSEF”). In addition, the CARES Act provides for an expansion of the Medicare Accelerated and Advance Payment Program whereby inpatient acute care hospitals and other eligible providers were able to request accelerated payment of up to 100% of their Medicare payment amount for a six-month period to be repaid through withholding of future Medicare fee-for-service payments. Various other state and local programs also exist to provide relief, either independently or through distribution of monies received via the CARES Act. During the year ended December 31, 2021, the Company was a beneficiary of these stimulus measures. The Company’s accounting policies for the recognition of these stimulus monies is as follows.

The Company directly received $4,993 in Paycheck Protection Program (“PPP”) loans under the CARES Act and indirectly received an additional $332 in PPP loans through acquisitions (see Note 16). PPP loans may be eligible for forgiveness if the funds were used for eligible payroll costs, payments on business mortgage interest payments, rent, or utilities during either the 8- or 24-week period after disbursement. The Company elected to account for the loans as current debt until such loans were forgiven. Forgiveness for $5,142 of the PPP loans was received during the year ended December 31, 2021. As of June 30, 2022, the balance of all PPP loans has been forgiven. As such, the Company recognized the loan principal balance and accrued interest as a gain on debt extinguishment in the Condensed Consolidated Statement of Income (Operations).

Table of Contents

The Company received $2,727 from CMS under the Accelerated and Advance Payment Program which is an advance on future Medicare payments and will be recouped from future payments due to the Company by Medicare after 120 days. Effective October 1, 2020, the program was amended such that providers are required to repay accelerated payments beginning one year after the payment was issued. After such one-year period, Medicare payments owed to providers will be recouped against Medicare payments according to the repayment terms. As of December 31, 2021, the Medicare accelerated payments are reflected within accrued expenses and other current liabilities in the condensed consolidated balance sheets.As of June 30, 2022, the Company repaid all advances received from CMS under the Accelerated and Advance Payment Program.

The Company received funding from United States Department of HHS as part of the Provider Relief Funding under the CARES Act. Provider Relief Funding is paid in the form of a grant and does not require repayment if used to cover lost revenue, as defined, attributable to COVID-19 and healthcare-related expenses, as defined, including qualifying direct labor, paid or purchased to prevent, prepare for, and respond to COVID-19. Under International Accounting Standard No. 20, Accounting for Government Grants (“IAS 20”), grants are recognized when an entity has reasonable assurance that 1) it will comply with the relevant conditions and 2) the grant will be received. The Company recognized $0 in other income related to the HHS funding during the three and six months ended June 30, 2022, and recognized $1,023 in other income related to HHS funding during the three and six months ended June 30, 2021 by applying IAS 20 by analogy.

Note 4. Accounts Receivable and Notes Receivable

The Company’s accounts receivable consists primarily of amounts due from third-party payors and patients. See Note 2 for a summary of the Company’s policies relating to accounts receivable.

Accounts Receivable as of June 30, 2022 and December 31, 2021 consist of the following:


(in thousands)	June 30, 2022		December 31, 2021
Oral drug accounts receivable	$	2,933	$	2,097
Capitated accounts receivable	518		665
FFS accounts receivable	19,985		12,530
Clinical trials accounts receivable	2,029		1,823
Other trade receivables	3,482		2,892
Total	$	28,947	$	20,007

During the three and six months ended June 30, 2022, the Company had net reversals of bad debt recoveries of $105 and $82, respectively and bad debt expense of $0, and $177, respectively. Bad debt write-offs were a result of accounts receivable on completed contracts that were deemed uncollectible during the period due to delayed collection efforts. During the three and six months ended June 30, 2021, the Company had bad debt recoveries of $722. There was no bad debt expense recognized during the three and six months ended June 30, 2021.

Note 5. Revenue

Management recognizes revenue in accordance with ASC 606 on the basis of its satisfaction of outstanding performance obligations. Management typically fulfills its performance obligations over time, either over the course of a single treatment (FFS), a month (capitation), or a number of months (clinical research). Management also has revenue that is satisfied at a point in time (dispensary). See Note 2 for summary of the Company’s policies and significant assumptions related to revenue recognition.

Disaggregation of Revenue

The Company categorizes revenue based on various factors such as the nature of contracts, payors, order to billing arrangements, and cash flows received by the Company, as follows:

Table of Contents


(in thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Patient services
Capitated revenue	$	13,944	$	12,897	$	28,460	$	25,227
FFS revenue	25,165		16,889		45,706		34,181
Subtotal	39,109		29,786		74,166		59,408
Dispensary revenue	20,218		17,782		38,897		35,400
Clinical research trials and other revenue	1,594		2,276		3,019		3,616
Total	$	60,921	$	49,844	$	116,082	$	98,424

Refer to Note 20 for Segment Reporting for disaggregation of revenue by reporting segment.

Contract Asset and Liabilities

Under ASC 606, contract assets represent rights to payment for performance contingent on something other than the passage of time and accounts receivable are rights to payment for performance without contingencies. The Company does not have any contract assets as of June 30, 2022 and December 31, 2021. Refer to Note 4 for accounts receivable as of June 30, 2022 and December 31, 2021.

Contract liabilities represent cash that has been received for contracts, but for which performance is still unsatisfied. As of June 30, 2022 and December 31, 2021, contract liabilities amounted to $1,348 and $220, respectively. Contract liabilities are included within other current liabilities and presented in Note 9 along with refund liabilities due to materiality.

Remaining Unsatisfied Performance Obligations

The accounting terms for the Company’s patient services and dispensary contracts do not extend past a year in duration. Additionally, the Company applies the ‘as invoiced’ practical expedient to its clinical research contracts.

Note 6. Inventories

The Company purchases intravenous chemotherapy drugs and oral prescription drugs from various suppliers. See Note 2 for a summary of the Company’s policies relating to intravenous chemotherapy and oral prescription drugs inventory.

The Company’s inventories as of June 30, 2022 and December 31, 2021 were as follows:


(in thousands)	June 30, 2022		December 31, 2021
Oral drug inventory	$	2,877	$	1,484
IV drug inventory	5,703		4,954
Total	$	8,580	$	6,438

Note 7. Fair Value Measurements and Hierarchy

See Note 2 for a summary of the Company’s policies relating to fair value measurements.

The following table presents the carrying amounts of the Company’s financial ~~position, results of operations or cash flows.~~

The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying unaudited condensed consolidated financial statements.

instruments at June 30, 2022 and December 31, 2021:

Table of Contents

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

~~3. Initial Public Offering.~~

(in thousands) June 30, 2022 December 31, 2021
Financial assets:
Cash and restricted cash $ 64,208 $ 115,174
Accounts receivable 28,947 20,007
Other receivables 422 1,237
Financial liabilities:
Accounts payable $ 13,900 $ 15,559
Derivative warrant liabilities 1,589 2,193
Earnout liabilities 9,778 60,018

~~Public Units~~

~~On March 13, 2020,~~

The carrying amounts of cash, accounts receivable, other receivables, and accounts payable approximate fair value because of the ~~Company consummated its Initial Public Offering~~short maturity and high liquidity of ~~23,000,000 Units, including 3,000,000 Over-Allotment Units,~~these instruments.

The following table presents information about the Company’s Level 3 liabilities that are measured at ~~$10.00 per Unit, generating gross proceeds~~fair value on a recurring basis at June 30, 2022:


(in thousands)	Derivative Warrant Liability		Earnout Liability




Balance at December 31, 2021	$	2,193	$	60,018
Change in fair value included in other expense	(604)		(50,240)
Balance at June 30, 2022	$	1,589	$	9,778

The derivative warrant and earnout liabilities were valued using a Binomial Lattice and Monte-Carlo Simulation Model, respectively, which are considered to be Level 3 fair value measurements. The primary unobservable input utilized in determining the fair value of ~~$230.0 million,~~the warrant and ~~incurring offering costs~~earnouts is the expected volatility of ~~approximately $10.4 million, inclusive~~the common stock. A summary of ~~approximately $6.3 million~~the inputs used in ~~deferred underwriting commissions. Of~~valuing the ~~Units sold~~derivative warrant and earnout liabilities is as follows:


	June 30, 2022									December 31, 2021
	Derivative Warrant Liability			First Tranche Earnout			Second Tranche Earnout			Derivative Warrant Liability			First Tranche Earnout			Second Tranche Earnout
Unit price	$	5.06		$	5.06		$	5.06		$	9.75		$	9.75		$	9.75
Term (in years)	4.37			1.36			1.75			4.87			1.87			2.87
Volatility	37.40		%	45.00		%	45.00		%	12.80		%	35.00		%	35.00		%
Risk-free rate	2.98		%	2.95		%	2.95		%	1.24		%	0.94		%	0.94		%
Dividend yield	—			—			—			—			—			—
Cost of equity	—			14.00		%	14.00		%	—			11.14		%	11.14		%

There wereno transfers between fair value measurement levels during the three and six months ended June 30, 2022 and 2021.

Uncertainty of Fair Value Measurement from Use of Significant Unobservable Inputs

The inputs to estimate the fair value of the Company’s derivative warrant and earnout liabilities were the market price of the Company’s common stock, their remaining expected term, the volatility of the Company’s common stock price and the risk-free interest rate over the expected term. Significant changes in any of those inputs in isolation can result in a significant change in the Initial Public Offering, 5,000,000 Units were purchased by certain domestic private pooled investment vehicles managed by Deerfield Management Company, L.P. and its affiliates (the “Deerfield Funds”).

~~Each Unit consists of 1~~fair value measurement.

Generally, an increase in the market price of the Company’s shares of ~~Class A~~ common stock, ~~$0.0001~~an increase in the volatility of the Company’s shares of common stock, and an increase in the remaining term of the derivative liabilities would each result in a directionally similar change in the estimated fair value of the Company’s derivative liabilities. Such changes would increase the associated liability while decreases in these assumptions would decrease the associated liability. An increase in the risk-free interest rate would result in a decrease in the estimated fair value measurement and thus a decrease in the associated liability.

Table of Contents

The Company has not, and does not plan to, declare dividends on its common stock and, as such, there is no change in the estimated fair value of the derivative warrant liabilities due to the dividend assumption.

Note 8. Property and Equipment, Net

The Company accounts for property and equipment at historical cost less accumulated depreciation. See Note 2 for a summary of the Company’s policies relating to property and equipment.

Property and equipment, net, consist of the following:


(in thousands)	Useful lives	June 30, 2022		December 31, 2021
Computers and software	60 months	$	1,233	$	961
Office furniture	80 months	531		343
Leasehold improvements	Shorter of lease term or estimated useful life	4,706		3,387
Medical equipment	60 months	981		805
Construction in progress		1,011		518
Finance lease ROU assets	Shorter of lease term or estimated useful life	205		162
Less: accumulated depreciation		(2,653)		(1,984)
Total property and equipment, net		$	6,014	$	4,192

Depreciation expense for the three months ended June 30, 2022 and 2021 was $359 and $173, respectively. Depreciation expense for the six months ended June 30, 2022 and 2021 was $673 and $338, respectively.

Note 9. Accrued Expenses and Other Current and Non-Current Liabilities

Accrued expenses and other current liabilities as of June 30, 2022 and December 31, 2021 consist of the following:


(in thousands)	June 30, 2022		December 31, 2021
Compensation, including bonuses, fringe benefits, and payroll taxes	$	4,279	$	3,325
Contract liabilities	1,348		262
Directors and officers insurance premiums	5,104		5,009
Deferred acquisition consideration (see Note 16)	3,459		2,359
Other liabilities	3,420		2,969
Total accrued expenses and other current liabilities	$	17,610	$	13,924

Contract liabilities as of June 30, 2022 and December 31, 2021 consist of cumulative adjustments made to capitated revenue recognized in prior periods.

Pursuant to the Business Combination, the Company has agreed to indemnify members of the Board and certain officers if they are named or threatened to be named as a party to any proceeding by reason of the fact that they acted in such capacity. The Company entered into a financing arrangement to pay premiums for directors’ and officers’ (“D&O”) insurance coverage to protect against such losses on November 12, 2021. As of June 30, 2022, the remaining D&O principal balance was $5,538, of which $434 is due to be paid after June 30, 2023 and classified as an other non-current liability. Additionally, the Company includes $2,550 of deferred consideration arising from acquisitions in other non-current liabilities to reflect when the deferred consideration will be paid (see Note 16 for details).

Note 10. Leases

The Company leases clinics, office buildings, and certain equipment under noncancellable financing and operating lease agreements that expire at various dates through November 2031. See Note 2 for a summary of the Company’s policies relating to leases.

The initial terms of operating leases range from 0 to 10 years and certain leases provide for free rent periods, periodic rent increases, and renewal options. Monthly payments for these leases range from $0 to $37. All lease agreements generally require the Company to pay maintenance, repairs, property taxes, and insurance costs, which are generally variable amounts based on actual costs incurred during each applicable period.

Table of Contents

Lease Expense

The components of lease expense were as follows for the three and six months ended June 30, 2022:


(in thousands)	Three Months Ended June 30, 2022		Six Months Ended June 30, 2022

Operating lease costs:	$	1,249	$	2,416
Finance lease costs:
Amortization of ROU asset	$	13	$	27
Interest expense	$	1	$	3
Other lease costs:
Short-term lease costs	$	103	$	212
Variable lease costs	$	222	$	427

Operating and other lease costs are presented as part of selling, general, and administrative expenses. The components of finance lease costs appear in depreciation and amortization and interest expense.

Maturity of Lease Liabilities

The aggregate future lease payments for the Company's leases in years subsequent to June 30, 2022 are as follows:


(in thousands)	Operating Leases		Finance Leases
2022	$	2,604	$	28
2023	4,965		46
2024	4,324		38
2025	3,561		4
2026	2,659		1
Thereafter	3,246		—
Total future lease payment	$	21,359	$	117
Less: amount representing interest	(2,259)		(6)
Present value of future lease payment (lease liability)	$	19,100	$	111
Reported as:
Lease liabilities, current	$	4,486	$	47
Lease liabilities, noncurrent	14,614		64
Total lease liabilities	$	19,100	$	111

Lease Term and Discount Rate

The following table provides the weighted average remaining lease terms and weighted average discount rates for the Company's leases as of June 30, 2022:


	June 30, 2022
Weighted-average remaining lease term (in years)
Operating	4.90
Finance	2.37
Weighted-average discount rate
Operating	4.17	%
Finance	4.42	%

Table of Contents

Supplemental Cash Flow Information

The following table provides certain cash flow and supplemental noncash information related to the Company's lease liabilities for the three and six months ended June 30, 2022.


(in thousands)	Six Months Ended June 30, 2022
Supplemental cash flow information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payment from operating leases	$	2,382
Financing cash payments for finance leases	31
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	20,347
Finance leases	40

Lease Modifications

During the three months ended June 30, 2022, the Company expanded its lease space and extended its lease term for a clinic in California, with a revised end date of April 1, 2029. This expansion and extension constitute a lease modification that qualifies as a change of accounting for the original lease and not a separate contract. Accordingly, in the three months ended June 30, 2022, the Company recognized the difference of $531 as an increase to the operating lease liability, and $531 as an increase to operating lease right-of-use asset. The modification did not affect rent expense.

During the six months ended June 30, 2022, the Company expanded its lease space and extended its lease term for two clinics in California. These expansions and extensions constitute lease modifications that qualify as a change of accounting for the original leases and not separate contracts. Accordingly, in the six months ended June 30, 2022, the Company recognized the difference of $1,306 as an increase to the operating lease liability; $1,213, net of lease incentives, as an increase to operating lease right-of-use asset, and $3 as a decrease to rent expense.

Note 11. Debt

The Company recorded a PPP loan as a result of the acquisition of the practice of Leo E. Orr, MD on November 12, 2021 with Pacific Western Bank in the amount of $183, with interest bearing at 1%. The maturity date of the loan is October 24, 2026. The application for the PPP funds required an entity to, in good faith, certify that the current economic uncertainty made the loan request necessary to support the ongoing operations of the entity. This certification further required the entity to take into account its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. The receipt of these funds, and the forgiveness of the loan attendant to these funds, is dependent on the entity having initially qualified for the loan and qualifying for the forgiveness of such loan based on its future adherence to the forgiveness criteria. During the six months ended June 30, 2022, the Company received notice of forgiveness of its PPP loan and accordingly has recognized the loan principal balance and accrued interest as a gain on debt extinguishment in the Condensed Consolidated Statement of Income (Operations).

Note 12. Income Taxes

The Company recorded income tax benefit of $32 for the three months ended June 30, 2022, and income tax expense of $148 for the six months ended June 30, 2022, as compared to income tax expense of $780 for the three months ended June 30, 2021, and income tax expense of $998 for the six months ended June 30, 2021. The decrease of $812 and $850, respectively, in income tax expenseis primarily related to the corresponding increase in the valuation allowance for TOI. The Company's effective tax rate decreased to 1.06% for the six months ended June 30, 2022, from 31.12% for the six months ended June 30, 2021, primarily due to the increase of the valuation allowance.

The Company's effective tax rate for the six months ended June 30, 2022, was different than the U.S. federal statutory tax rate of 21.00%, primarily due to the increased valuation allowance, partially offset by the tax effect of the change in fair market value of the warrant and earn out liability, non-deductible transaction costs, and Section 162(m) limitation on compensation for covered employees, which is not taxable for federal income tax purposes.

Table of Contents

Note 13. Stockholders' Equity

The Condensed Consolidated Statements of Preferred Shares and Changes in Stockholders’ Equity (Deficit) has been retroactively adjusted for all periods presented to reflect the Business Combination and reverse recapitalization described in Note 1. The balances as of June 30, 2021 from the condensed consolidated financial statements of Legacy TOI as of that date, share activity (Legacy TOI preferred stock, Legacy TOI common stock, and additional paid-in capital) and per share amounts were retroactively adjusted, where applicable, using the Common Stock Exchange Ratio.

Common Stock

Upon the Closing Date of the Business Combination on November 12, 2021, pursuant to the terms of the Amended and Restated Certificate of Incorporation, the Company authorized 500,000,000 shares of common stock with a par value of $0.0001. As of June 30, 2022 and December 31, 2021, there were 71,980,872 and 73,249,042 shares, respectively, of common stock outstanding.

In connection with the Closing Date, all previously issued and outstanding shares of Legacy TOI preferred stock were converted into Legacy TOI common stock and received i) shares of Company common stock pursuant to a 591:1 ratio of Company common shares to Legacy TOI common shares (the "Common Stock Exchange Ratio") and ii) cash. The Company has retroactively adjusted shares issued and outstanding prior to November 11, 2021 to give effect to the Common Stock Exchange Ratio to determine the number of shares of common stock into which they were converted.

Voting

The holders of the Company’s common stock are entitled to 1 vote for each share of common stock held at all meetings of stockholders (and written actions in lieu of meetings), and there is no cumulative voting.

Dividends

Common stockholders are entitled to receive dividends whenever funds are legally available and when declared by the board of directors. No dividends have been declared as of June 30, 2022.

Preferred Stock

Upon the Closing Date of the Business Combination, pursuant to the terms of the Amended and Restated Certificate of Incorporation, the Company authorized 10,000,000 shares of Series A Common Equivalent Preferred Stock (“preferred stock”) with a par value and ~~one-fourth~~liquidation preference of $0.0001 per share. The Company’s board of directors has the authority, without further action by the stockholders to issue such shares of preferred stock in one ~~redeemable~~or more series, to establish, from time to time the number of shares to be included in each such series, and to fix the dividend, voting, and other rights, preferences, and privileges of the shares. Immediately following the Closing Date and as of December 31, 2021, there were 163,510 shares of preferred stock outstanding. As of June 30, 2022, there were 166,640 shares of preferred stock outstanding.

Conversion

Each share of preferred stock is convertible, at any time on the part of the holder except with respect to the Beneficial Ownership Limitation (defined below), into 100 shares of common stock.

Blocker/Beneficial Ownership Limitation

The preferred stock is subject to a beneficial ownership limitation such that the preferred stock may not, at any time, be convertible into more than 4.9% of the total number of shares of common stock outstanding (“Beneficial Ownership Limitation”).

Voting

The holders of preferred stock do not have voting rights in the Company.

Dividends

The holders of preferred stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors on an as-converted basis. No dividends have been declared as of June 30, 2022.

Table of Contents

Assumed Public Warrants and Private Placement Warrants

Following the consummation of the Business Combination, holders of the public warrants and private placement warrants are entitled to acquire common stock of the Company. The warrants became exercisable 30 days from the completion of the Business Combination, on December 12, 2021, and will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation. As of June 30, 2022, there are 5,749,986 public warrants outstanding and 3,177,542 private placement warrants outstanding.

Each warrant ~~(the “Warrants”). Each whole Warrant~~ entitles the holder to purchase 1 share of ~~Class A~~ common stock ~~at a price of~~for $11.50 per share. ~~The exercise price and number of shares of Class A common stock issuable upon exercise of~~Private warrants held by the ~~Warrants~~initial purchaser or certain permitted transferees may be ~~adjusted in certain circumstances including in~~exercised on a cashless basis.

If the ~~event of a stock dividend, or recapitalization, reorganization, merger or consolidation.~~

~~4. Related Party Transactions.~~

~~Founder Shares~~

On December 30, 2019, the Sponsor received 4,312,500 shares of Class B common stock (the “Founder Shares”) in exchange for a capital contribution of $25,000, or approximately $0.004 per share. In January 2020, the Sponsor transferred 100,000 Founder Shares to each of Steven Hochberg, the Company’s President and Chief Executive Officer, ~~Christopher Wolfe, the Company’s Chief Financial Officer and Secretary, and~~ ~~Richard Barasch, the Company’s Executive Chairman, and 30,000 Founder Shares to each of Dr. Jennifer Carter,~~ ~~Dr. Mohit Kaushal~~ ~~and~~ ~~Dr. Gregory Sorensen~~, the Company’s independent director nominees, for the same per-share price initially paid by the Sponsor, resulting in the Sponsor holding 3,922,500 Founder Shares. On February 19, 2020, the Company effected a split of its Class B common stock resulting in the Sponsor holding 5,360,000 Founder Shares, resulting in an increase in the total number of Founder Shares from 4,312,500 to 5,750,000.

The Founder Shares are identical to the shares of Class A common stock included in the Units being sold in the Initial Public Offering except that the Founder Shares are subject to certain transfer restrictions.

The initial stockholders have agreed not to transfer, assign or sell any of their Founder Shares until the earlier of (A) one year after the completion of the Company’s initial Business Combination, or earlier if, subsequent to the Company’s initial Business Combination, the closingreported last sale price of the ~~Company’s~~ common stock equals or exceeds ~~$12.00~~$18.00 per share ~~(as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like)~~ for any 20 trading days within ~~any~~ 30~~-trading~~a 30-trading day period ~~commencing at least 150~~ending 3 business days ~~after the Company’s initial Business Combination and (B) the date on which~~before the Company ~~completes a liquidation, merger, capital stock exchange or other similar transaction after~~sends the ~~initial Business Combination that results in all~~notice of redemption to the ~~Company’s stockholders having the right to exchange their common stock for cash, securities or other property.~~

~~Private Placement Warrants~~

~~Simultaneously with the closing of the Initial Public Offering,~~warrant holders, the Company ~~sold 3,733,334 Private Placement Warrants to~~may redeem all the ~~Sponsor~~public warrants at a price of ~~$1.50~~$0.01 per ~~Private Placement Warrant in a Private Placement, generating proceeds of $5.6 million.~~

Each Private Placement Warrant entitles the holder to purchase 1 share of Class A common stock at $11.50 per share. Certain proceeds of the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. warrant upon not less than 30 days’ prior written notice.

If the Company ~~does not complete a Business Combination,~~calls the ~~proceeds of the Private Placement~~public warrants for redemption, management will ~~be part of the liquidating distribution to the Public Stockholders and the Warrants issued to the Sponsor will expire worthless.~~

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

~~Sponsor Loan~~

The Sponsor agreed to loan the Company up to an aggregate of $200,000 by the issuance of an unsecured promissory note (the “Note”) to cover expenses related to this Initial Public Offering. The Note was payable, without interest, upon the completion of the Initial Public Offering. The Company received the $200,000 proceeds under the Note and repaid this Note in full on March 13, 2020. Subsequent to the repayment, the facility was no longer available to the Company.

~~Administrative Services Agreement~~

Commencing on the date that the Company’s securities were first listed on Nasdaq, the Company has paid and will pay the Sponsor $10,000 per month for office space, secretarial and administrative services provided to members of the Company’s management team. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying such monthly fees. The Company incurred $30,000 and $90,000, in expenses in connection with such services during the three and nine months ended September 30, 2021 and 2020, respectively, as ~~included in general and administrative expenses - related party on t~~he accompanying unaudited condensed consolidated statements of operations. As of September 30, 2021 and December 31, 2020, the Company has $10,000, in connection with such services payable and included as accrued expenses - related parties, in the accompanying condensed consolidated balance sheets.

~~Wolfe Strategic Services Agreement~~

Commencing on the date that the Company’s securities were first listed on Nasdaq, the Company will pay and has paid its Chief Financial Officer, Christopher Wolfe, $7,500 per month for his services prior to the initial Business Combination. The Company incurred $22,500 and $67,500 in expenses in connection with such services during the three and nine months ended September 30, 2021, as included in general and administrative expenses ~~- related party~~ on the accompanying unaudited condensed consolidated statements of operations, respectively. During the three and nine months ended September 30, 2020, the Company had incurred $22,500 and $52,500 in expenses in connection with such services, respectively. As of September 30, 2021, and December 31, 2020, the Company had $7,500 in connection with such services in accrued expenses - related parties, as ~~included~~ ~~in the accompanying condensed consolidated balance sheets.~~

~~Working Capital Loans~~

In order to finance transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required for working capital (the “Working Capital Loans”). Up to $1.1 million of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.50 per warrant athave the option ~~of the lender. Such warrants would be identical~~ to the Private Placement Warrants. As of September 30, 2021, and December 31, 2020, except for the foregoing, the terms of such loans, if any, have not been determined, no written agreements exist with respect to such loans and 0 amounts have been borrowed under such loans to date.

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

~~5. Commitments and Contingencies.~~

~~Registration Rights~~

~~The initial stockholders and~~require all holders of the Private Placement Warrants are entitled to registration rights pursuant to a registration rights agreement. The initial stockholders and holders of the Private Placement Warrants will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities for sale under the Securities Act. In addition, these holders will have “piggy-back” registration rights to include their securities in other registration statements filed by the Company. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

~~Underwriting Agreement~~

~~The Company granted the underwriters a~~ 45-day option to purchase up to 3,000,000 additional Units to cover any over-allotments, at the initial public offering price less the underwriting discounts and commissions. The warrants that were issued in connection with the 3,000,000 over-allotment Units are identical to the Public Warrants and have no net cash settlement provisions. The underwriters exercised the over-allotment option in full on March 13, 2020.

The underwriters did not receive any underwriting discounts or commission on the Units purchased by the Deerfield Funds. The Company paid an underwriting discount of 2.0% of the per Unit offering price, or $3.6 million, at the closing of the Initial Public Offering, with an additional fee (the “Deferred Underwriting Fees”) of 3.5% of the gross offering proceeds, or $6.3 million, payable upon the Company’s completion of an Initial Business Combination. The Deferred Underwriting Fees will become payable to the underwriters from the amounts held in the Trust Account solely in the event the Company completes its initial Business Combination.

~~Risks and uncertainties~~

Management continues to evaluate the impact of the COVID-19 pandemic on its industry and has concluded that, while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or close of the proposed transaction, the specific impact is not readily determinable as of the date of these unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~6. Derivative Warrant Liabilities.~~

~~As of September 30, 2021, and December 31, 2020, the Company has 9,483,334 Public Warrants and Private Placement Warrants outstanding.~~

Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the shares of Class A common stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permits holderswish to exercise ~~their Public Warrants on a cashless basis under certain circumstances). The Company has agreed that, as soon as practicable, but in no event later than~~ 15 ~~business days after~~ the closing of a Business Combination, the Company will use its best efforts to file with the SEC and have declared effective a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the Class A common stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial Business Combination, warrantholders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Company’s shares of Class A common stock are at the time of any exercise of a warrant not listed on

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise theirpublic warrants to do so on a ~~“cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the~~cashless basis. The Company will not be required to ~~file or maintain in effect~~net cash settle the warrants.

The private warrants are exercisable on a ~~registration statement,~~cashless basis and in the event the Company does not so elect, it will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

~~The Private Placement Warrants~~ are identical to the Public Warrants, except that the Private Placement Warrants and the shares of Class A common stock issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination and they will be non-redeemable ~~for cash~~ so long as they are held by the initial purchasers ~~of the Private Placement Warrants~~ or their permitted transferees. If the ~~Private Placement Warrants~~private warrants are held by someone other than the initial purchasers of ~~the Private Placement Warrants or~~ their permitted transferees, the ~~Private Placement Warrants~~private warrants will be redeemable by the Company and exercisable by such holders on the same basis as the ~~warrants included in~~public warrants.

Share Repurchase Program

On May 10, 2022, the ~~Units being sold in~~Company's Board consented to the ~~Initial Public Offering.~~

adoption and approval of the Share Repurchase Program, authorizing up to $20,000 to be spent on the repurchase of the Company's common stock, expiring on December 31, 2022. The Company ~~may call the Public Warrants for redemption:~~

●

~~in whole and not in part;~~

●

~~at a price of $0.01 per warrant;~~

●

~~upon a minimum of 30 days’ prior written notice of redemption; and~~

●

~~if, and only if, the last reported sales price of the Class A common stock equals or exceeds $18.00 per share (as adjusted) for any~~ 20 ~~trading days within the~~ 30~~-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.~~

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement.

~~In addition, commencing ninety days after the warrants become exercisable, the Company may redeem the outstanding warrants for~~repurchased and immediately retired 1,500,000 shares of ~~Class A common stock:~~

●

~~in whole and not in part;~~

●

at a price of $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table set forth under “Description of Securities—Warrants—Public Stockholders’ Warrants” based on the redemption date and the “fair market value” of our Class A common stock (as defined below) except as otherwise described in “Description of Securities—Warrants—Public Stockholders’ Warrants”;

●

~~if, and only if, the last reported sale price of~~ its Class A common stock equals or exceeds $10.00 per share (as adjusted per stock splits, stock dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which it sends the notice of redemption to the warrant holders;

●

if, and only if, the Private Placement Warrants are also concurrently exchanged at the same price (equal to a number of shares of Class A common stock) as the outstanding Public Warrants, as described above; and

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

●

if, and only if, there is an effective registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the 30~~-day period after written notice of redemption is given.~~

~~The “fair market value” of the Company’s Class A common stock shall mean the average last reported sale price of its Class A~~ common stock for $9,000 from a related party (see Note 21) during the ~~10 trading days ending~~three months ended June 30, 2022. At June 30, 2022, $11,000 of the Share Repurchase Program authorization remained available for repurchases.

Note 14. Share-Based Compensation

Non-Qualified Stock Option Plan

On January 2, 2019, the Company issued and adopted the 2019 Non-Qualified Stock Option Plan (the “2019 Plan”) to incentivize directors, consultants, advisors, and other key employees of the Company and its subsidiaries to continue their association by providing opportunities to participate in the ownership and further growth of the Company. The 2019 Plan provides for the grant of options (the “Stock Options”) to acquire common shares of the Company.

Stock Options are exercised from the pool of shares designated by the appropriate Committee of the Board of Directors. The grant-date fair value of each option award is estimated on the ~~third trading day~~date of grant using the Black-Scholes-Merton option-pricing model. The grant date fair value of the service vesting and the performance vesting options is recognized as an expense over the requisite service period and upon the achievement of the performance condition deemed probable of being achieved, respectively. The exercise price of each Stock Option shall be determined by the Committee and may not be less than the fair market value of the common shares on the date of grant. Stock Options have 10-year terms, after which they expire and are no longer exercisable.

The total number of common shares for which Stock Options may be granted under the 2019 Plan shall not exceed 13,640. The 2019 Plan was amended on November 6, 2020, pursuant to which the total number of common shares for which Stock Options may be granted under the 2019 Plan shall not exceed 15,640.

Stock Options become vested upon fulfillment of either service vesting conditions, performance vesting conditions, or both, as determined by the award agreement entered into by the Company and optionee. The service vesting requirement states that: (i) 25% of the service vesting options shall vest on the first anniversary of the grant date and (ii) the remaining 75% shall vest on an equal monthly-basis, so long as the optionee has remained continuously employed by the Company from the date of the award through the fourth anniversary of the grant date. The performance vesting requirement states that Stock Options shall vest upon sale of the Company only if the optionee has been continuously employed by the Company or its subsidiaries from the grant date through the date of such sale of the Company. For the awards vesting based on service conditions only and that have a graded vesting schedule, the Company recognizes compensation expense for vested awards in earnings, net of actual forfeitures in the period they occur, on a straight-line basis over the requisite service period.

Table of Contents

Conversion of the Stock Options

In conjunction with the Business Combination, the Company amended and fully restated the 2019 Plan through the establishment of the 2021 Incentive Plan (“2021 Plan”). Pursuant to the 2021 Plan, each remaining legacy Stock Option from the 2019 Plan that was outstanding immediately prior to the ~~date on which the notice~~Business Combination, whether vested or unvested, was converted into an option to purchase a number of ~~redemption is sent~~shares of common stock (each such option, an “Exchanged Option”) equal to the ~~holders of warrants. This redemption feature differs from the typical warrant redemption features used in other blank check offerings.~~

~~No fractional shares of Class A common stock will be issued upon redemption. If, upon redemption, a holder would be entitled to receive a fractional interest in a share, the Company will round~~product (rounded down to the nearest whole ~~number~~number) of (i) the number of shares of ~~Class A common stock~~Legacy TOI stockholders subject to such Stock Option immediately prior to the Business Combination, and (ii) an exercise price per share equal to (A) the exercise price per share of such Stock Option immediately prior to the consummation of the Business Combination, divided by (B) the Common Stock Exchange Ratio ("Stock Option Exchange Ratio"). Following the Business Combination, each Exchanged Option that was previously subject to time vesting only, will continue to be ~~issued~~governed by the same terms and conditions (including vesting and exercisability terms) as were applicable to the ~~holder.~~

~~Pursuant~~corresponding former old Stock Option immediately prior to the warrant agreement, references above to Class A common stock shall include a security other than Class A common stock into which the Class A common stock has been converted or exchanged for in the event the Company is not the surviving company in its initial Business Combination.

In no event will the Company be required to net cash settle any warrant. If the Company does not complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outsideconsummation of the ~~Trust Account with the respect~~Business Combination. Each Exchanged Option that was previously subject to ~~such warrants. Accordingly, the warrants may expire worthless.~~

~~7. Class A Common Stock Subject to Possible Redemption.~~

~~The Company’s Class A common stock feature certain redemption rights that are considered to~~performance vesting, will no longer be ~~outside of the Company’s control and~~ subject to the ~~occurrence~~sale of ~~future events.~~the Company, and was modified to include service requirements only, under which, the Exchange Options will vest on a monthly-basis, so long as the optionee has remained continuously employed by the Company from the date of the Business Combination through the third anniversary of the Closing Date. The Company ~~is authorized~~treated the Exchanged Options that were previously subject to ~~issue 100,000,000 shares of Class A common stock with~~performance conditions as a ~~par value of $0.0001 per share. Holders~~new award granted at the Closing Date. The Exchanged Options that were previously subject to service vesting only were not modified as a result of the ~~Company’s Class A common~~Business Combination. All stock ~~are entitled~~option activity was retroactively restated to ~~1 vote for each share.~~ reflect the Exchanged Options.

As of ~~September 30, 2021, there~~the Closing Date, the 11,850 Stock Options outstanding under the 2019 Plan were ~~23,000,000 shares~~converted into 6,925,219 Exchanged Options after effect of ~~Class A common stock outstanding, which were all subject to possible redemption and are classified outside~~the Common Stock Exchange Ratio. This effect of ~~permanent equity in~~ the Common Stock Exchange Ratio has been retroactively adjusted throughout the Company's condensed ~~balance sheet.~~

~~The Class A common stock subject to possible redemption reflected on the condensed balance sheet is reconciled on the following table:~~

Gross proceeds

$
230,000,000
Less:


Amount allocated to Public Warrants

(6,727,500)
Class A common stock issuance costs

(10,110,406)
Plus:


Accretion of carrying value to redemption value

16,837,906
Class A common stock subject to possible redemption

$
230,000,000

~~8. Stockholder’s Equity (Deficit).~~

~~Preferred Stock~~ ~~— The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share.~~ consolidated financial statements.

As of ~~September~~June 30, ~~2021, and December 31, 2020, there are 0 shares of preferred stock issued or outstanding.~~

~~Class A Common Stock~~ — The Company is authorized to issue 100,000,000 shares of Class A common stock with a par value of $0.0001 per share. As of September 30, 2021, and December 31, 2020, there were 23,000,000 shares of Class A common stock issued and outstanding, including 23,000,000 shares of Class A common stock subject to possible redemption which were classified as temporary equity. See Note 7.

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

~~Class B Common Stock~~ — The Company is authorized to issue 10,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of the Company’s Class B common stock are entitled to 1 vote for each share. As of September 30, 2021, and December 31, 2020, there were 5,750,000 shares of Class B common stock issued outstanding.

The Class B common stock will automatically convert into Class A common stock at the time of the Initial Business Combination on a one-for-1 basis, subject to adjustment. In the case that additional shares of Class A common stock or equity-linked securities are issued or deemed issued in connection with the initial Business Combination, the number of shares of Class A common stock issuable upon conversion of all Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of2022, the total number of shares of ~~Class A~~ common stock remaining available for future awards (e.g., non-qualified stock options, incentive stock options, restricted stock units, restricted stock awards) under the 2021 Plan is 10,822,981.

The weighted average assumptions used in the Black-Scholes-Merton option-pricing model for the units granted during the six months ended June 30, 2022 and 2021 Stock Options are provided in the following table:


	2022	2021
Valuation assumptions:
Expected dividend yield	—%	—%
Expected volatility	35.0% to 45.0%	38.60% to 40.20%
Risk-free interest rate	2.33% to 2.84%	0.76% to 1.12%
Expected term (years)	6.07 to 6.65	7.00

The Company used the simplified method to calculate the expected term of stock option grants because sufficient historical exercise data was not available to provide a reasonable basis for the expected term. Under the simplified method, the expected term is estimated to be the mid-point between the vesting date and the contractual term of the option.

Stock option activity during the six months ended June 30, 2022 and 2021 is as follows:


Stock options	Number of shares	Weighted average exercise price		Weighted average remaining contractual term	Aggregate intrinsic value (in thousands)
Balance at January 1, 2022	6,921,180	$	0.89
Granted	1,550,485	7.14
Exercised	(366,684)	0.92
Forfeited	(833,687)	2.17
Expired	(936)	1.02
Balance at June 30, 2022	7,270,358	$	2.07	7.75	$	24,632
Vested Options Exercisable at June 30, 2022	2,424,960	$	0.87	6.92	$	10,168

Table of Contents


Stock options	Number of shares	Weighted average exercise price		Weighted average remaining contractual term	Aggregate intrinsic value (in thousands)
Balance at January 1, 2021	8,683,952	$	0.85
Granted	1,182,218	1.08
Exercised	—	—
Forfeited	(665,034)	0.86
Expired	—	—
Balance at June 30, 2021	9,201,136	$	0.88	8.57	$	—
Vested Options Exercisable at June 30, 2021	1,182,353	$	0.85	7.94	$	—

Total share-based compensation expense during the three months ended June 30, 2022 and 2021 was $2,826 and $51, related to the Stock Options, respectively. Total share-based compensation expense during the six months ended June 30, 2022 and 2021 was $6,081 and $93, related to the Stock Options, respectively.

At June 30, 2022, there was $26,461 of total unrecognized compensation cost related to unvested service Stock Options that are expected to vest. That cost is expected to be recognized over a weighted average period of 2.66 years. The total fair value of common shares vested during the six months ended June 30, 2022 and 2021 was $6,304 and $237, respectively.

Restricted Stock Awards (“RSAs”) and Restricted Stock Units (“RSUs”)

Agajanian Holdings (“Holdings”), a holder of Series A Preferred Shares of Legacy TOI, entered into arrangements with physicians employed by the TOI PCs to issue RSAs which represent Series A Preferred Shares of Legacy TOI. The Legacy TOI RSAs only have performance vesting requirements linked to the sale of the Company so long as the grantee remains continuously and actively employed by the Company’s subsidiaries through the vesting date.

Conversion of the RSAs

Each of the Legacy TOI RSAs, from the Plan that was outstanding ~~after such conversion (after giving effect~~immediately prior to ~~any redemptions~~the Business Combination, whether vested or unvested, was converted into an RSU equal to the product (rounded down to the nearest whole number) of ~~shares of Class A common stock by Public Stockholders), including~~(i) the ~~total~~ number of shares of ~~Class~~RSAs immediately prior to the Business Combination, (ii) conversion rate of 1:10 of the Series A ~~common stock issued, or deemed issued or issuable upon conversion or exercise~~Preferred Shares of ~~any equity-linked securities or rights issued or deemed issued,~~Legacy TOI, and (iii) the Common Stock Exchange Ratio. Following the Business Combination, each RSU will no longer be subject to the sale of the Company event in order to vest, but was modified to include service requirements only. The service vesting requirement states that: (i) 16.67% of the RSUs shall vest on the sixth month anniversary of the Closing Date, and (ii) the remaining 83.33% shall vest on an equal quarterly-basis, so long as the grantee has remained continuously employed by the Company ~~in connection with or in relation to~~from the ~~consummation~~date of the ~~initial~~award through the third anniversary of the grant date. The Company treated the RSUs that were previously subject to performance conditions as a new award granted at the Closing Date. All RSAs activity was retroactively restated to reflect the RSUs.

As of the Closing Date, the 2,210 RSAs outstanding under the Plan were converted into 1,291,492 RSUs upon the completion of the Business Combination excluding any shares of Class A common stock or equity-linked securities or rights exercisable for or convertible into shares of Class A common stock issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, officers or directors upon conversion of Working Capital Loans, provided that such conversion of Founder Shares will never occur on a less than one-for-one basis.

9. ~~Fair Value Measurements.~~

~~The following table presents information about the Company’s assets that are measured at fair value on a recurring basis and indicate the fair value hierarchy~~after effect of the ~~valuation techniques that the Company utilized to determine such fair value.~~

~~September 30, 2021~~

Quoted Prices in

Significant Other

Significant Other

Active Markets

Observable Inputs

Unobservable Inputs
Description

(Level 1)

(Level 2)

(Level 3)
Assets

Investments held in Trust Account

$
230,012,623

$
—

$
—
Liabilities

Derivative warrant liabilities - Public Warrants

$
9,257,500

$
—

$
—
Derivative warrant liabilities - Private Warrants

$
—

$
—

$
6,010,670

~~December 31, 2020~~

Quoted Prices in

Significant Other

Significant Other

Active Markets

Observable Inputs

Unobservable Inputs
Description

(Level 1)

(Level 2)

(Level 3)
Assets






Assets held in Trust Account:






U.S. Treasury securities

$
230,253,395

$
—

$
—
Cash equivalents - money market funds

754

—

—

$
230,254,149

$
—

$
—
Liabilities






Derivative warrant liabilities - Public Warrants

$
11,212,500

$
—

$
—
Derivative warrant liabilities - Private Warrants

$
—

$
—

$
7,578,670

~~Transfers to/from Levels 1, 2, and 3 are recognized at the beginning~~Common Stock Exchange Ratio. This effect of the ~~reporting period.~~ Common Stock Exchange Ratio has been retroactively adjusted throughout our condensed~~There~~ consolidated financial statements.

~~were~~ ~~0 transfers between levels for three and nine months ended September 30, 2021.~~

~~Level 1 assets include investments in money market funds that invest solely in U.S. government securities and investments in U.S. Treasury Securities.~~

The ~~Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments.~~

~~Table of Contents~~

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

The fair value of Public Warrants issued in connection with the Initial Public Offering are measured based on the listed market price of such warrants, a quoted price in an active market, a Level 1 measurement. Thegrant date fair value of the ~~Private Placement Warrants has been estimated using a Monte Carlo simulation model each measurement date.~~

~~For the~~RSUs granted during three months ended June 30, 2022 and ~~nine months ended September 30, 2021, the Company recognized a gain resulting from a decrease in~~as of Closing Date was determined to be $7.58 and $10.98, respectively, based on the fair value of the ~~derivative warrant liabilities~~Company’s common share at the grant date.

A summary of ~~approximately~~ ~~$1.1~~ ~~million~~the activity for the RSUs and ~~approximately $3.5 million,~~RSAs for the six months ended June 30, 2022 and 2021, respectively, ~~presented as change~~are shown in ~~fair value~~the following tables:


			Number of Shares
Balance at January 1, 2022			1,291,492
Granted			1,413,159
Vested			(242,429)
Forfeited			(279,686)
Balance at June 30, 2022			2,182,536

Table of ~~derivative warrant liabilities on the accompanying unaudited condensed consolidated statements of operations.~~

Contents


			Number of Shares
Balance at January 1, 2021			1,390,839
Granted			—
Vested			—
Forfeited			(23,376)
Balance at June 30, 2021			1,367,463

~~For~~The total share-based compensation expense during the three and ~~nine~~six months ended ~~September~~June 30, 2022 was $2,001 and $3,492 related to the RSUs, respectively. The sale of the Company was not considered probable until consummation of the transaction, and therefore, during the three and six months ended June 30, 2021 and prior to the Business Combination, no compensation costs were recognized related to the RSAs.

As of June 30, 2022 there was $18,304 of unrecognized compensation expense related to the RSUs that are expected to vest. That cost is expected to be recognized over a weighted average period of 2.77 years as of June 30, 2022. As of June 30, 2022, 242,429 of the RSUs have vested, 64,331 were net settled to cover the required withholding tax upon vesting.

2020 Sale Bonus Plan

Starting December 2020, the Company issued bonus awards under the 2020 Sale Bonus Plan (the “Bonus Plan”) along with the Stock Options with performance vesting conditions to certain physicians of the Practice. The Stock Options and the bonus awards under the Bonus Plan vest upon the sale of the Company. The bonus award the optionee was eligible for was equal to the exercise price of the Stock Option, and was intended to incentivize the physicians to remain employed with the Practice.

The Company accounted for the bonus awards in accordance with ASC Topic No. 710, Compensation — General (“ASC 710”). The sale of the Company was not considered probable until consummation of the transaction, and therefore, for the six months ended June 30, 2021, no liability associated with the bonus awards was recognized ~~a loss of approximately $2.3 million and approximately~~ ~~$5.2~~by the Company. ~~million resulting from a decrease an increase~~

In conjunction with the Business Combination, the Company settled the 2020 Sale Bonus Plan obligation in cash at the Closing Date, in the amount of $635.

Earnout Shares granted to Employees

As part of the Business Combination, DFPH issued to eligible Legacy TOI stockholders and Legacy TOI employees the contingent right to receive up to $12.5 million additional shares of common stock (“Legacy TOI Earnout Shares”), in 2 tranches of $5.0 million ("First Earnout Tranche") and $7.5 million ("Second Earnout Tranche"), respectively, upon the Company common stock achieving a price per share of $12.50 during the two-year period following the Closing or a price per share of $15.00 during the three-year period following the Closing Date, in each case, as its last reported sales price per share for any 20 trading days within any 30 consecutive trading day period within the applicable period ("Earnout Terms"); provided, that (i) if one or both of the share price triggers has not been achieved prior to the end of the three-year period following the Closing Date, (ii) the Company enters into a definitive agreement that would result in a change of control and (iii) the price per share of the Company’s common stock in such transaction is equal to or greater than one or both of the share price triggers, then at the Closing Date of such transaction, the Company shall issue the applicable portion of the Legacy TOI Earnout Shares as if such share price trigger had been achieved.

In addition, certain DFPH common stockholders deposited 575,000 shares of DFPH common stock in an escrow account that will vest and be released to such holders in 2 tranches of 50%, each (“DFPH Earnout Shares”), upon the Company common stock achieving the Earnout Terms as described above; provided, that (i) if one or both of the share price triggers has not been achieved prior to the end of the three-year period following the closing, (ii) the Company enters into a definitive agreement that would result in a change of control and (iii) the price per share of common stock in such transaction is equal to or greater than one or both of the share price triggers, then at the closing of such transaction, the Company shall issue the applicable portion of the DFPH Earnout Shares as if such share price trigger had been achieved. To the extent any DFPH Earnout Shares remain unvested at the expiration of the three-year period following the closing, such DFPH Earnout Shares shall be forfeited and cancelled without any consideration.

Collectively, the Legacy TOI Earnout Shares and DFPH Earnout Shares constitute the “Earnout Shares”, the “Earnout”, and the “Earnout Liability”.

The Company issued Legacy TOI Earnout Shares to Legacy TOI option holders and Legacy RSU holders (“Option-holders Earnout” and “RSU-holders Earnout”, respectively, together “Employees Earnout Shares”).

Table of Contents

The Option-holders Earnout vests upon the Company common stock achieving the price per share as provided above, so long as the optionee has remained continuously employed by the Company at that date. The RSU-holders Earnout vests upon (a) the Company common stock achieving the price per share as provided above, and (b) the underlying RSU vested, so long as the optionee has remained continuously employed by the Company at that date.

The grant date fair value of the ~~derivative warrant liabilities, respectively, presented~~First Earnout Tranche and Second Earnout Tranche as ~~change~~of Closing Date was determined to be $8.35 and $6.76, respectively. The assumptions used in ~~fair value of derivative warrant liabilities~~the Monte-Carlo Simulation model for the Earnout Shares granted on the ~~accompanying unaudited condensed consolidated statements of operations.~~

Closing Date are provided in the following table:


	November 12, 2021
Valuation assumptions
Expected dividend yield	—	%
Expected volatility	35.00	%
Risk-free interest rate	0.85	%

~~The estimated fair value~~

A summary of the ~~Private Placement Warrants~~activity for the Employees Earnout Shares for the six months ended June 30, 2022 is determined using Level 3 inputs. Inherent in a Monte Carlo simulation are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock based on historical volatility of select peer companies that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.

~~The following table provides quantitative information regarding Level 3 fair value measurements inputs as their measurement dates:~~

As of September 30, 2021

As of December 31, 2020

Stock Price

$
9.94

$
10.80

Volatility

22.8
%

24.0
%
Expected life of the options to convert

5.13

5.75

Risk-free rate

1.00
%

0.47
%
Dividend yield

0.0
%

0.0
%

~~The change~~shown in the ~~fair value of the warrant liabilities measured with Level 3 inputs for~~following table:


	Number of Shares
Balance at January 1, 2022	$	1,602,435
Granted	—
Forfeited	(165,297)
Balance at June 30, 2022	$	1,437,138

The total share-based compensation expense during the three and ~~nine~~six months ended ~~September~~June 30, 2022 was $1,687 and $5,494, related to the Employees Earnout Shares, respectively.

As of June 30, 2022, there was $2,962 of unrecognized compensation expense related to the Employees Earnout Shares, that are expected to vest. That cost is expected to be recognized over a weighted average period of 0.36 years as of June 30, 2022. As of June 30, 2022, none of the Employee Earnout Shares have vested.

Note 15. Commitments and Contingencies

The Company evaluates contingencies based upon available evidence. In addition, allowances for losses are provided each year for disputed items which have continuing significance. The Company believes that allowances for losses have been provided to the extent necessary, and that its assessment of contingencies is reasonable. Due to the inherent uncertainties and subjectivity involved in accounting for contingencies, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. To the extent that the resolution of contingencies results in amounts which vary from management’s estimates, future operating results will be charged or credited. The principal commitments and contingencies are described below.

Legal Matters

The Company is subject to certain outside claims and litigation arising in the ordinary course of business. In the opinion of Management, the outcome of such matters will not have a material effect on the Company’s condensed consolidated financial statements. Loss contingencies entail uncertainty and a possibility of loss to an entity. If the loss is probable and the amount of loss can be reasonably estimated, the loss should be accrued according to Accounting Standards Codification No. 450-20, Disclosure of Certain Loss Contingencies. As of the end of December 31, 2021, the Company settled a loss contingency for a legal matter related to an employee lawsuit for $350.

Indemnities

The Company’s Articles of Incorporation and bylaws require it, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines, and settlements, paid by the individual in connection with any action, suit, or proceeding arising out of the individual’s status or service as its director or officer, other than liabilities arising from willful misconduct or conduct that is ~~summarized~~knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the

Table of Contents

individual may be entitled to indemnification by the Company. The Company also indemnifies its lessor in connection with its facility lease for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments it could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed consolidated balance sheets.

The Health Insurance Portability and Accountability Act

The Health Insurance Portability and Accountability Act (“HIPAA”) assures health insurance portability, reduces healthcare fraud and abuse, guarantees security and privacy of health information, and enforces standards for health information. Organizations are required to be in compliance with HIPAA provisions. The Health Information Technology for Economic and Clinical Health Act (“HITECH”) imposes notification requirements in the event of certain security breaches relating to protected health information. Organizations are subject to significant fines and penalties if found not to be compliant with the provisions outlined in the regulations. The Company believes it is in compliance with these laws.

Regulatory Matters

Laws and regulations governing the Medicare program and healthcare generally, are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as ~~follows:~~

Level 3 - Derivative warrant liabilities at December 31, 2020

$
7,578,670
Change in fair value of derivative warrant liabilities

(2,426,670)
Level 3 - Derivative warrant liabilities at March 31, 2021

$
5,152,000
Change in fair value of derivative warrant liabilities

1,306,670
Level 3 - Derivative warrant liabilities at June 30, 2021

$
6,458,670
Change in fair value of derivative warrant liabilities

$
(448,000)
Level 3 - Derivative warrant liabilities at September 30, 2021

$
6,010,670

~~10. Subsequent Events.~~

~~On November 12,~~well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.

Many of the Company’s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations. The Company does not have any reserves for regulatory matters as of June 30, 2022 and December 31, 2021.

Liability Insurance

The Company believes that its insurance coverage is appropriate based upon the Company’s claims experience and the nature and risks of the Company’s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities, arising out of claims asserted against the Company or the Company’s affiliated professional organizations, in the future where the outcomes of such claims are unfavorable.

The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company’s insurance coverage, will not have a material adverse effect on the Company’s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company’s business. Contracted physicians are required to obtain their own insurance coverage.

Note 16. Business Combinations

During the year ended December 31, 2021, ~~(the “Closing Date”), DFP Healthcare Acquisitions Corp. (“DFP”) completed~~ the Company merged with DFPH with the intent to raise capital and gain access to the public markets. Additionally, the Company closed on 5 business ~~combination pursuant~~combinations and 1 asset acquisition, consistent with the intent to ~~that certain~~strategically grow its existing markets and ~~Plan of~~expand into new markets. During the six months ended June 30, 2022, the Company closed on one business combination.

DFPH-Legacy TOI Merger ~~dated~~

On June 28, 2021, ~~by and among DFP,~~DFPH, Orion Merger Sub I, Inc.~~, a Delaware corporation and a direct, wholly owned subsidiary of DFP (“~~ ("First Merger ~~Sub”~~Sub"), and Orion Merger Sub II, LLC ~~a Delaware limited liability company and a direct, wholly owned subsidiary of DFP (“~~("Second Merger ~~Sub”~~Sub") entered into an agreement and plan of merger ("Merger Agreement") with Legacy TOI ~~Parent, Inc.~~to affect the Business Combination. In connection with the Business Combination, DFPH entered into subscription agreements with certain investors (the “PIPE Investors”), ~~a Delaware corporation~~whereby it issued 17.5 million shares of common stock at $10.00 per share and 100,000 shares of preferred share (collectively, the “PIPE Shares”) for an aggregate investment of $275,000 (“~~Old TOI”~~PIPE Investment”) ~~(as it may be amended and/or restated from time to time,~~, which closed simultaneously with the ~~“Merger Agreement”). As contemplated by the Merger Agreement, immediately prior to the effective time~~consummation of the ~~First Merger (the “Effective Time”),~~Business Combination.

On the Closing Date, (i) ~~the~~ First Merger Sub merged with and into ~~Old~~Legacy TOI, ~~(the “First Merger”),~~ with ~~Old~~Legacy TOI being the surviving corporation and (ii) immediately following, ~~the First Merger, Old~~Legacy TOI merged with and into ~~the~~ Second Merger Sub, ~~(the “Second Merger”),~~ with ~~the~~ Second Merger Sub being the surviving entity and a wholly owned subsidiary

of DFPH.

Table of Contents

~~THE ONCOLOGY INSTITUTE, INC.~~

~~{FORMERLY KNOWN AS DFP HEALTHCARE ACQUISITIONS CORP.}~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (As Restated)~~

The total merger consideration on the Closing Date was $762,052, consisting of ~~DFP (the First Merger~~$595,468 in share consideration (consisting of 51.3 million shares of DFPH common stock issued to Legacy TOI at $10.00 per share as well as shares of DFPH common stock issuable per restricted stock units and ~~Second Merger together,~~ the ~~“Business Combination”~~exercise of Legacy TOI stock options), and $166,584 in cash. Gross proceeds from the transaction were $333,946. Of that, $167,510 was cash consideration to Legacy TOI equity holders. Legacy TOI also issued 12.5 million shares of common stock pursuant to the terms of an earnout (“Earnout Shares”). ~~Upon~~The earnout shares are allocable to both Legacy TOI stockholders and Legacy TOI option holders. In connection with the ~~closing~~Business Combination, the Company incurred $39,914 of equity issuance costs, consisting of advisory, legal, deferred underwriting, share registration, and other professional fees, of which $6,769 was ascribed to the earnout liability and expensed with the remainder being netted against additional paid-in capital.

On the Closing Date, shares of DFPH common stock that were not otherwise redeemed as part of the DFPH public stockholder vote were automatically converted into shares of TOI common stock on a 1-for-one basis. Further, PIPE Shares as well as DFPH common stock that was not otherwise forfeited or subject to earnout automatically converted into TOI common stock on a 1-for-one basis. Additionally, holders of DFPH forfeited 555,791 Private Placement Warrants.

All periods prior to the Closing Date reflect the balances and activity of Legacy TOI. The consolidated balances as of December 31, 2020 from the audited consolidated financial statements of Legacy TOI as of that date, share activity (convertible redeemable preferred stock and common stock) and per share amounts in these Condensed Consolidated Statements of Convertible Preferred Shares and Changes in Stockholders' Equity (Deficit) were retroactively adjusted, where applicable, using the recapitalization exchange ratio of 591:1. All previously issued and outstanding shares of Legacy TOI preferred stock classified as mezzanine equity were converted into Legacy TOI common stock and was retroactively adjusted and reclassified to permanent equity as a result of the reverse recapitalization. As a result of the Business Combination, ~~DFP changed~~$142,557 of additional paid-in capital was recognized.

Practice Acquisitions

For the acquisition of various clinical practices, the Company applied the acquisition method of accounting, where the total purchase price was allocated, or preliminarily allocated, to the tangible and intangible assets acquired and liabilities assumed, based on their fair values as of the acquisition dates.

Raiker Practice Acquisition

On February 12, 2021 ("Raiker Acquisition Date"), the Company entered into an asset purchase agreement and master services agreement ("Raiker MSA") with Anil N Raiker, M.D., P.L.C., d/b/a Pinellas Cancer Center (the "Raiker Practice") and Anil Raiker, M.D., an individual. Pursuant to the asset purchase agreement, the Company purchased from PCC certain non-clinical assets, properties, and rights. Pursuant to the Raiker MSA, TOI Management established an ongoing management services agreement which grants TOI Management the right to control the non-clinical and management operations of the Raiker Practice. Anil Raiker, M.D. continued to own all of the issued and outstanding equity interests of the Raiker Practice.

Pursuant to the Raiker MSA, and as further described in Note 17, TOI Management became the Raiker Practice's primary beneficiary and thus consolidated the Raiker Practice and its subsidiaries. The consolidation of the Raiker Practice (the "Raiker Practice Acquisition") at the Raiker Acquisition Date constituted a business combination in accordance with ASC 805.

The total consideration for the Acquisition was $1,710, comprised of a cash payment of $892 and deferred consideration of $818. The deferred cash consideration is to be paid in 2 equal installments on the first and second anniversary of the Raiker Acquisition Date (February 12, 2022 and 2023, respectively). On February 12, 2022, the Company transferred the first installment of deferred consideration of $409. Considering the Company's incremental borrowing rate, the present value of the deferred cash consideration is not materially different than its stated value.

Subsequent to the Acquisition, the Company filed an amendment to the articles of incorporation of PCC to legally change the name to ~~“The~~The Oncology Institute ~~Inc.”~~FL, LLC (TOI FL). The change was solely nominal, and the legal form, tax attributes, and books and records of PCC all remained.

Grant Practice Acquisition

On November 12, 2021 ("Grant Acquisition Date"), the Company acquired certain non-clinical assets of Ellsworth Grant, M.D., A Medical Corporation (the “Grant Practice”) from Ellsworth Grant, M.D. (“Dr. Grant”). Further, TOI ~~continues~~CA acquired certain clinical assets of the ~~existing business operations~~Grant Practice from Dr. Grant.Intangible assets of ~~Old TOI as a publicly traded company.~~

~~Management has evaluated subsequent events and transactions that occurred after the balance sheet date up~~$450 were recognized pursuant to the acquisition in the form of clinical contracts with a weighted average amortization period of 5 years The Company transferred cash consideration of $849 and deferred consideration of $200 to Dr. Grant for the purchase. The deferred cash consideration is

Table of Contents

to be paid in 2 equal installments on the first and second anniversary of the Grant Acquisition Date (November 12, 2022 and 2023, respectively). Considering the Company's incremental borrowing rate, the present value of the deferred cash consideration is not materially different than its stated value.

The Grant Practice Acquisition was determined to constitute a business combination in accordance with ASC 805.

Orr Practice Acquisition

On November 12, 2021 ("Orr Acquisition Date"), the Company acquired certain non-clinical assets of Leo E. Orr, M.D., Inc. (the “Orr Practice”) from Leo E. Orr, M.D. (“Dr. Orr”). Further, TOI CA acquired certain clinical assets of the Orr Practice from Dr. Orr. Intangible assets of $150 were recognized pursuant to the acquisition in the form of clinical contracts with a weighted average amortization period of 5 years. The Company transferred cash consideration of $816 and deferred consideration of $200 to Dr. Orr for the purchase. The deferred cash consideration is to be paid in 2 equal installments on the first and second anniversary of the Orr Acquisition Date (November 12, 2022 and 2023, respectively). Considering the Company's incremental borrowing rate, the present value of the deferred cash consideration is not materially different than its stated value.

The Orr Practice Acquisition was determined to constitute a business combination in accordance with ASC 805.

Dave Practice Acquisition

On November 19, 2021 ("Dave Acquisition Date"), the Company acquired certain non-clinical assets of Sulaba Dave M.D., d.b.a. Radiation Oncology Associates (the “Dave Practice”) from Sulaba Dave M.D. (the “Dr. Dave”). Further, TOI CA acquired certain clinical assets of the Dave Practice from Dr. Dave. Intangible assets of $77 were recognized pursuant to the acquisition in the form of clinical contracts with a weighted average amortization period of 2 years. The Company transferred cash consideration of $2,000 and deferred consideration of $750 to Dr. Dave for the purchase. The deferred cash consideration is to be paid in 3 equal installments on the six, twelfth, and eighteen month anniversaries of the Dave Acquisition Date (May 19, 2022, November 19, 2022, and May 19, 2023, respectively). On May 19, 2022, the Company transferred the first installment of deferred consideration of $250. Considering the Company's incremental borrowing rate, the present value of the deferred cash consideration is not materially different than its stated value.

The Dave Practice Acquisition was determined to constitute a business combination in accordance with ASC 805.

Yang Practice Acquisition

On December 9, 2021 ("Yang Acquisition Date"), the Company, acquired certain non-clinical assets of Global Oncology, Inc. (the “Yang Practice”) from Dr. Honghao Yang M.D. (“Dr. Yang”). Further, TOI CA acquired certain clinical assets of the Practice from Dr. Yang. Intangible assets of $68 were recognized pursuant to the acquisition in the form of clinical contracts with a weighted average amortization period of 5 years. The Company transferred cash consideration of $4,615 and deferred consideration of $2,500 to Dr. Yang for the purchase. The deferred cash consideration is to be paid in 2 equal installments on the first and second anniversary of the Yang Acquisition Date (December 9, 2022 and 2023, respectively). The Transaction resulted in the sale of nearly all assets of the practice. Additionally, on the Yang Acquisition Date, Dr. Yang entered into an employment agreement with the Clinical Buyer whereupon Dr. Yang will provide professional services to the Clinical Buyer.

The Yang Practice Acquisition was determined to constitute a business combination in accordance with ASC 805.

Perkins Practice Acquisition

On April 30, 2022 ("Perkins Acquisition Date"), the Company acquired certain non-clinical assets of California Oncology of the Central Valley Medical Group, Inc., (the “Perkins Practice”) from Christopher Perkins, M.D. (“Dr. Perkins”). Further, TOI CA acquired certain clinical assets of the Perkins Practice from Dr. Perkins. In conjunction with the acquisition, the Company also entered into a Professional Service Agreement with Oncology Associates of Fresno Medical Group, Inc. Intangible assets of $2,550 were recognized pursuant to the acquisition in the form of trade names of $2,480 and clinical contracts of $70, with weighted average amortization periods of 10 years and 5 years respectively. The Company transferred cash consideration of $8,920 and deferred consideration of $2,000 to Dr. Perkins for the purchase. The deferred cash consideration is to be paid in 2 equal installments on the first and second anniversary of the transaction closing date (April 29, 2023 and 2024, respectively). Considering the ~~unaudited~~Company's incremental borrowing rate, the present value of the deferred cash consideration is not materially different than its stated value.

The Perkins Practice Acquisition was determined to constitute a business combination in accordance with ASC 805.

Table of Contents

Summary of Consideration Transferred

Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Such assets include synergies we expect to achieve, such as the use of our existing infrastructure to support the added membership, and future economic benefits arising from the assembled workforce. The purchase consideration for the acquisitions has been allocated under the acquisition method of accounting to the estimated fair market value of the net assets acquired including a residual amount of tax deductible goodwill as noted in the provisional fair value table below.

Acquisition costs amounted to $111 and $107 for the three months ended June 30, 2022 and 2021 respectively, and $533 and $197 for the six months ended June 30, 2022 and 2021 respectively, and were recorded as “General and administrative expenses” in the accompanying Condensed Consolidated Statements of Income (Operations).

The following table summarizes the provisional fair values assigned to identifiable assets acquired and liabilities assumed.


	Acquisition
(in thousands)	Raiker		Grant		Orr		Dave		Yang		Perkins		Total
Consideration:
Cash	$	892	$	849	$	816	$	2,000	$	4,615	$	8,920	$	18,092
Deferred	818		200		200		750		2,500		2,000		6,468
Fair value of total consideration transferred	$	1,710	$	1,049	$	1,016	$	2,750	$	7,115	$	10,920	$	24,560






Estimated fair value of identifiable assets acquired and liabilities assumed:
Cash	$	65	$	—	$	—	$	—	$	—	$	—	$	65
Accounts receivable	398		—		183		—		—		—		581
Inventory	62		49		16		—		115		409		651

Property and equipment, net	—		—		13		35		19		123		190
Clinical contracts	—		450		150		77		68		2,550		3,295

Goodwill	1,454		550		837		2,645		6,913		7,850		20,249
Total assets acquired	1,979		1,049		1,199		2,757		7,115		10,932		25,031
Accounts payable	120		—		—		—		—		—		120
Accrued liabilities	—		—		—		7		—		12		19
Current portion of long term debt	149		—		183		—		—		—		332
Total liabilities assumed	269		—		183		7		—		12		471
Net assets acquired	$	1,710	$	1,049	$	1,016	$	2,750	$	7,115	$	10,920	$	24,560

The establishment of the allocation to goodwill requires the extensive use of accounting estimates and management judgement. The fair values assigned to the assets acquired are based on estimates and assumptions from data that is readily available.

Summary of UnauditedSupplementalProFormaInformation

The revenues, earnings, and pro forma effects of the Raiker Practice Acquisition, which occurred during the six months ended June 30, 2021, are not, and would not have been, material to the results of operations, individually and in aggregate. The Company recognized $2,370 cumulative revenue and $230 cumulative net loss in its Condensed Consolidated Statement of Income (Operations) for the three and six months ended June 30, 2022, from the clinical practices acquired during the three and six months ended June 30, 2022.

The pro forma results presented below include the effects of the Perkins Acquisition, as if it had occurred on January 1, 2021. The pro forma results for the three and six months ended June 30, 2022 and 2021 include the additional amortization resulting from the adjustments to the value of intangible assets resulting from purchase accounting. The pro forma results do not include any anticipated synergies or other expected benefits of the acquisitions. The pro forma information does not purport to be indicative of what the Company's results of operations would have been if the acquisitions had in fact occurred at the beginning of the period presented and is not intended to be a projection of the Company's future results of operations. Transaction expenses are included within the pro forma results.

Table of Contents


(in thousands)	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2022		2021		2022		2021
Revenue	$	62,386	$	54,455	$	122,096	$	107,646
Net income (loss)	$	(5,160)	$	4,126	$	15,034	$	4,051

Mendez Asset Acquisition

On May 1, 2021, TOI Management, through PCC, entered into a purchase agreement to acquire certain clinical assets from Oncology Association, P.A. ("OA") from Pedro Mendez, M.D. Management determined the acquisition of OA is an asset acquisition. The Company paid $500, consisting of cash consideration of $200 and deferred cash consideration of $300, in exchange for intangible assets in the form of payor contracts. The entire $500 was assigned to the payor contract intangible asset class with a weighted average amortization period of 10 years. The deferred cash consideration is to be paid in 3 equal installments on the first, second, and third anniversaries of the Mendez Asset Acquisition Date (May 1, 2022, May 1, 2023, and May 1, 2024, respectively).On May 1, 2022, the Company transferred the first installment of deferred consideration of $100. Considering the Company's incremental borrowing rate, the present value of the deferred cash consideration is not materially different than its stated value.

Note 17. Variable Interest Entities

The Company prepares its condensed consolidated financial statements ~~were issued. Based upon this review, other than described here~~in accordance with Accounting Standards Codification Topic No. 810, Consolidations (“ASC 810”), which provides for the consolidation of VIEs of which an entity is the primary beneficiary.

Pursuant to the MSAs established with the TOI PCs, TOI Management is entitled to receive a management fee, which represents a variable interest in and the ~~restatements described in Note 2~~right to receive the ~~Company did not identify any subsequent events~~benefits of the TOI PCs. Through the terms of the MSAs, TOI Management receives the right to direct the most significant activities of the TOI PCs. Therefore, the TOI PCs are variable interest entities and TOI Management is the primary beneficiary that ~~would have required adjustment or disclosure in~~consolidates the ~~unaudited~~TOI PCs, and their subsidiaries.

The condensed consolidated financial ~~statements.~~

statements include the accounts of TOI and its subsidiaries and VIEs. All inter-company profits, transactions, and balances have been eliminated upon consolidation.


(in thousands)	June 30, 2022		December 31, 2021
Assets
Current assets:
Cash and restricted cash	$	1,351	$	1,618
Accounts receivable	28,947		20,007
Other receivables	212		935
Inventories, net	8,580		6,438
Prepaid expenses	935		781
Total current assets	40,025		29,779
Property and equipment, net	26		—
Other assets	347		276
Intangible assets, net	3,543		1,181
Goodwill	18,946		11,096
Total assets	$	62,887	$	42,332
Liabilities
Current liabilities:
Accounts payable	$	12,028	$	14,204
Income taxes payable	132		132
Accrued expenses and other current liabilities	7,643		5,539
Current portion of long-term debt	—		183
Amounts due to affiliates	99,583		56,312
Total current liabilities	119,386		76,370

Table of Contents


(in thousands)	June 30, 2022		December 31, 2021
Other non-current liabilities	2,565		3,203
Deferred income taxes liability	32		6
Total liabilities	$	121,983	$	79,579

Single physician holders, who are officers of the Company, retain equity ownership in TOI CA, TOI FL and TOI TX, which represents nominal noncontrolling interests. The noncontrolling interests do not participate in the profit or loss of TOI CA or TOI FL, however.

As such, for the three months ended June 30, 2022, net loss of $(5,453) and $0 were attributable to TOI and to the noncontrolling interest, respectively. For the three months ended June 30, 2021, net income of $3,205 and $0 were attributable to TOI and to the noncontrolling interest, respectively.

For the six months ended June 30, 2022, net income of $13,833 and $0 were attributable to TOI and to the noncontrolling interest, respectively. For the six months ended June 30, 2021, net income of $2,209 and $0 were attributable to TOI and to the noncontrolling interest, respectively.

Note 18. Goodwill and Intangible Assets

The Company accounts for goodwill at acquisition-date fair value and other intangible assets at acquisition-date fair value less accumulated amortization. See Note 2 for a summary of the Company’s policies relating to goodwill and intangible assets.

Intangible Assets

As of June 30, 2022, the Company’s intangible assets, net consists of the following:


(in thousands)	Weighted average amortization period	Gross carrying amount		Accumulated amortization		Net carrying amount
Intangible assets
Amortizing intangible assets:
Payor contracts	10 years	$	19,400	$	(7,095)	$	12,305
Trade names	10 years	6,650		(1,614)		5,036
Clinical contracts	9 years	2,979		(937)		2,042
Total intangible assets		$	29,029	$	(9,646)	$	19,383

As of December 31, 2021, the Company’s intangible assets, net consists of the following:


(in thousands)	Weighted average amortization period	Gross carrying amount		Accumulated amortization		Net carrying amount
Intangible assets
Amortizing intangible assets:
Payor contracts	10 years	$	19,400	$	(6,152)	$	13,248
Trade names	10 years	4,170		(1,350)		2,820
Clinical contracts	9 years	2,909		(732)		2,177
Total intangible assets		$	26,479	$	(8,234)	$	18,245

Table of Contents

The estimated aggregate amortization expense for each of the five succeeding fiscal years as of June 30, 2022 is as follows:


(in thousands)	Amount
Year ending December 31:
2022	$	1,469
2023	2,901
2024	2,901
2025	2,901
2026	2,879
Thereafter	6,332
Total	$	19,383

The aggregate amortization expense during the three months ended June 30, 2022 and 2021 were $739 and $621, respectively. The aggregate amortization expense during the six months ended June 30, 2022 and 2021 were $1,412 and $1,233, respectively.

Goodwill

The Company evaluates goodwill at the reporting unit level, which, for the Company, is at the level of the reportable segments, dispensary, patient services, and clinical trials & other. The goodwill allocated to each of the reporting units as of June 30, 2022 and December 31, 2021 is as follows:


(in thousands)	June 30, 2022		December 31, 2021
Patient services	$	29,293	$	21,443
Dispensary	4,551		4,551
Clinical trials & other	632		632
Total goodwill	$	34,476	$	26,626

The changes in the carrying amount of goodwill for the six months ended June 30, 2022 and for the year ended December 31, 2021 are as follows:


(in thousands)	2022		2021
Balance as of January 1:
Gross goodwill	$	26,626	$	14,227
Goodwill acquired during the period	7,850		12,399
Accumulated impairment losses	—		—
Goodwill, net as of June 30 and December 31	$	34,476	$	26,626

Note 19. Net Income (Loss) Per Share

The following table sets forth the computation of the Company's basic net income (loss) per share to common stockholders for the three and six months ended June 30, 2022 and 2021.


(in thousands, except share data)	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net income (loss) attributable to TOI	$	(5,453)	$	3,205	$	13,833	$	2,209
Less: Deemed dividend	64		—		64		—
Net income (loss) attributable to TOI available for distribution	(5,517)		3,205		13,769		2,209
Net income (loss) attributable to participating securities, basic	(1,013)		—		2,521		—
Net income (loss) attributable to common stockholders, basic	$	(4,504)	$	3,205	$	11,248	$	2,209

Table of Contents


(in thousands, except share data)	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Weighted average common shares outstanding, basic	72,996,836		66,021,829		73,123,895		64,446,377
Net income (loss) per share attributable to common stockholders, basic	$	(0.06)	$	0.05	$	0.15	$	0.03

The following table sets forth the computation of the Company's diluted net income (loss) per share to common stockholders for the three and six months ended June 30, 2022 and 2021.


(in thousands, except share data)	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net income (loss) attributable to TOI	$	(5,453)	$	3,205	$	13,833	$	2,209
Less: Deemed dividend	64		—		64		—
Net income (loss) attributable to TOI available for distribution	(5,517)		3,205		13,769		2,209
Less: Net income attributable to participating securities, diluted	(1,013)		—		2,441		—
Net income (loss) attributable to common stockholders, diluted	$	(4,504)	$	3,205	$	11,328	$	2,209
Weighted average shares outstanding, diluted	72,996,836		66,021,829		76,106,201		64,446,377
Net income (loss) per share attributable to common stockholders, diluted	$	(0.06)	$	0.05	$	0.15	$	0.03

The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented:


	Three Months Ended June 30,		Six Months Ended June 30,
	2022	2021	2022	2021
Stock options	7,270,358	9,201,136	4,429,451	9,201,136
RSUs	2,182,536	1,367,463	1,471,052	1,367,463
Earnout Shares	1,437,138	—	1,437,138	—
Public Warrants	5,749,986	—	5,749,986	—
Private Warrants	3,177,542	—	3,177,542	—

Note 20. Segment Information

The Company operates its business and reports its results through 3 operating and reportable segments: dispensary, patient services, and clinical trials & other in accordance with ASC 280. See Note 2 for a summary of the Company’s policy on segment information.

Summarized financial information for the Company’s segments is shown in the following tables:


(in thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Revenue
Patient services	$	39,109	$	29,786	$	74,166	$	59,408
Dispensary	20,218		17,782		38,897		35,400
Clinical trials & other	1,594		2,276		3,019		3,616
Consolidated revenue	60,921		49,844		116,082		98,424

Direct costs
Patient services	32,875		23,574		60,253		46,660

Table of Contents


(in thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Dispensary	16,754		15,237		32,078		30,360
Clinical trials & other	150		143		287		312
Total segment direct costs	49,779		38,954		92,618		77,332

Depreciation expense
Patient services	282		139		532		266
Dispensary	—		—		—		—
Clinical trials & other	1		2		3		3
Total segment depreciation expense	283		141		535		269

Amortization of intangible assets
Patient services	686		568		1,307		1,128
Dispensary	—		—		—		—
Clinical trials & other	52		52		105		105
Total segment amortization	738		620		1,412		1,233

Operating income
Patient services	5,266		5,505		12,074		11,354
Dispensary	3,464		2,545		6,819		5,040
Clinical trials & other	1,391		2,079		2,624		3,196
Total segment operating income	10,121		10,129		21,517		19,590

Selling, general and administrative expense	28,348		11,212		58,154		22,390
Non-segment depreciation and amortization	77		33		138		69
Total consolidated operating loss	$	(18,304)	$	(1,116)	$	(36,775)	$	(2,869)


(in thousands)	June 30, 2022		December 31, 2021
Assets
Patient services	$	54,157	$	44,223
Dispensary	6,542		4,277
Clinical trials & other	12,481		14,504
Non-segment assets	116,560		140,435
Total assets	$	189,740	$	203,439

Note 21. Related Party Transactions

Related party transactions include payments for consulting services provided to the Company, clinical trials, board fees, and share repurchases. Related party payments for the three and six months ended June 30, 2022 and 2021 were as follows:

Table of Contents


(in thousands)		Three Months Ended June 30,				Six Months Ended June 30,
	Type	2022		2021		2022		2021
American Institute of Research	Consulting	$	42	$	33	$	82	$	63
Karen M Johnson	Board Fees	—		—		19		—
Richard Barasch	Board Fees	—		—		5		—
Anne M. McGeorge	Board Fees	—		—		19		—
Mohit Kaushal	Board Fees	—		—		19		—
Ravi Sarin	Board Fees	—		—		19		—
Maeve O'Meara Duke	Board Fees	—		—		19		—
Havencrest Capital Management, LLC	Management Fees	—		75		—		75
M33 Growth LLC	Management Fees	—		230		—		230

Richy Agajanian MD	Share Repurchase	8,748		5		8,764		9
Veeral Desai	Board Fees	—		12		—		25

Total		$	8,790	$	355	$	8,946	$	402

Note 22. Subsequent Events

Parikh Practice Acquisition

On July 22, 2022, the Company entered into an Asset Purchase Agreement with Nutan K Parikh, M.D., LTD., A Professional Corporation (the "Parikh Practice") and Nutan K Parikh, M.D., an individual. The terms of the agreement states that the Company will purchase from the Parikh Practice certain assets, properties, and rights owned by the Parikh Practice, and the intangible assets associated with the practice acquisition. The Company will pay $2,000, with $1,600 of the consideration being paid in cash at closing and the remainder paid equally in 2 cash installments on each annual anniversary thereafter.

Facility Agreement, Convertible Notes, Warrants

On August 9, 2022, the Company, entered into a Facility Agreement (the “Facility Agreement”) by the Company, as borrower, certain of the Company’s subsidiaries from time to time as guarantors and Deerfield Partners, L.P. (“Deerfield”), as agent for itself and the lenders, providing for the issuance and sale by the Company to Deerfield of $110,000 of principal amount of 4.0% secured senior convertible notes (the “Convertible Notes”) upon the terms and conditions set forth in the Facility Agreement (the “Deerfield Financing”). The Convertible Notes will be secured by (i) a security interest in substantially all of the assets of the Company and its subsidiaries and (ii) a pledge by the Company of the equity interest of all its direct and indirect subsidiaries and will mature on August 9, 2027, unless earlier converted or redeemed, and are convertible into shares of the Company’s common stock. The Convertible Notes were issued in a private placement to Deerfield pursuant to an exemption for transactions by an issuer not involving a public offering under Section 4(a)(2) of the Securities Act.

The Facility Agreement also provides for the issuance of warrants to purchase Company common stock to the extent that the obligations under the Facility Agreement and the Convertible Notes are prepaid. The Convertible Notes are convertible at any time at the option of the holders thereof, subject to certain ownership thresholds. The Company may redeem all or any portion of the principal amount of the Convertible Notes for cash. Upon redemption of any Convertible Notes, the Company will issue warrants covering the same number of shares of common stock underlying, and at an exercise price equal to the conversion price of, the redeemed Convertible Notes. The Company is subject to a number of affirmative and restrictive covenants pursuant to the Facility Agreement and is also restricted from paying dividends or making other distributions or payments on its capital stock, subject to limited exceptions.

In connection with the Facility Agreement, on August 9, 2022, the Company and Deerfield entered into a Registration Rights Agreement (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company has agreed to prepare and file with the Securities and Exchange Commission a Registration Statement on Form S-3, or such other form as required to effect a registration of the Company common stock issued or issuable upon conversion of or pursuant to the Convertible Notes or the warrants. Such Registration Statement must be filed within 30 calendar days following the date of the Registration Rights Agreement.

Table of Contents

~~ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS~~

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to DFP Healthcare Acquisitions Corp. References to our “management” or our “management team” refer to our officers

Item 2. Management's Discussion and ~~directors~~Analysis of Financial Condition and ~~references to the “Sponsor” refer to DFP Sponsor LLC.~~ Results of Operations

The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of the ~~Company’s financial condition and~~consolidated results of operations and financial condition of The Oncology Institute, Inc. ("TOI") along with its consolidating subsidiaries (the "Company"). The discussion should be read ~~in conjunction~~together with the unaudited condensed consolidated financial statements and the related notes ~~thereto contained~~that are included elsewhere in this ~~Quarterly Report (the “Financial Statements”). Capitalized terms used but not otherwise defined herein have the meaning set forth~~Report. The information in ~~the Financial Statements. Certain information contained in the~~this discussion ~~and analysis set forth below includes~~contains forward-looking statements ~~that involve risks and uncertainties.~~

~~Special Note Regarding Forward-Looking Statements~~

~~This Quarterly Report includes “forward-looking statements”~~ within the meaning of Section 27A of the Securities Act of 1933 ("Securities Act"), as amended, ~~(the “Securities Act”)~~ and Section 21E of the Securities and Exchange Act of 1934, as ~~amended (the “Exchange Act”)~~amended. Such statements are based upon current expectations, as well as management's beliefs and assumptions and involve a high degree of risk and uncertainty. Any statements contained herein that are not statements of historical ~~facts~~fact may be deemed to be forward-looking statements. Statements that include the words "believes," "anticipates," "plans," "expects." "intends," and ~~involve risks and uncertainties~~similar expressions that ~~could cause~~convey uncertainty of future events or outcomes are forward-looking statements. Our actual results tocould differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future eventsdiscussed or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipatedsuggested in the forward-looking statements ~~please refer~~herein. Factors that could cause or contribute to such differences include those described under the ~~Risk Factors section of the Company’s 10-K/A~~heading "Risk Factors" in our Annual Report on Form 10-K for the ~~fiscal~~ year 2020 filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 24, 2021 (the “FY 2020 10-K/A”). The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whetherended December 31, 2021. In addition, as a result of ~~new~~these and other factors, our past financial performance should not be relied on as an indication of future performance. All forward-looking statements in this document are based on information ~~future events or otherwise.~~

~~Overview~~

~~We are a blank check company incorporated on November 1, 2019~~available to us as ~~a Delaware corporation and formed for~~of the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). We intend to focus our investment effort broadly across the entire healthcare industry, which encompasses services, therapeutics, devices, diagnostics and animal health. We intend to effectuate our initial Business Combination using cash from the proceedsfiling date of this ~~offering~~Quarterly Report on Form 10-Q and ~~the private placement of the private placement warrants, the proceeds of the sale of our shares in connection with our initial Business Combination (pursuant~~we assume no obligation to forward purchase agreements or backstop agreements we may enter into following the consummation of our initial public offering or otherwise), shares issued to the owners of the target, debt issued to bank or other lendersupdate any forward-looking statements or the ~~owners of the target, or a combination of the foregoing. Our sponsor is DFP Sponsor LLC, a Delaware limited liability company (the “Sponsor”).~~

~~Our registration statement for~~reasons why our initial public offering (the “Initial Public Offering”) was declared effective by the SEC on March 10, 2020. On March 13, 2020, we consummated our Initial Public Offering of 23,000,000 units (the “Units” and, with respect to the Class A common stock includedactual results may differ. All dollar values are expressed in the Units being offered, the “Public Shares”), including 3,000,000 additional Units to cover over-allotments (the “Over-Allotment Units”), at $10.00 per Unit, generating gross proceeds of $230.0 million, and incurring offering costs of approximately $10.4 million, inclusive of approximately $6.3 million in deferred underwriting commissions.

Simultaneously with the closing of the Initial Public Offering, we consummated the private placement (“Private Placement”) of 3,733,334 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant in a private placement to our Sponsor, generating proceeds of $5.6 million.

thousands, unless otherwise noted.

~~Table of Contents~~

Overview

~~Upon~~The Company is a leading value-based oncology company that manages community-based oncology practices that serve patients at 69 clinic locations across 13 markets and five states throughout the closing of the Initial Public Offering and the Private Placement, $230.0 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a trust account (the “Trust Account”) and was invested in permitted United States, ~~“government securities” within the meaning~~which are staffed with 104 oncologists and advanced practice providers. 55 of ~~Section 2(a)(16) of the Investment Company Act of 1940, as amended,~~these clinics are staffed with 93 providers employed by our affiliated physician-owned professional corporations, which ~~we refer~~management refers to as the ~~Investment~~"TOI PCs", which have provided care for more than 51,000 patients in 2021 and managed a population of approximately 1.7 million patients under value-based agreements as of June 30, 2022. The Company ~~Act, having~~also provides management services on behalf of 14 clinic locations owned by independent oncology practices. The Company's mission is to heal and empower cancer patients through compassion, innovation, and state-of-the-art medical care.

The Company's managed clinics provide a ~~maturity~~range of ~~185 days~~medical oncology services, including physician services, in-house infusion and dispensary, clinical trial services, radiation, innovative programs like outpatient stem cell transplants and transfusions, along with 24/7 patient support. Many of our services, such as managing clinical trials, palliative care programs and stem cell transplants, are traditionally accessed through academic and tertiary care settings, while the TOI PCs bring these services to patients in a community setting. As scientific research progresses and more treatment options become available, cancer care is shifting from acute care episodes to chronic disease management. With this shift, it is increasingly important for high-quality, high-value cancer care to be available in a local community setting to all patients in need.

As a value-based oncology company, the Company seeks to deliver both better quality care and lower cost of care. The Company works to accomplish this goal by reducing wasteful, inefficient or ~~less or in money market funds meeting certain conditions under Rule 2a-7 promulgated~~counterproductive care that drives up costs but does not improve outcomes. The Company believes payors and employers are aligned with the value-based model due to its enhanced access, improved outcomes, and lower costs. Patients under the ~~Investment~~Company's affiliated providers’ care can benefit from evidence-based and personalized care plans, gain access to sub-specialized care in convenient community locations, and lower out-of-pocket costs. The Company ~~Act that invest only in direct U.S. government treasury obligations. Our management has broad discretion with respect~~believes its affiliated providers enjoy the stability and predictability of a large multi-state practice, are not incentivized or pressured to ~~the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to~~overtreat when it may be ~~applied generally toward consummating a Business Combination.~~

We have only have 24 months from the closing of the Initial Public Offering, or March 13, 2022, to complete our initial Business Combination (the “Combination Period”). If we do not complete a Business Combination within this period of time, it will (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the Public Shares for a per share pro rata portion of the Trust Account, including interest and not previously released to us to fund our working capital requirements (subject to an annual limit of $500,000) (less taxes payable and up to $100,000 of such net interest to pay dissolution expenses) and (iii) as promptly as possible following such redemption, liquidate and dissolve the balance of our net assets to our remaining stockholders, as part of our plan of dissolution and liquidation.

~~The issuance of additional shares in connection~~inconsistent with a ~~Business Combination to the owners~~patient’s goals of ~~the target or other investors:~~

●

may significantly dilute the equity interest of investors in this offering, which dilution would increase if the anti-dilution provisions in the Class B common stock resulted in the issuance of Class A common stock on a greater than one-to-one basis upon conversion of the Class B common stock;

●

~~may subordinate the rights of holders of Class A common stock if shares of preferred stock are issued with rights senior to those afforded our Class A common stock;~~

●

could cause a change in control if a substantial number of shares of our Class A common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors;

●

~~may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and~~

●

~~may adversely affect prevailing market prices for our units, Class A common stock and/or warrants.~~

~~Similarly, if we issue debt securities or otherwise incur significant debt to bank or other lenders or the owners of a target, it could result in:~~

●

~~default and foreclosure on our assets if our operating revenues after an initial Business Combination are insufficient to repay our debt obligations;~~

●

acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;

●

~~our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand;~~

●

~~our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding;~~

●

~~our inability to pay dividends on our Class A common stock;~~

care, and can focus on practicing outstanding evidence-based medicine, rather than business building.

~~Table of Contents~~

●

using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A common stock if declared, expenses, capital expenditures, acquisitions and other general corporate purposes;

●

~~limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;~~

●

~~increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and~~

●

limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt.

As indicated in the accompanying unaudited condensed consolidated financial statements as of September 30, 2021, we had approximately $0.6 million in our operating bank account. We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete our initialThe Business Combination ~~will be successful.~~

~~Proposed Business Combination~~

On June 28, 2021, ~~the Company entered into an Agreement and Plan of Merger by and among~~ DFP Healthcare Acquisition Corp. ("DFPH"), Orion Merger Sub I, Inc.~~, a Delaware corporation~~ ("First Merger Sub") and ~~a direct, wholly-owned subsidiary of DFP,~~ Orion Merger Sub II, LLC ~~a Delaware limited liability company~~("Second Merger Sub") entered into an agreement and ~~a direct, wholly-owned subsidiary of) and~~plan of merger ("Merger Agreement") with TOI Parent, Inc. ("TOI Parent") (collectively, the "Business Combination"). In connection with the Business Combination, DFPH entered into subscription agreements with certain investors (the “PIPE Investors”), ~~a Delaware corporation, as disclosed in a Form 8-K filed on June 29, 2021.~~

~~Liquidity~~whereby it issued 17.5 million shares of common stock at $10.00 per share and ~~Going Concern Considerations~~

~~Our liquidity needs to date have been satisfied through a $25,000 contribution from our Sponsor in exchange~~100,000 shares of preferred stock at $1,000.00 per share (“PIPE Shares”) for ~~the issuance~~an aggregate investment of ~~our founder shares to our Sponsor, the promissory note of $200,000 from our Sponsor, and the proceeds from~~$275,000 (“PIPE Investment”), which closed simultaneously with the consummation of the ~~Private Placement not held in the Trust Account. On March 13, 2020, we repaid the promissory note in full to our Sponsor. In addition, in order to finance transaction costs in connection with a~~Business Combination.

The Business Combination ~~our Sponsor~~closed on November 12, 2021 ("Closing Date"). On the Closing Date, (i) First Merger Sub merged with and into TOI Parent, with TOI Parent being the surviving corporation and (ii) immediately following, TOI Parent merged with and into Second Merger Sub ("Legacy TOI"), with Second Merger Sub being the surviving entity and a wholly

Table of Contents

owned subsidiary of DFPH. DFPH was renamed “The Oncology Institute, Inc.” and TOI Common Stock and Public Warrants continued to be listed on Nasdaq under the ticker symbols “TOI” and “TOIIW,” respectively.

The total merger consideration on the Closing Date was $762,052, consisting of 51.3 million shares of common stock, valued at $10.00 per share (aggregate $595,468, inclusive of shares of DFPH common stock issuable per restricted stock units and the exercise of Legacy TOI stock options), and $166,584 in cash. Legacy TOI also issued 12.5 million shares of common stock pursuant to the terms of an earnout (“Earnout Shares”). The earnout shares are allocable to both Legacy TOI stockholders and Legacy TOI option holders. On the Closing Date, shares of DFPH common stock that were not otherwise redeemed as part of the DFPH public stockholder vote and PIPE Shares automatically converted into shares of TOI stock on a one-for-one basis.

The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. generally accepted accounting principles (“U.S. GAAP"). Under this method of accounting, DFPH was treated as the “acquired” company for accounting purposes and the Business Combination was treated as the equivalent of Legacy TOI issuing stock for the net assets of DFPH, accompanied by a recapitalization. The net assets of DFPH are stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination were those of Legacy TOI.

Public Company Costs

Subsequent to the Business Combination, the Company continues as an ~~affiliate~~SEC-registered and Nasdaq-listed company. The Company expects to hire additional staff and implement new processes and procedures to address public company requirements. The Company also expects to incur substantial additional expenses for, among other things, directors’ and officers’ liability insurance, director fees, and additional internal and external costs for investor relations, accounting, audit, legal and other functions.

Impact of ~~our Sponsor, or~~COVID-19

The measures to contain the spread and impact of COVID-19 and other developments related to COVID-19 have affected the way in which the Company conducts its day-to-day business. The Company has followed U.S. guidance to protect its employees and operations during the pandemic and implemented a partially remote environment for certain ~~of our officers and directors may, but are not obligated to, provide us Working Capital Loans. As of September 30, 2021, and December 31, 2020, there were no Working Capital Loans outstanding.~~

~~Management continues to evaluate~~business activities. The Company cannot predict the ~~impact~~ongoing impacts of the COVID-19 pandemic or the distribution of vaccines on ~~our industry~~its business or operations, but will continue to actively monitor the related issues and ~~has concluded~~may take further action that ~~while~~alters its business operations, including as may be required by federal, state, local or foreign authorities or that it ~~is reasonably possible that~~determines are in the ~~virus could have a negative effect on the Company’s financial position, results~~best interests of its ~~operations and/or close~~employees, payors, partners and stockholders.

As a result of the ~~proposed transaction,~~COVID-19 pandemic, federal and state governments have passed legislation, promulgated regulations, and taken other administrative actions intended to assist healthcare providers in providing care to COVID-19 and other patients during the ~~specific impact is not readily determinable as~~public health emergency. Sources of relief include the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020, the Paycheck Protection Program and Health Care Enhancement Act (the “PPPHCE Act”), which was enacted on April 24, 2020, and the Consolidated Appropriations Act, 2021 (the “CAA”), which was enacted on December 27, 2020. In addition, the CARES Act provides for an expansion of the ~~date~~Medicare Accelerated and Advance Payment Program whereby inpatient acute care hospitals and other eligible providers were able to request accelerated payment of up to 100% of their Medicare payment amount for a six-month period to be repaid through withholding of future Medicare fee-for-service payments. Various other state and local programs also exist to provide relief, either independently or through distribution of monies received via the ~~unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements do not include any adjustments that might result from~~CARES Act. During 2021 and 2020, the ~~outcome~~Company obtained loans of ~~this uncertainty.~~

In connection with our assessment of going concern considerations in accordance with FASB ASC Topic 205-40, “Presentation of Financial Statements - Going Concern,” management has determined that the liquidity condition and date for mandatory liquidation and subsequent dissolution raise substantial doubt about our ability to continue as a going concern. No adjustments have been made$4,993 pursuant to the ~~carrying amounts~~CARES Act; $2,727 under the Accelerated and Advance Payment Program; and $2,001 from Provider Relief Funding under the CARES Act. Additionally, the Company obtained loans of ~~assets or liabilities should we be required to liquidate after March 13, 2022.~~

~~Results of Operations~~

~~Our entire activity since inception through September 30, 2021, related to our formation,~~$332 under the preparation for the Initial Public Offering, and since the closing of the Initial Public Offering, the search for a prospective initial Business Combination. We have neither engaged in any operations nor generated any revenues to date. We will not generate any operating revenues until after completion of our initial Business Combination. We will generate non-operating income in the form of interest income and dividends on investments held in Trust Account. We expect to incur increased expensesCARES Act as a result of ~~being~~ acquisitions of physician practices. As of June 30, 2022, all loans obtained by the Company have been forgiven.

Key Factors Affecting Performance

Through the TOI PCs, the Company serves adult and senior cancer patients in markets that have Medicare Advantage (“MA”) plans. The Company plans to leverage its long-established, strong relationships with payors to continue to build out its network and increase access to cancer patients in adjacent markets, while at the same time, decreasing oncology care costs for both patients and payors. The Company seeks to provide high quality and lower cost care delivery through the following capabilities:

•a ~~public~~recruiting process focused on selecting physicians that want to practice evidence-based medicine;

•technology-enabled care pathways ensuring adherence to evidence-based clinical protocols;

•strong clinical culture and physician oversight;

Table of Contents

•care management to prevent unnecessary hospitalizations;

•care delivered in community clinics versus hospital setting;

•clinically appropriate integration of palliative care and hospice aligned with patients’ goals for care;

•access to clinical trials providing cutting-edge treatment options at low or no cost to patients or payors; and

•appropriate provider training on clinical documentation to ensure proper risk adjustment and reimbursement for complex patients.

Key Business Metrics

In addition to our financial information, the Company's management reviews a number of operating and financial metrics, including the following key metrics, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans, and make strategic decisions.


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Clinics (1)	69		58		69		58
Markets	13		9		13		9
Lives under value-based contracts (millions)	1.7		1.5		1.7		1.5
Adjusted EBITDA (in thousands)	$	(6,867)	$	343	$	(12,051)	$	412

(1) Includes independent oncology practices to which we provide limited management services, but do not bear the operating costs.

The Company defines adjusted EBITDA as net income (loss) excluding:

•Depreciation and amortization,

•Interest expense,

•Income tax expense,

•Board and management fees,

•Non-cash addbacks,

•Changes in fair value of liabilities,

•Stock-based compensation,

•Practice acquisition-related costs,

•Consulting and legal fees,

•Public company ~~(for legal,~~transaction costs, and

•Other specific charges.

The Company includes adjusted EBITDA because it is an important measure upon which our management uses to assess the results of operations, to evaluate factors and trends affecting the business, and to plan and forecast future periods.

Adjusted EBITDA is “non-GAAP” financial ~~reporting, accounting~~measure within the meaning of Item 10 of Regulation S-K promulgated by the SEC. Management believes that this measure provides an additional way of viewing aspects of the Company's operations that, when viewed with the GAAP results, provides a more complete understanding of the Company's results of operations and ~~auditing compliance)~~the factors and trends affecting the business. However, non-GAAP financial measures should be considered a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with U.S. GAAP. Non-GAAP financial measures used by management may differ from the non-GAAP measures used by other companies, including the Company's competitors. Management encourages investors and others to review the Company's financial information in its entirety, not to rely on any single financial measure.

Table of Contents

The following table provides a reconciliation of net income (loss), ~~as well as for due diligence expenses.~~

~~For~~the most closely comparable GAAP financial measure, to Adjusted EBITDA:


	Three Months Ended June 30,				Change
(dollars in thousands)	2022		2021		$		%
Net income (loss)	$	(5,453)	$	3,205	$	(8,658)	(270.1)	%
Depreciation and amortization	1,098		794		304		38.3	%
Interest expense	61		81		(20)		(24.7)	%
Income tax expense	(32)		780		(812)		(104.1)	%
Board and management fees	62		102		(40)		(39.2)	%
Non-cash addbacks(1)	108		(5,728)		5,836		(101.9)	%
Share-based compensation	6,515		51		6,464		12,674.5	%
Change in fair value of liabilities	(12,865)		—		(12,865)		N/A
Practice acquisition-related costs(2)	111		107		4		3.7	%
Consulting and legal fees(3)	1,144		543		601		110.7	%
Other, net(4)	1,634		408		1,226		300.5	%
Public company transaction costs	750		—		750		N/A
Adjusted EBITDA	$	(6,867)	$	343	$	(7,210)	(2,102.0)	%

(1) During the three months ended ~~September~~June 30, 2022, non-cash addbacks were primarily comprised of reversals of bad debt recoveries of $105 and non-cash rent of $3. During the three months ended June 30, 2021, non-cash addbacks were primarily comprised of gain on debt extinguishment of $5,186 and bad debt recoveries of $722.

(2) Practice acquisition-related costs were comprised of consulting and legal fees incurred to perform due diligence, execute, and integrate acquisitions of various oncology practices.

(3) Consulting and legal fees were comprised of a subset of the Company’s total consulting and legal fees during the three months ended June 30, 2022 and 2021, and related to certain advisory projects, software implementations, and legal fees for debt financing and predecessor litigation matters.

(4) Other, net is comprised of severance expenses resulting from cost rationalization programs of $67 and $0, as well as temporary labor of $329 and $292, recruiting expenses to build out corporate infrastructure of $1,207 and $116 and other miscellaneous charges of $31 and $0 during the three months ended June 30, 2022 and 2021, respectively.


	Six Months Ended June 30,				Change
(dollars in thousands)	2022		2021		$		%
Net income (loss)	$	13,833	$	2,209	$	11,624	526.2	%
Depreciation and amortization	2,085		1,571		514		32.7	%
Interest expense	135		182		(47)		(25.8)	%
Income tax expense	148		998		(850)		(85.2)	%
Board and management fees	107		208		(101)		(48.6)	%
Non-cash addbacks(1)	305		(5,741)		6,046		(105.3)	%
Share-based compensation	15,067		93		14,974		16,101.1	%
Change in fair value of liabilities	(50,844)		—		(50,844)		N/A
Practice acquisition-related costs(2)	533		197		336		170.6	%
Consulting and legal fees(3)	1,799		930		869		93.4	%
Other, net(4)	2,587		(235)		2,822		(1,200.9)	%
Public company transaction costs	2,194		—		2,194		N/A
Adjusted EBITDA	$	(12,051)	$	412	$	(12,463)	(3,025.0)	%

(1) During the six months ended June 30, 2022, non-cash addbacks were primarily comprised of net bad debt write-offs of $259, non-cash rent of $32 and other miscellaneous charges of $14. During the six months ended June 30, 2021, non-cash addbacks were primarily comprised of gain on debt extinguishment of $5,186 and bad debt recoveries of $722.

Table of Contents

(2) Practice acquisition-related costs were comprised of consulting and legal fees incurred to perform due diligence, execute, and integrate acquisitions of various oncology practices.

(3) Consulting and legal fees were comprised of a subset of the Company’s total consulting and legal fees during the six months ended June 30, 2022 and 2021, and related to certain advisory projects, software implementations, and legal fees for debt financing and predecessor litigation matters.

(4) Other, net is comprised of severance expenses resulting from cost rationalization programs of $85 and $0, as well as temporary labor of $814 and $516, recruiting expenses to build out corporate infrastructure of $1,631 and $272, and other miscellaneous expense of $57 and $0 during the six months ended June 30, 2022 and 2021, respectively. During the six months ended June 30, 2022 and 2021 such expenses were partially offset by $0 and $1,023, respectively, of stimulus funds received under the CARES Act.

Components of Results of Operations

Revenue

The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) pharmacy benefit managers (“PBMs”), (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”); (iv) state governments under Medicaid and other programs; (v) other third-party payors and managed care organizations (e.g., risk bearing organizations and independent practice associations (“IPAs”)); and (vi) individual patients and clients.

Revenue primarily consists of capitation revenue, fee-for-service (“FFS”) revenue, dispensary revenue, and clinical trials revenue. Capitation and FFS revenue comprise the revenues within the Company’s patient services segment and are presented together in the results of operations. The following paragraphs provide a summary of the principal forms of our billing arrangements and how revenue is recognized for each type of revenue.

Capitation

Capitation revenues consist primarily of fees for medical services provided by the TOI PCs to the Company's patients under a capitated arrangement with various managed care organizations. Capitation revenue is paid monthly based on the number of enrollees by the contracted managed care organization (per member per month or “PMPM”). Capitation contracts generally have a legal term of one year or longer. Payments in capitation contracts are variable since they primarily include PMPM fees associated with unspecified membership that fluctuates throughout the term of the contract; however, based on our experience, our total underlying membership generally increases over time as penetration of MA products grows. Certain contracts include terms for a capitation deduction where the cost of out-of-network referrals of members are deducted from the future payment. Revenue is recognized in the month services are rendered on the basis of the transaction price established at that time.

Fee-for-service revenue

FFS revenue represents revenue earned under contracts in which we ~~had~~bill and collect for medical services rendered by the TOI PCs’ employed physicians. The terms for FFS contracts are short in duration and only last for the period over which services are rendered (typically, one day). FFS revenue consists of fees for medical services provided to patients. As specialist providers, our FFS revenue is dependent on referrals from other physicians, such as primary care physicians. The Company's affiliated providers build trusted, professional relationships with these physicians and their associated medical groups, which can lead to recurring FFS volume; however, this volume is subject to numerous factors the Company cannot control and can fluctuate over time. The Company also receives FFS revenue for capitated patients that receive medical services which are excluded from the Company's capitation contracts. Under the FFS arrangements, third-party payors and patients are billed for patient care services provided by the TOI PCs. Payments for services provided are generally less than billed charges. The Company records revenue net of an allowance for contractual adjustments, which represents the net revenue expected to be collected from third-party payors (including managed care, commercial, and governmental payors such as Medicare and Medicaid), and patients. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient’s healthcare plan, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries). The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on certain factors, such as the proper completion of medical charts following a ~~net loss~~patient visit, the forwarding of ~~approximately $432,000,~~such charts to our billing center for medical coding and entering into the Company's billing system, and the verification of each patient’s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded on the date the services are rendered based on the

Table of Contents

information known at the time of entering of such information into the Company's billing systems as well as an estimate of the revenue associated with medical services.

Dispensary

Oral prescription drugs prescribed by doctors to their patients are sold directly through the TOI PCs’ dispensaries. Revenue for the prescriptions is based on fee schedules set by various PBMs and other third-party payors. The fee schedule is often subject to direct and indirect remuneration (“DIR”) fees, which ~~consisted~~are based primarily on pre-established metrics. DIR fees may be assessed in the periods after payments are received against future payments. The Company recognizes revenue, deducted by estimated DIR fees, at the time the patient takes possession of ~~approximately $1.5 million~~the oral drug.

Clinical trials revenue

The TOI PCs also enter into contracts to perform clinical research trials. The terms for clinical trial contracts last many months as the clinical research is performed. Each contract represents a single, integrated set of research activities that are satisfied over time as the output of results from the trial is captured for the trial sponsor to review. Under the clinical trial contracts, the TOI PCs receive a fixed payment for administrative, set-up, and close-down fees; a fixed amount for each patient site visit; and certain expense reimbursements. The Company recognizes revenue for these arrangements on the fees earned to date based on the state of the trial, as established under contract with the customer.

Operating Expenses

Cost of services

Cost of services primarily includes chemotherapy drug costs, clinician salaries and benefits, and medical supplies. Clinicians include oncologists, advanced practice providers such as physician assistants and nurse practitioners, and registered nurses employed by the TOI PCs.

Dispensary cost

Dispensary cost primarily includes the cost of oral medications dispensed in the TOI PCs’ clinic locations.

Selling, general and administrative expense

Selling, general and administrative expenses ~~$52,500 in~~include employee-related expenses, including both clinic and field support staff as well as central administrative and corporate staff. These expenses include salaries and related ~~party~~costs and stock-based compensation for our executives and physicians. The Company's selling, general and administrative expenses also includes occupancy costs, technology infrastructure, operations, clinical and ~~approximately $50,000~~quality support, finance, legal, human resources, and business development. The Company expects its general and administrative expenses to increase over time following the consummation of the Business Combination due to the additional legal, accounting, insurance, investor relations and other costs that the Company will incur as a public company, as well as other costs associated with continuing to grow the business. While the Company expects its selling, general and administrative expenses to increase in ~~franchise tax expense, partially~~absolute dollars in the foreseeable future. such expenses are on average expected to decrease as a percentage of revenue over the long term.

Results of Operations

The following table sets forth our Condensed Consolidated Statements of Income (Operations) data expressed as a percentage of total revenues for the periods indicated. The Company’s management is not aware of material events or uncertainties that would cause the financial information below to not be indicative of future operating results or results of future financial condition.

Table of Contents


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Revenue
Patient services	64.2	%	59.8	%	63.9	%	60.4	%
Dispensary	33.2	%	35.6	%	33.5	%	35.9	%
Clinical trials & other	2.6	%	4.6	%	2.6	%	3.7	%
Total operating revenue	100.0	%	100.0	%	100.0	%	100.0	%
Operating expenses
Direct costs – patient services	54.0	%	47.3	%	51.9	%	47.4	%
Direct costs – dispensary	27.5	%	30.6	%	27.6	%	30.9	%
Direct costs – clinical trials & other	0.2	%	0.3	%	0.3	%	0.3	%
Selling, general and administrative expense	46.5	%	22.5	%	50.1	%	22.7	%
Depreciation and amortization	1.8	%	1.5	%	1.8	%	1.6	%
Total operating expenses	130.0	%	102.2	%	131.7	%	102.9	%
Loss from operations	(30.0)	%	(2.2)	%	(31.7)	%	(2.9)	%
Other non-operating expense (income)
Interest expense	0.1	%	0.2	%	0.1	%	0.2	%
Change in fair value of derivative warrant liabilities	(3.4)	%	—	%	(0.5)	%	—	%
Change in fair value of earnout liabilities	(17.7)	%	—	%	(43.2)	%	—	%
Gain on debt extinguishment	—	%	(10.4)	%	(0.2)	%	(5.3)	%
Other, net	—	%	—	%	0.1	%	(1.0)	%
Total other non-operating income	(21.0)	%	(10.2)	%	(43.7)	%	(6.1)	%
Income before provision for income (loss) taxes	(9.0)	%	8.0	%	12.0	%	3.2	%
Income tax (expense) benefit	—	%	(1.6)	%	(0.1)	%	(1.0)	%
Net income (loss)	(9.0)	%	6.4	%	11.9	%	2.2	%

Comparison of the Three and Six Months Ended June 30, 2022 and 2021

Revenue


	Three Months Ended June 30,				Change				Six Months Ended June 30,				Change
(dollars in thousands)	2022		2021		$		%		2022		2021		$		%
Patient services	$	39,109	$	29,786	$	9,323	31.3	%	$	74,166	$	59,408	$	14,758	24.8	%
Dispensary	20,218		17,782		2,436		13.7	%	38,897		35,400		3,497		9.9	%
Clinical trials & other	1,594		2,276		(682)		(30.0)	%	3,019		3,616		(597)		(16.5)	%
Total operating revenue	$	60,921	$	49,844	$	11,077	22.2	%	$	116,082	$	98,424	$	17,658	17.9	%

Patient services

Three Months Ended June 30, 2022 and 2021

The increase in patient services revenue was primarily due to a 27.0% increase in FFS revenue as a result of practice acquisitions and an overall increase in clinic count as well as a 3.5% increase in capitation revenue due to new capitation contracts entered into in the latter half of 2021.

Six Months Ended June 30, 2022 and 2021

The increase in patient services revenue was primarily due to a 18.2% increase in FFS revenue as a result of practice acquisitions and an overall increase in clinic count as well as a 5.4% increase in capitation revenue due to new capitation contracts entered into in the latter half of 2021.

Table of Contents

Dispensary

Three Months Ended June 30, 2022 and 2021

The increase in dispensary revenue was primarily due to a 12.6% increase in the average revenue per fill in addition to a 1.0% increase in the number of fills.

Six Months Ended June 30, 2022 and 2021

The increase in dispensary revenue was primarily due to a 15.6% increase in the average revenue per fill offset by a 4.9% decline in the number of fills due to the new Medi-Cal reimbursement policy that was implemented in 2022 that transitioned claims processing from medical claims to pharmacy claims.

Clinical trials & other

The decrease in clinical trials and other revenue was primarily due to a decrease in visits and lower reimbursement revenue compared to prior year.

Operating Expenses


	Three Months Ended June 30,			Change				Six Months Ended June 30,			Change
(dollars in thousands)	2022	2021		$		%		2022	2021		$		%
Direct costs – patient services	$32,875	$	23,574	$	9,301	39.5	%	$60,253	$	46,660	$	13,593	29.1	%
Direct costs – dispensary	16,754	15,237		1,517		10.0	%	32,078	30,360		1,718		5.7	%
Direct costs – clinical trials & other	150	143		7		4.9	%	287	312		(25)		(8.0)	%
Selling, general and administrative expense	28,348	11,212		17,136		152.8	%	58,154	22,390		35,764		159.7	%
Depreciation and amortization	1,098	794		304		38.3	%	2,085	1,571		514		32.7	%
Total operating expenses	$79,225	$	50,960	$	28,265	55.5	%	$152,857	$	101,293	$	51,564	50.9	%

Patient services cost

Three Months Ended June 30, 2022 and 2021

The increase in patient services cost was primarily due to a 20.3% increase in intravenous drug costs, driven by the Company's patient mix and volume, as well as 16.8% increase in clinical payroll costs due to the growth in clinic count.

Six Months Ended June 30, 2022 and 2021

The increase in patient services cost was primarily due to a 13.4% increase in intravenous drug costs, driven by the Company's patient mix and volume, as well as 14.1% increase in clinical payroll costs due to the growth in clinic count.

Dispensary cost

Three Months Ended June 30, 2022 and 2021

The increase in dispensary cost was primarily due to a 8.9% increase in the average cost of the prescriptions filled in addition to a 1.0% increase in the number of prescriptions filled.

Six Months Ended June 30, 2022 and 2021

The increase in dispensary cost was primarily due to a 11.1% increase in the average cost of the prescriptions filled offset by a 4.9% decline in the number of prescriptions filled.

Table of Contents

Selling, general and administrative expense

Three Months Ended June 30, 2022 and 2021

The increase in selling, general and administrative expense was primarily driven by an ~~approximately $1.1 million gain from changes~~increase in share-based compensation expense of 57.6% and an increase of 6.7% in transaction costs related to the Business Combination. In addition, salaries and benefits increased 31.2% due to the growth in the Company's management and corporate team. The remainder of the increases were primarily to support the continued growth of our business.

Six Months Ended June 30, 2022 and 2021

The increase in selling, general and administrative expense was primarily driven by an increase in share-based compensation expense of 66.9% and an increase of 9.8% in transaction costs related to the Business Combination. In addition, salaries and benefits increased 30.7% due to the growth in the Company's management and corporate team. The remainder of the increases were primarily to support the continued growth of our business.

Other Expenses (Income)


	Three Months Ended June 30,				Change				Six Months Ended June 30,				Change
(dollars in thousands)	2022		2021		$		%		2022		2021		$		%
Interest expense	$	61	$	81	$	(20)	(24.7)	%	$	135	$	182	$	(47)	(25.8)	%
Change in fair value of derivative warrant liabilities	(2,065)		—		(2,065)		N/A		(604)		—		(604)		N/A
Change in fair value of earnout liabilities	(10,800)		—		(10,800)		N/A		(50,240)		—		(50,240)		N/A
Gain on debt extinguishment	—		(5,186)		5,186		N/A		(183)		(5,186)		5,003		(96.5)	%
Other, net	(15)		4		(19)		(475.0)	%	136		(1,072)		1,208		(112.7)	%
Total other non-operating (income) expense	$	(12,819)	$	(5,101)	$	(7,718)	151.3	%	$	(50,756)	$	(6,076)	$	(44,680)	735.4	%

Interest expense

The decrease in interest expense was due to the pay-off of our term loan balance in Q4 2021.

Change in fair value of liabilities

Three Months Ended June 30, 2022 and 2021

The increase in non-operating (income) expense was primarily due to gains of $2,065 and $10,800, respectively, as a result of an decrease in the fair value of derivative warrant liabilities and ~~approximately $6,000~~derivative earnout liabilities which were created as part of the Business Combination.

Six Months Ended June 30, 2022 and 2021

The increase in ~~interest earned from investments held~~non-operating (income) expense was primarily due to gains of $604 and $50,240, respectively, as a result of an decrease in the ~~Trust Account.~~

~~Table of Contents~~

For the three months ended September 30, 2020, we had a net loss of approximately $2.4 million, which consisted of approximately $96,000 in general and administrative expenses, $52,500 in related party general and administrative expenses, $50,000 in franchise tax expense, approximately $13,000 in income tax expense and an approximately $2.3 million loss from changes in fair value of derivative warrant liabilities, partially offset by approximately $73,000 in interest earned from investments held in the Trust Account.

For the nine months ended September 30, 2021, we had a net loss of approximately $867,000, which consisted of approximately $4.1 million in general and administrative expenses, $157,500 in related party general and administrative expenses and approximately $150,000 in franchise tax expense, partially offset by an approximately $3.5 million gain from changes in fair value of derivative warrant liabilities and ~~approximately $58,000 in interest earned from investments held in~~derivative earnout liabilities which were created as part of the ~~Trust Account.~~

~~For~~Business Combination.

Gain on debt extinguishment

Three Months Ended June 30, 2022 and 2021

There was no gain on debt extinguishment during the ~~nine~~three months ended ~~September~~June 30, ~~2020, we~~2022. During the three months ended June 30, 2021, gain on debt extinguishment of $5,186 was a result of forgiveness of a CARES Act loan and a physician practice acquisition.

Table of Contents

Six Months Ended June 30, 2022 and 2021

During the six months ended June 30, 2022, gain on debt extinguishment of $183 was a result of forgiveness of a CARES Act loan that was acquired as part of a physician practice acquisition. During the six months ended June 30, 2021, gain on debt extinguishment of $5,186 was a result of forgiveness of a CARES Act loan and a physician practice acquisition.

Other, net

The change in other, net was primarily due to Provider Relief Funding under the CARES Act received during the six months ended June 30, 2021.

Liquidity and Capital Resources

General

To date, the Company has financed its operations principally through private placements of its equity securities and payments received from various payors. As of June 30, 2022, the Company had ~~a net loss~~$64,208 of ~~approximately $5.8 million,~~cash, of which ~~consisted of approximately $209,000~~$0 is restricted cash.

The Company may incur operating losses and generate negative cash flows from operations for the foreseeable future due to the investments management intends to continue to make in expanding operations and sales and marketing and due to additional general and administrative expenses ~~$122,500~~management expects to incur in ~~related party general~~connection with operating as a public company. As a result, the Company may require additional capital resources to execute strategic initiatives to grow the business.

Management believes that the cash on hand and ~~administrative expenses, approximately $150,000~~cash conferred from the Business Combination will be sufficient to fund the Company's operating and capital needs for at least the next 12 months. Management's assessment of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties. The Company's actual results could vary because of, and its future capital requirements will depend on, many factors, including our growth rate, the timing and extent of spending to open or acquire new clinics and expand into new markets and the expansion of sales and marketing activities. The Company may in ~~franchise tax expense, approximately $315,000~~the future enter into arrangements to acquire or invest in ~~offering costs associated with derivative warrant liabilities, approximately $13,000~~complementary businesses, services and technologies, including intellectual property rights. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than management currently expects. The Company may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, the Company may not be able to raise it on terms acceptable to management or at all. If unable to raise additional capital when desired, or if the Company cannot expand operations or otherwise capitalize on business opportunities because the Company's lack of sufficient capital, the Company's business, results of operations, and financial condition would be adversely affected.

Cash Flows

The following table presents a summary of the Company's consolidated cash flows from operating, investing, and financing activities for the periods indicated.


	Six Months Ended June 30,				Change
(dollars in thousands)	2022		2021		$		%
Net cash and restricted cash (used in) provided by operating activities	$	(27,360)	$	(6,666)	$	(20,694)	310	%
Net cash and restricted cash used in investing activities	(11,264)		(2,053)		(9,211)		449	%
Net cash and restricted cash (used in) provided by financing activities	(12,342)		17,890		(30,232)		(169)	%
Net (decrease) increase in cash and restricted cash	$	(50,966)	$	9,171	$	(60,137)	(656)	%
Cash and restricted cash at beginning of period	115,174		5,998		109,176		1,820	%
Cash and restricted cash at end of period	$	64,208	$	15,169	$	49,039	323	%

Operating Activities

Significant changes impacting net cash (used in) provided by operating activities for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 were as follows:

Table of Contents

•Net income increased $11,624, share-based compensation increased $14,974, and the gain on debt extinguishment decreased $5,003, offset by a decrease in ~~income tax expense and a approximately $5.2 million loss from changes in~~the fair value of ~~derivative warrant liabilities, partially offset~~liability classified earnouts of $50,240, for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021;

•Cash used by ~~approximately $195,000 in interest earned from investments held~~accounts receivable increased $7,406 for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 due to the growth in the ~~Trust Account.~~

~~Contractual Obligations~~

WeCompany's business;

•Cash used by accounts payable, accrued expenses and income taxes payable increased $2,168 for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 primarily due to an increase in vendor payables due to the growth in the Company's business; and

•Cash used by inventory increased $1,461 for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 due to the growth in the Company's business.

Investing Activities

Net cash used in investing activities increased $9,211 for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 due an increase cash used for purchases of practice acquisitions and intangibles of $7,893, as well as an increase in cash used for purchases of property and equipment of $1,318 for new clinic builds and clinic remodels.

Financing Activities

Net cash used in financing activities for the six months ended June 30, 2022 primarily relates to cash paid of $9,000 to repurchase common stock and common stock options. For the six months ended June 30, 2021, net cash provided by financing activities primarily relates to the issuance of $20,000 of Legacy Preferred Stock.

Material Cash Requirements

The Company's material cash requirements for the following five years consist of operating leases and other miscellaneous administrative expenses. Additionally, the Company is subject to certain outside claims and litigation arising out of the ordinary course of business, however, no such litigation requires future cash expenditure as of June 30, 2022.


	Material Cash Requirements Due by the Year Ended December 31,
(dollars in thousands)	2022		2023-2024		2025-2026		Thereafter		Total
Operating leases	$	2,604	$	9,289	$	6,220	$	3,246	$	21,359
Deferred acquisition consideration	1,700		4,309		—		—		6,009
Other1	2,639		3,132		5		—		5,776
Total material cash requirements	$	6,943	$	16,730	$	6,225	$	3,246	$	33,144

(1) Other is comprised of finance leases and directors and officers insurance premiums.

JOBS Act

The Company qualifies as an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and has elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have ~~any long-term debt obligations, capital lease obligations, operating lease obligations, purchase obligations~~a class of securities registered under the Exchange Act) are required to comply with the new or ~~long-term liabilities, other than an agreement~~revised financial accounting standards. The JOBS Act provides that a company can elect to pay our Sponsor a monthly fee of $10,000 for office space, secretarial and administrative services and an agreement to pay our Chief Financial Officer, Christopher Wolfe, $7,500 per month for his services prior to the initial Business Combination.

~~Registration Rights~~

~~The initial stockholders and holders~~opt out of the ~~Private Placement Warrants are entitled~~extended transition period and comply with the requirements that apply to ~~registration rights pursuant~~non-emerging growth companies, but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a ~~registration rights agreement. The initial stockholders~~standard is issued or revised and ~~holders~~it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company that is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the Private Placement Warrants will be entitled to make up to three demands, excluding short form registration demands, that we register such securities for sale under the Securities Act. In addition, these holders will have “piggy-back” registration rights to include their securitiespotential differences in ~~other registration statements filed by us. We will bear the expenses incurred in connection with the filing~~accounting standards used.

Table of ~~any such registration statements.~~

Contents

~~Underwriting Agreement~~

The underwriters did not receive any underwriting discounts or commission on the 5,000,000 Units purchased in the Initial Public Offering by certain domestic private pooled investment vehicles managed by Deerfield Management Company, L.P. We paid an underwriting discount of 2.0% of the per Unit offering price, or $3.6 million, at the closing of the Initial Public Offering, with an additional fee (the “Deferred Underwriting Fees”) of 3.5% of the gross offering proceeds, or $6.3 million, payable upon our completion of an Initial Business Combination. The Deferred Underwriting Fees will become payable to the underwriters from the amounts held in the Trust Account solely in the event we complete our initial Business Combination.

Critical Accounting Policies

~~Use of Estimates~~

The ~~preparation of unaudited condensed consolidated~~Company prepares its financial statements in ~~conformity~~accordance with ~~GAAP~~generally accepted accounting principles in the United States ("U.S. GAAP"), which requires ~~our~~ management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the ~~unaudited~~ condensed consolidated financial statements and the reported amounts of ~~revenue~~revenues and expenses during the reporting period. ~~Making~~Actual results could differ from those estimates under different assumptions or conditions.

Leases

On January 1, 2022, the Company adopted ASU 2016-02, Leases, with various amendments issued in 2018 and 2019 (collectively, “ASC 842”) using the modified retrospective approach, for leases that existed on January 1, 2022. ASC 842 requires ~~our management~~lessees to ~~exercise significant judgment. It~~recognize assets and liabilities for most leases. The Company evaluates whether an arrangement is or contains a lease at ~~least reasonably possible that~~contract inception. A lease exists when a contract conveys to the ~~estimate~~customer the right to control the use of an identified asset for a period of time in exchange for consideration. Upon lease commencement, the ~~effect~~date on which a lessor makes the underlying asset available to the Company for use, the Company classifies the lease as either an operating or finance lease. The Company applied certain practical expedients permitted under the transition guidance, including the package of practical expedients, which permits the Company not to reassess its prior conclusions related to lease identification, lease classification, and initial direct costs capitalization. The Company solely acts as a lessee and its leases primarily consist of operating leases for its real estate in the states in which the Company operates. The Company has other operating or financing leases for various clinical and non-clinical equipment.

Generally, upon the commencement of a ~~condition, situation or set of circumstances that existed~~lease, the Company will record a right-of-use (“ROU”) asset and lease liability. An ROU asset represents the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are measured at the date of the unaudited condensed consolidated financial statements, which our management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fairpresent value of the ~~derivative warrant liabilities. Accordingly,~~remaining, fixed lease payments at lease commencement. The Company uses its incremental borrowing rate, based on the ~~actual results could differ significantly from those estimates.~~

~~Table~~information available at the later of ~~Contents~~

~~Investments Held~~adoption, inception, or modification in determining the present value of lease payments. ROU assets are measured at an amount equal to the initial lease liability, plus any prepaid lease payments (less any incentives received) and initial direct costs, at the lease commencement date. The Company has elected to account for lease and non-lease components as a single lease component for all underlying classes of assets. As a result, the fixed payments that would otherwise be allocable to the non-lease components are account for as lease payments and included in the ~~Trust Account~~

~~Our portfolio~~measurement of ~~investments held~~the Company’s right-of-use asset and lease liability.

Lease arrangements with an initial term of 12 months or less are considered short-term leases and are not recorded on the balance sheet. The short-term lease payments are recognized as an expense on a straight-line basis over the lease term. The lease term includes any period covered by renewal options available that the Company is reasonably certain to exercise and any options to terminate the lease that the Company is not reasonably certain to exercise.

Variable Interest Entities

The Company consolidates entities for which it has a variable interest and is determined to be the primary beneficiary. The Company holds variable interests in the ~~Trust Account is~~TOI PCs, comprised of ~~U.S. government securities, within~~TOI CA, TOI FL, and TOI TX all of which the ~~meaning set forth~~Company cannot legally own due to jurisdictional laws governing the corporate practice of medicine. The TOI PCs employ physicians and other clinicians in ~~Section 2(a)(16)~~order to provide professional services to patients of our managed clinics, and under substantially similar MSAs, we serve as the exclusive manager and administrator of the ~~Investment~~TOI PCs’ non-medical functions and services. The TOI PCs are considered variable interest entities (“VIEs”) as they do not have sufficient equity to finance their activities without additional financial support from the Company. An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it has both power and benefits — that is, it has (1) the power to direct the activities of a VIE that most significantly impacts the VIE’s economic performance (power), and (2) the obligation to absorb the losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company ~~Act, with a maturity~~has the power to control all financial activities of ~~185 days or less, or investments in money market funds that invest in U.S. government securities~~the TOI PCs, the rights to receive substantially all benefits from the VIEs, and ~~generally have a readily determinable fair value, or a combination thereof. When~~consequently consolidates the ~~Company’s investments held~~TOI PCs. Revenues, expenses, and income from the TOI PCs are included in the ~~Trust Account are comprised of U.S. government securities, the investments are classified~~consolidated amounts as trading securities. When our investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the ~~balance sheets at fair value at~~Condensed Consolidated Statements of Income (Operations).

Segment Reporting

The Company presents the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income on investments held in the Trust Account in the accompanying unaudited condensed consolidatedfinancial statements ~~of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.~~

~~Class A Common Stock Subject to Possible Redemption~~

~~We account for our Class A common stock subject to possible redemption~~by segment in accordance with the ~~guidance~~relevant accounting literature to provide investors with transparency into how the chief operating decision maker (“CODM”) manages the business. The Company's

Table of Contents

CODM is our Chief Executive Officer. The CODM reviews financial information and allocates resources across three operating segments: dispensary, patient care, and clinical trials & other.

Revenue Recognition

The Company recognizes consolidated revenue based upon the principle of the transfer of control of our goods and services to customers in ~~ASC Topic 480 “Distinguishing Liabilities~~an amount that reflects the consideration it expects to be entitled. This principle is achieved through applying the following five-step approach:

1.Identification of the contract, or contracts, with a customer.

2.Identification of the performance obligations in the contract.

3.Determination of the transaction price.

4.Allocation of the transaction price to the performance obligations in the contract.

5.Recognition of revenue when, or as, the entity satisfies a performance obligation.

Consolidated revenue primarily consists of capitation revenue, fee-for-service (FFS) revenue, dispensary revenue, and clinical trials revenue. Revenue is recognized in the period in which services are rendered or the period in which the TOI PCs are obligated to provide services. The form of billing and related risk of collection for such services may vary by type of revenue and the payor. The following paragraphs provide a summary of the principal forms of billing arrangements and how revenue is recognized for each.

Capitation

Capitation contracts have a single performance obligation that is a stand ready obligation to perform specified healthcare services to the population of enrolled members and constitutes a series for the provision of managed healthcare services for the term of the contract, which is deemed to be one month since the mix of patient-customers can and do change month over month. The transaction price for capitation contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the term of the contract. Further, we adjust the transaction price for capitation deductions based on historical experience. Revenue is recognized in the month services are rendered on the basis of the transaction price established at that time. If subsequent information resolves uncertainties related to the transaction price, adjustments will be recognized in the period they are resolved. When payment has been received but services have not yet been rendered, the payment is recognized as a contract liability.

Fee For Service

FFS revenue consists of fees for medical services actually provided to patients. These medical services are distinct since the patient can benefit from ~~Equity.” Class A common stock~~the medical services on their own. Each service constitutes a single performance obligation for which the patient accepts and receives the benefit of the medical services as they are performed.

The transaction price from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to patients, and reimbursement of provider costs, all of which can vary from period to period. The Company estimates the transaction price using the most likely methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. As a practical expedient, the Company adopted a portfolio approach to determine the transaction price for the medical services provided under FFS arrangements. Under this approach, the Company bifurcated the types of services provided and grouped health plans with similar fees and negotiated payment rates.

At these levels, portfolios share the characteristics conducive to ensuring that the results do not materially differ from the standard applied to individual patient contracts related to each medical service provided.

Revenue is recorded on the date the services are rendered based on the information known at the time of entering of such information into our billing systems as well as an estimate of the revenue associated with medical services. When the performance obligation is not satisfied, the billing is recognized as a contract liability.

Table of Contents

Dispensary

Dispensed prescriptions that are filled and delivered to the patient are considered a distinct performance obligation. The transaction price for the prescriptions is based on fee schedules set by PBMs and other third-party payors. The fee schedule is often subject to ~~mandatory redemption (if any)~~DIR fees, which are based primarily on pre-established metrics. DIR fees may be assessed in periods after payments are received against future payments. The Company estimates DIR fees to arrive at the transaction price for prescriptions. Revenue is ~~classified as liability instruments and are measured~~recognized based on the transaction at ~~fair value. Conditionally redeemable Class A common stock (including Class A common stock that features redemption rights that are either within~~ the ~~control~~time the patient takes possession of the ~~holder or subject~~oral drug.

Clinical Research

Clinical research contracts represent a single, integrated set of research activities and thus are a single performance obligation. The performance obligation is satisfied over time as the output is captured in data and documentation that is available for the customer to ~~redemption upon~~consume over the ~~occurrence~~course of uncertain events not solely within our control) are classified as temporary equity. At all other times, Class A common stock is classified as stockholders’ equity. Our Class A common stock features certain redemption rights that are considered to be outside of our controlarrangement and subject to the occurrence of uncertain future events. Accordingly, as of September 30, 2021, and December 31, 2020, 23,000,000 shares of Class A common stock subject to possible redemption are presented as temporary equity, outsidefurthers progress of the ~~stockholders’ equity section of our condensed consolidated balance sheets.~~

~~Under ASC 480-10-S99, the~~clinical trial. The Company has elected to recognize revenue for clinical trials using the ‘as-invoiced’ practical expedient. The customer is invoiced periodically based on the progress of the trial such that each invoice captures the revenue earned to date based on the state of the trial as established under contract with the customer.

Direct Costs of Sales

Direct cost of sales primarily consists of wages paid to clinical personnel and other health professionals, oral and IV drug costs, and other medical supplies used to provide patient care. Costs for clinical personnel wages are expensed as incurred and costs for inventory and medical supplies are expensed when used, generally by applying the specific identification method.

Goodwill and Intangible Assets

Goodwill is not amortized but is required to be evaluated for impairment at the same time every year. The Company performs annual testing of impairment for goodwill in the fourth quarter of each year. When impairment indicators are identified, the Company compares the reporting unit’s fair value to its carrying amount, including goodwill. An impairment loss is recognized as the difference, if any, between the reporting unit’s carrying amount and its fair value to the extent the difference does not exceed the total amount of goodwill allocated to the reporting unit.

Finite-lived intangible assets are stated at acquisition-date fair value. Intangible assets are amortized using the straight-line method. Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the ~~redemption value immediately as they occur and adjust~~carrying amount of an asset may not be recoverable. When circumstances indicate that recoverability may be impaired, the Company assesses its ability to recover the carrying value of the ~~security to equal~~asset group from the ~~redemption value at the end of each reporting period. This method would view the end~~expected future pre-tax cash flows (undiscounted and without interest charges) of the ~~reporting period as if it were also~~related operations. If these cash flows are less than the ~~redemption date~~carrying value of such asset, an impairment loss is recognized for the security. Effective with the closing of the Initial Public Offering, we recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit.

~~Net Income (Loss) Per Share of Common Stock~~

We comply with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” We have two classes of shares, which are referred to as Class A common stock and Class B common stock. Income and losses are shared pro ratadifference between the two classes of shares. Net income (loss) per share of common stock is calculated by dividing the net income (loss) by the weighted average shares of common stock outstanding for the respective period.

~~Derivative Warrant Liabilities~~

We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. We evaluate all of our financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

~~Table of Contents~~

~~The Public Warrants and the Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, we recognize the warrant instruments as liabilities at~~estimated fair value and ~~adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair~~carrying value. Fair value is recognized in our unaudited condensed consolidated statements of operations. The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model and subsequently, the fair value of the Private Placement Warrants have been estimated using a Monte Carlo simulation model each measurement date. The fair value of Public Warrants issued in connection with the Initial Public Offering have subsequently been measureddetermined based on ~~the listed market price of such warrants.~~

~~Recent Accounting Pronouncements~~

~~In August 2020, the FASB issued ASU No. 2020-06, Debt—~~Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. We early adopted the ASU on January 1, 2021. Adoption of the ASU did not have a material impact on our financial position, results of operations or cash flows.

Our management does not believe that any other recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying unaudited condensed consolidated financial statements.

~~Off-Balance Sheet Arrangements~~

~~As of September 30, 2021, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.~~

~~Inflation~~

~~We do not believe that inflation had a material impact on our business, revenues or operating results during the period presented.~~

~~JOBS Act~~

The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, the unaudited condensed consolidated financial statements may not be comparable to those of companies that comply with new or revised accounting pronouncements as of public company effective dates.

Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the unaudited condensed consolidated financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our Initial Public Offering or until we are no longer an “emerging growth company,” whichever is earlier.

appropriate valuation techniques.

~~ITEM~~

Item 3. ~~QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~

Quantitative and Qualitative Disclosures About Market Risk

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure due to potential changes in inflation or interest rates. We do not hold financial instruments for trading purposes.

Interest Rate Risk

We held cash and cash equivalents of $64,208 as of June 30, 2022, consisting of bank deposits. Such interest-earning instruments carry a degree of interest rate risk. The goals of our investment policy are liquidity and capital preservation. We believe that we do not have any material exposure to changes in the fair value of these assets as a ~~smaller reporting company as defined~~results of changes in interest rates due to the short-term nature of our cash and cash equivalents.

Inflation Risk

Recently, inflation has increased throughout the U.S. economy. Inflation can adversely affect us by ~~Rule 12b-2~~increasing the costs of drugs, clinical trials and research, administration and other costs of doing business. We may experience increases in the ~~Exchange Act~~prices of labor and ~~are~~other costs of doing business. In an inflationary environment, cost increases may outpace our expectations, causing us to use our cash and other liquid assets faster than forecasted. If this happens, we may need to raise additional capital to fund our operations, which may not ~~required to provide the information otherwise required under this item.~~

be available in sufficient amounts or on reasonable terms, if at all, sooner than expected.

Table of Contents

~~ITEM~~

Item 4. ~~CONTROLS AND PROCEDURES~~

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to ensure that the information relating to our Company, including our consolidated subsidiaries, that required to be disclosed in our

~~Under~~Securities and Exchange Commission ("SEC") reports, is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow for timely decisions regarding required disclosure. We conducted an evaluation, under the supervision and with the participation of ~~our~~ management, including our ~~principal executive officer~~Chief Executive Officer and ~~principal financial officer, we conducted an evaluation~~Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures ~~as of the end of the fiscal quarter ended September 30, 2021, as such term is~~(as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange ~~Act.~~Act of 1934, as amended) as of June 30, 2022. Based on this evaluation, our ~~principal executive officer~~Chief Executive Officer and ~~principal financial officer has~~Chief Financial Officer concluded that, ~~during the period covered by this report,~~as of June 30, 2022, our disclosure controls and procedures were not effective ~~as of September 30, 2021, because of a~~due to material ~~weakness~~weaknesses in our internal control over financial ~~reporting.~~ reporting, as described below.

Material Weaknesses in Internal Controls Over Financial Reporting

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of ~~the Company’s~~our annual or interim financial statements will not be prevented or detected on a timely basis. ~~Specifically,~~Accordingly, a material weakness increases the ~~Company’s management has concluded~~risk that the financial information we report contains material errors. If we fail to remediate these material weaknesses, determine that our internal controls over financial reporting are not effective, discover areas that need improvement in the future or discover additional material weaknesses, these shortcomings could have an adverse effect on our business and financial results, and the price of our common stock could be negatively affected.

As of June 30, 2022, we have identified deficiencies in our control ~~around~~environment. These deficiencies include material weaknesses relate to: (i) segregation of duties in the ~~interpretation~~financial closing and reporting process; (ii) internal controls over review of complex accounting ~~for certain complex features~~transactions and (iii) internal control over reviews of revenue process.

During 2022, our management continued to execute against the remediation plan under the oversight of the ~~Class A common stock~~Audit Committee. This involves hiring and ~~warrants issued by~~training additional qualified personnel, performing detailed risk assessments in key process areas to identify risks of material misstatement, further document and implement control procedures to address the ~~Company was not effectively designed or maintained. This~~identified risks of material ~~weakness resulted in the restatement of the Company’s balance sheet as of March 13, 2020, its annual financial statements for the period ended December 31, 2020,~~misstatements, and its interim financial statements notes and Item 4 or Part 1 of the Form 10-Q for the quarters ended March 31, 2020, June 30, 2020, September 30, 2020, March 31, 2021, June 30, 2021, and September 30, 2021.

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and thatimplement monitoring activities over such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

control procedures.

Changes in Internal Control over Financial Reporting

~~There was~~

Except for the progress that has been made toward remediating the material weaknesses noted above, there were no ~~change~~changes in ~~our~~the Company’s internal control over financial reporting that occurred during the ~~fiscal quarter~~three and six months ended ~~September~~June 30, ~~2021, covered by this Quarterly Report on Form 10-Q~~2022 that ~~has~~have materially affected, or isare reasonably likely to materially affect, ~~our~~the Company’s internal control over financial ~~reporting except.~~

~~Our principal executive officer~~reporting.

Limitations on Effectiveness of Disclosure Controls and ~~principal financial officer performed additional accounting~~Procedures

In designing and ~~financial analyses~~evaluating our disclosure controls and ~~other post-closing~~ procedures, management, including ~~consulting with subject~~the Chief Executive Officer and Chief Financial Officer, recognizes that any controls and procedures, no matter ~~experts related to~~how well designed and operated, can provide only reasonable assurance of achieving the ~~accounting for certain complex features~~desired control objectives. Because of the ~~Class A common stock~~inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and ~~warrants.~~instances of fraud, if any, within the company have been detected. The ~~Company’s management has expended,~~design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will ~~continue to expend, a substantial amount~~succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of ~~effort and resources for~~changes in conditions, or the ~~remediation and improvement~~degree of ~~our internal control over financial reporting. While we have processes to properly identify and evaluate~~compliance with the ~~appropriate accounting technical pronouncements and other literature for all significant~~policies or ~~unusual transactions, we have expanded and will continue to improve these processes to ensure that the nuances of such transactions are effectively evaluated in the context~~procedures may deteriorate. Because of the ~~increasingly complex accounting standards.~~

inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Table of Contents

PART II ~~- OTHER INFORMATION~~

~~ITEM~~

Item 1. ~~LEGAL PROCEEDINGS.~~

~~None.~~

Legal Proceedings

See Item 1A. “Risk Factors”.

From time to time, we may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business. Although the results of litigation and claims are inherently unpredictable and uncertain, we are not currently a party to any legal proceedings the outcome of which, if determined adversely to us, are believed to, either individually or taken together, have a material adverse effect on our business, operating results, cash flows or financial condition. Regardless of the outcome, litigation has the potential to have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

~~ITEM~~

Item 1A. ~~RISK FACTORS.~~

Risk Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our amendment no.2 an annual report on Form 10-K/A filed with the SEC on December 13, 2021. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there

There have been no material changes to the risk factors ~~disclosed~~previously described in Item 1A of our ~~amendment no.2 an annual report~~Annual Report on Form ~~10-K/A filed with~~10-K for the ~~SEC on~~fiscal year ended December ~~13, 2021, except we may disclose~~31, 2021. These risk factors describe some of the assumptions, risks, uncertainties and other factors that could adversely affect our business or that could otherwise result in changes ~~to such factors or disclose additional factors~~that differ materially from ~~time to time in~~ our ~~future filings with the SEC.~~

expectations.

~~ITEM~~

Item 2. ~~UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.~~

~~None.~~

Unregistered Sales of Equity Securities and Use of Proceeds

On May 10, 2022, the Company's Board consented to the adoption and approval of the Share Repurchase Program, authorizing up to $20,000 to be spent on the repurchase of the Company's common stock, expiring on December 31, 2022. The Company repurchased $9,000 of its common stock in the second quarter of 2022. At June 30, 2022, $11,000 of the Share Repurchase Program authorization remained available for repurchases. The table below reflects our purchases of common stock during each of the three months in the three-month period ended June 30, 2022.


Period	Total Number of Shares of Stock Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Program	Approximate Dollar Value that May Yet be Purchased Under the Program
April 1, 2022 - April 30, 2022	—	$	—	—	—
May 1, 2022 - May 31, 2022	—	—		—	$	20,000
June 1, 2022 - June 30, 2022	1,500,000	6.00		1,500,000	$	11,000
Total	1,500,000	$	6.00	1,500,000

~~ITEM~~

Item 3. ~~DEFAULTS UPON SENIOR SECURITIES.~~

~~None.~~

Defaults Upon Senior Securities

Not applicable.

~~ITEM~~

Item 4. ~~MINE SAFETY DISCLOSURES.~~

Mine Safety Disclosures

Not applicable.

~~ITEM~~

Item 5. ~~OTHER INFORMATION.~~

~~None.~~

Other Information

Not applicable.

Table of Contents

~~ITEM~~Item 6. ~~EXHIBITS.~~

~~The following exhibits are filed as part~~Exhibits
Incorporated by Reference Filed or Furnished Herewith
Exhibit Number Description Form File Number Exhibit Filing Date
2.1
Agreement and Plan of Merger, dated as of June 28, 2021, by and among DFP Healthcare Acquisitions Corp., Orion Merger Sub I, Inc., Orion Merger Sub II, LLC and TOI Parent, Inc.
S-4/A 333-258152 2.1 October 20, 2021
3.1
Amended and Restated Certificate of Incorporation of The Oncology Institute, Inc.
8-K 001-39248 3.1 November 18, 2021
3.2
Amended and Restated Bylaws of The Oncology Institute, Inc.
8-K 001-39248 3.2 November 18, 2021
3.3
Certificate of Designation of Series A Common Stock Equivalent Convertible Preferred Stock
8-K/A 001-39248 3.3 November 22, 2021
4.1
Warrant Agreement, dated March 10, 2020, by and between DFP and Continental Stock Transfer & Trust Company, as warrant agent
8-K 001-39248 4.1 March 13, 2020
4.2
Specimen Preferred Stock Certificate of The Oncology Institute, Inc.
8-K/A 001-39248 4.2 November 22, 2021
10.1
Separation Agreement by and between the Company and Scott Dalgleish
X
10.2
Executive Employment Agreement - Mihir Shah
10-Q 001-39248 10.1 May 10, 2022
31.1
Certification Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 of the Principal Executive Officer.
X
31.2
Certification Pursuant to Rule 13a-14(a) under Securities Exchange Act of 1934 of the Principal Financial Officer.
X
32.1
Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer.
X
32.2
Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer
X
101
Interactive Data File — the following financial statements from The Oncology Institute's Quarterly Report on Form 10-Q formatted in inline XBRL (Extensible Business Reporting Language) includes: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income (Operations), (iii) the Condensed Consolidated Statements of Convertible Preferred Shares and Changes in Stockholders’ Equity (Deficit), (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Condensed Consolidated Financial Statements.
101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF XBRL Taxonomy Extension Definition Linkbase Document

Table of ~~or incorporated by reference into, this Quarterly Report.~~

Contents

~~No.~~

~~Description of Exhibit~~

~~2.1~~

~~Agreement and Plan of Merger, dated as of June 28, 2021,~~Incorporated by and among DFP Healthcare Acquisitions Corp. Orion Merger Sub I, Inc., Orion Merger Sub II, LLC and TOI Parent Inc. (attached as Annex A to the proxy statement/prospectus which forms a part of the registration statement on Form S-4 filed by DFP Healthcare Acquisitions Corp. with the SEC on July 23, 2021).Reference

Filed or Furnished Herewith

Exhibit Number

Description

Form

File Number

Exhibit

Filing Date

~~10.1~~

101.LAB

Form Subscription Agreement, by and between DFP and the undersigned subscribers party thereto (attached as Annex D to the proxy statement/prospectus which forms a part of the registration statement on Form S-4 filed by DFP Healthcare Acquisitions Corp. with the SEC on July 23, 2021).

~~10.2~~

Form of Deerfield Subscription Agreement, by and between DFP and the undersigned subscribers party thereto (attached as Annex E to the proxy statement/prospectus which forms a part of the registration statement on Form S-4 filed by DFP Healthcare Acquisitions Corp. with the SEC on July 23, 2021).

~~10.3~~

Stockholder Support Agreement, dated as of June 29, 2021, by and among DFP Healthcare Acquisitions Corp., TOI Parent Inc., DFP Sponsor LLC and the other signatories thereto. (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed by DFP Healthcare Acquisitions Corp. filed with the SEC on June 29, 2021).

~~10.4~~

Company Support Agreement, dated as of June 28, 2021, by and among DFP Healthcare Acquisitions Corp., TOI Parent Inc. and the other signatories thereto (incorporated by reference to Exhibit 10.4 of the Current Report on Form 8-K filed by DFP Healthcare Acquisitions Corp. filed with the SEC on June 29, 2021).

~~10.5~~

Consent and Waiver Letter, dated as of June 28, 2021, by and among DFP Healthcare Acquisitions Corp., DFP Sponsor LLC, Deerfield Private Design Fund IV, L.P. and Deerfield Partners, L.P (incorporated by reference to Exhibit 10.5 of the Current Report on Form 8-K filed by DFP Healthcare Acquisitions Corp. filed with the SEC on June 29, 2021).

31.1*

~~Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002~~

31.2*

~~Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002~~

32.1**

~~Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002~~

32.2**

~~Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002~~

101.INS*

~~Inline XBRL Instance Document~~

101.CAL*

~~Inline~~ XBRL Taxonomy Extension ~~Calculation~~Label Linkbase Document

104

101.SCH*

~~Inline XBRL Taxonomy Extension Schema Document~~

101.DEF*

~~Inline XBRL Taxonomy Extension Definition Linkbase Document~~

101.LAB*

~~Inline XBRL Taxonomy Extension Labels Linkbase Document~~

101.PRE*

~~Inline XBRL Taxonomy Extension Presentation Linkbase Document~~

~~104~~

Cover Page Interactive Data File - (formatted as ~~inline~~Inline XBRL and contained in Exhibit 101)

~~Filed herewith.~~

~~Furnished.~~

Table of Contents

~~SIGNATURES~~

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this ~~report~~Registration Statement to be signed on its behalf by the undersigned ~~thereunto~~hereunto duly ~~authorized.~~

authorized, on this the day of August 9, 2022.



	THE ONCOLOGY INSTITUTE, ~~INC~~ INC.
			~~(FORMERLY KNOWN ASDFP HEALTHCARE ACQUISITIONS CORP.)~~

~~Date: December 13, 2021~~ By:				/s/ ~~Brad Hively~~ Mihir Shah
			~~Name:~~	~~Brad Hively~~ Mihir Shah
			~~Title:~~	Chief Executive Officer and Director (Principal Executive Officer)

~~Date: December 13, 2021~~		~~/s/ Scott Dalgleish~~
	~~Name:~~	~~Scott Dalgleish~~
	~~Title:~~	Chief Financial Officer (Principal Financial Officer and ~~Accounting~~Duly Authorized Officer)


	September 30,2021		December 31, 2020
		(unaudited)
Assets:
Current assets:
Cash	$	204,865	$	916,987
Prepaid expenses		82,245		152,474
Total current assets		287,110		1,069,461
Cash and investments held in Trust Account		230,012,623		230,254,149
Total Assets	$	230,299,733	$	231,323,610

Liabilities, Class A Common Stock Subject to Possible Redemption, and Stockholders' Equity (Deficit):
Current liabilities:
Accounts payable	$	961,084	$	—
Accrued expenses		2,625,925		50,000
Accrued expenses - related parties		17,500		17,500
Franchise tax payable		29,639		200,050
Total current liabilities		3,634,148		267,550
Deferred underwriting commissions		6,300,000		6,300,000
Derivative warrant liabilities		15,268,170		18,791,170
Total liabilities		25,202,318		25,358,720

Commitments and Contingencies

Class A common stock subject to possible redemption, $0.0001 par value; 23,000,000 shares at $10.00 per share as of September 30, 2021 and December 31, 2020		230,000,000		230,000,000

Stockholders' Equity (Deficit):
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding		—		—
Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 0 non-redeemable shares issued or outstanding		—		—
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 5,750,000 shares issued and outstanding as of September 30, 2021 and December 31, 2020		575		575
Accumulated deficit		(24,903,160)		(24,035,685)
Total stockholders' equity (deficit)		(24,902,585)		(24,035,110)
Total Liabilities, Class A Common Stock Subject to Possible Redemption, and Stockholders' Equity (Deficit)	$	230,299,733	$	231,323,610


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
General and administrative expenses	$	1,472,921	$	95,980	$	4,141,810	$	208,562
General and administrative expenses - related party		52,500		52,500		157,500		122,500
Franchise tax expense		50,411		50,000		149,639		149,750
Loss from operations		(1,575,832)		(198,480)		(4,448,949)		(480,812)
Other income (expense)
Interest income from investments in Trust Account		5,798		73,393		58,474		194,901
Change in fair value of derivative warrant liabilities		1,138,000		(2,279,000)		3,523,000		(5,198,670)
Financing cost - derivative warrant liabilities		—		—		—		(315,080)
Loss before income tax expense		(432,034)		(2,404,087)		(867,475)		(5,799,661)
Income tax expense		—		(12,573)		—		(12,573)
Net loss	$	(432,034)	$	(2,416,660)	$	(867,475)	$	(5,812,234)

Weighted average shares outstanding of Class A common stock, basic and diluted		23,000,000		23,000,000		23,000,000		16,956,204
Basic and diluted net loss per share, Class A	$	(0.02)	$	(0.08)	$	(0.03)	$	(0.26)

Weighted average shares outstanding of Class B common stock, basic		5,750,000		5,750,000		5,750,000		5,552,920
Weighted average shares outstanding of Class B common stock, diluted		5,750,000		5,750,000		5,750,000		5,750,000
Basic and diluted net loss per share, Class B	$	(0.02)	$	(0.08)	$	(0.03)	$	(0.26)


	Common Stock										Total
	Class A			Class B			Additional Paid-In		Accumulated		Stockholders’
	Shares	Amount		Shares	Amount		Capital		Deficit		Deficit
Balance - December 31, 2020 (as restated)	—	$	—	5,750,000	$	575	$	—	$	(24,035,685)	$	(24,035,110)
Net income	—		—	—		—		—		5,685,300		5,685,300
Balance - March 31, 2021 (unaudited) (as restated)	—	$	—	5,750,000	$	575	$	—	$	(18,350,385)	$	(18,349,810)
Net loss	—		—	—		—		—		(6,120,741)		(6,120,741)
Balance - June 30, 2021 (unaudited) (as restated)	—	$	—	5,750,000	$	575	$	—	$	(24,471,126)	$	(24,470,551)
Net loss	—		—	—		—		—		(432,034)		(432,034)
Balance - September 30, 2021 (unaudited)	—	$	—	5,750,000	$	575	$	—	$	(24,903,160)	$	(24,902,585)


As of March 31, 2021 (unaudited)	As Reported		Adjustment		As Restated
Total assets	$	231,036,262	$	—	$	231,036,262
Total liabilities	$	19,386,072	$	—	$	19,386,072
Class A common stock subject to possible redemption		206,650,180		23,349,820		230,000,000
Preferred stock		—		—		—
Class A common stock		233		(233)		—
Class B common stock		575		—		575
Additional paid-in capital		7,656,106		(7,656,106)		—
Accumulated deficit		(2,656,904)		(15,693,481)		(18,350,385)
Total stockholders' equity (deficit)	$	5,000,010	$	(23,349,820)	$	(18,349,810)
Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders' Equity (Deficit)	$	231,036,262	$	—	$	231,036,262
Shares of Class A common stock subject to possible redemption		20,665,018		2,334,982		23,000,000
Shares of Class A common stock		2,334,982		(2,334,982)		—


As of June 30, 2021 (unaudited)	As Reported		Adjustment		As Restated
Total assets	$	230,754,006	$	—	$	230,754,006
Total liabilities	$	25,224,557	$	—	$	25,224,557
Class A common stock subject to possible redemption		200,529,440		29,470,560		230,000,000
Preferred stock		—		—		—
Class A common stock		295		(295)		—
Class B common stock		575		—		575
Additional paid-in capital		13,776,784		(13,776,784)		—
Accumulated deficit		(8,777,645)		(15,693,481)		(24,471,126)
Total stockholders’ equity (deficit)	$	5,000,009	$	(29,470,560)	$	(24,470,551)
Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Equity (Deficit)	$	230,754,006	$	—	$	230,754,006
Shares of Class A common stock subject to possible redemption		20,052,944		2,947,056		23,000,000
Shares of Class A common stock		2,947,056		(2,947,056)		—


	Earnings (Loss) Per Share
	As Previously
	Restated		Adjustment		Restated
For the three months ended March 31, 2021 (unaudited)
Net income	$	5,685,300	$	—	$	5,685,300
Weighted average shares outstanding - Class A common stock		23,000,000		—		23,000,000
Basic and diluted earnings per share - Class A common stock	$	—	$	0.20	$	0.20
Weighted average shares outstanding - Class B common stock		5,750,000		—		5,750,000
Basic and diluted earnings per share - Class B common stock	$	0.99	$	(0.79)	$	0.20
For the three months ended June 30, 2021 (unaudited)
Net loss	$	(6,120,741)	$	—	$	(6,120,741)
Weighted average shares outstanding - Class A common stock		23,000,000		—		23,000,000
Basic and diluted earnings per share - Class A common stock	$	—	$	(0.21)	$	(0.21)
Weighted average shares outstanding - Class B common stock		5,750,000		—		5,750,000
Basic and diluted earnings per share - Class B common stock	$	(1.06)	$	0.85	$	(0.21)
For the six months ended June 30, 2021 (unaudited)
Net loss	$	(435,441)	$	—	$	(435,441)
Weighted average shares outstanding - Class A common stock		23,000,000		—		23,000,000
Basic and diluted earnings per share - Class A common stock	$	—	$	(0.02)	$	(0.02)
Weighted average shares outstanding - Class B common stock		5,750,000		—		5,750,000
Basic and diluted earnings per share - Class B common stock	$	(0.08)	$	0.06	$	(0.02)


Gross proceeds	$	230,000,000
Less:
Amount allocated to Public Warrants		(6,727,500)
Class A common stock issuance costs		(10,110,406)
Plus:
Accretion of carrying value to redemption value		16,837,906
Class A common stock subject to possible redemption	$	230,000,000


	Quoted Prices in		Significant Other		Significant Other
	Active Markets		Observable Inputs		Unobservable Inputs
Description	(Level 1)		(Level 2)		(Level 3)
Assets
Investments held in Trust Account	$	230,012,623	$	—	$	—
Liabilities
Derivative warrant liabilities - Public Warrants	$	9,257,500	$	—	$	—
Derivative warrant liabilities - Private Warrants	$	—	$	—	$	6,010,670


	As of September 30, 2021			As of December 31, 2020
Stock Price	$	9.94		$	10.80
Volatility		22.8	%		24.0	%
Expected life of the options to convert		5.13			5.75
Risk-free rate		1.00	%		0.47	%
Dividend yield		0.0	%		0.0	%


Level 3 - Derivative warrant liabilities at December 31, 2020	$	7,578,670
Change in fair value of derivative warrant liabilities		(2,426,670)
Level 3 - Derivative warrant liabilities at March 31, 2021	$	5,152,000
Change in fair value of derivative warrant liabilities		1,306,670
Level 3 - Derivative warrant liabilities at June 30, 2021	$	6,458,670
Change in fair value of derivative warrant liabilities	$	(448,000)
Level 3 - Derivative warrant liabilities at September 30, 2021	$	6,010,670